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ABSTRACT 
Over the last two decades epigenetic modifications have been targeted as a 
possible cause for inheritance of nonmendelian diseases. Epigenetics refers to the 
study of heritable changes in gene expression or cellular phenotype that is not 
encoded in the DNA itself. Epigenetic modifications can be influenced by 
environmental stimuli; as such it is thought that heritable diseases that are known to 
be influenced environmentally are potentially controlled and regulated through these 
modifications. Asthma is one such disease. However, the epigenome is regulated by 
a number of epigenetic modifications including methylation, acetylation, 
phosphorylation and miRNA. Thus, discovering a direct epigenetic cause of asthma 
has proved to be difficult. However, there is evidence that the epigenetic 
modification histone acetylation may contribute to the inflammatory response 
observed in asthma airways.   
Histone acetylation is an epigenetic modification that directly alters the configuration 
of chromatin and as such affects gene transcription pathways. Histone acetylation is 
controlled by the enzymes; histone acetyltransferases (HATs) and histone 
deacetylases (HDACs). The acetylation equilibrium is mostly maintained through the 
physical and functional interplay between HAT and HDAC enzymes. As such the 
expression levels and regulation of these enzymes within asthma airways was the 
focus of this thesis.  Furthermore, as epigenetic modifications can be 
environmentally influenced this thesis also examined whether an inflammatory status 
could alter the expression levels of HAT and HDAC enzymes. The aims of this thesis 
were based on the hypothesis that an imbalance of the acetylation equilibrium within 
innate immune cells caused by dysfunction of HAT and HDAC enzymes, leads to an 
influx of pro-inflammatory cytokines and chemokines to the airways.  
To investigate these aims the project was split into two components. The first study 
investigated the expression of HAT and HDAC enzymes in sputum samples 
collected from the airways of individual with mild asthma (n=19) and healthy 
controls (n=17) using quantitative PCR. The second study was designed to 
investigate the expression of these enzymes in response to induced inflammation 
within the airways. This study utilised 3 subject cohorts, healthy (n=15), mild asthma 
(individuals treating with β2 agonists only, n=15) and severe asthma (individuals 
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treating with inhaled corticosteroids, n=14). Subject participation in this study 
required the completion of 3 separate sputum induction sessions. The first two 
sessions were used to establish a baseline expression level for the enzymes within the 
airway. The third session measured the enzymes response to induced inflammation.  
HAT and HDAC enzymes appear to be differentially expressed between the airways 
of asthma and healthy subjects. Particularly the HAT enzyme CBP and HDAC 
enzymes: HDAC1, HDAC5, SIRT5 and SIRT6 appear to have different stable phase 
levels in asthma airways compared to healthy airways. Furthermore, lower CBP 
expression levels are associated with decreased pulmonary function (r=0.4, P < 
0.05). The project also found that the expression levels of HAT and HDAC enzymes 
can be altered and influenced under inflammatory conditions.  Particularly, mRNA 
levels of CBP were increased under inflammatory conditions in the airways of 
individuals from all cohorts. This suggests that CBP is up regulated as part of an 
inflammatory response. Furthermore, protein levels of HDAC1 appear to be 
increased in inflamed airways, however; a greater increase of HDAC1 level is 
observed in the healthy and asthma ICS group compared to the asthma β2 cohort.  
This suggests that the dysfunction of HDAC1 in asthma airways could potentially 
contribute to the exacerbated inflammatory response that is observed in asthma. 
Finally, the study also found that the expression levels of SIRT1 and SIRT6 in 
asthma β2 airways is not as tightly controlled or regulated as those observed in the 
healthy airways.   
The number of individuals suffering from asthma is expected to rise considerably 
over the next 15 years and although effective treatment for asthma exists, there are an 
increasing number of individuals who are resistant to this medication. Furthermore, 
at present no therapies exist which target the four major biological influences of 
asthma: airway inflammation, bronchoconstriction, airway hyper responsiveness and 
excess mucus production. Isolation of these chromatin modifying enzymes (HAT and 
HDACs) as potential contributors to the asthma phenotype allows for a more focused 
research approach in future studies, and the potential for these molecules to be 
targeted therapeutically for new treatment intervention. 
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CHAPTER 1:  INTRODUCTION AND LITERATURE REVIEW 
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The human body consists of trillions of living cells that require oxygen to survive. 
Without oxygen the body would survive a couple of minutes before its vital organs 
shutdown. Thus, the physical condition of the airways has a direct and immediate 
impact on the overall health of the body. Asthma is a chronic inflammatory disease 
of the lungs that is increasingly observed in developed countries. In genetically 
susceptible individuals, exposure to a wide variety of environmental stimuli such as 
allergens, infection, airborne pollutants, physical stimuli, and drugs can either induce 
and/or exacerbate the disease.  As the world becomes more industrialised our airways 
are under constant attack from minute and harmful particles. The number of 
individuals suffering from asthma is expected to increase greatly within the next 15 
years. Understanding the underlying biology of this environmentally influenced 
disease will greatly improve the health of future generations. 
1.1 ASTHMA: A DEFINITION 
The accepted definition for asthma is: “Asthma is a chronic inflammatory disorder of 
the airways in which many cells and cellular elements play a role. The chronic 
inflammation is associated with airway hyper responsiveness that leads to recurrent 
episodes of wheezing, breathlessness, chest tightness, and coughing particularly at 
night or in the early morning. These episodes are usually associated with 
widespread, but variable, airflow obstruction within the lung that is often reversible 
either spontaneously or with treatment (Global Initiative for Asthma (GINA), 2011).” 
1.2 EPIDEMIOLOGY OF ASTHMA 
Asthma is a chronic disease of the lower respiratory tract that affects over 300 
million people worldwide  (Braman, 2006). It is a disease with a symptom-based 
diagnosis and, as such, diagnosis and treatment is heavily dependent on the 
clinician’s interpretations of the patient symptoms at the time of visit. This makes 
reliable comparison of reported prevalence around the world problematic. However, 
based on standardized spirometry methods, global asthma prevalence is estimated to 
occur within 1-18% of the population depending upon the country investigated 
(GINA, 2011). The industrialised world appears to have much higher asthma rates 
compared to the third world (GINA, 2011).  The disparity between the two 
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populations is likely due to the gene-environment phenotype of the disease with 
higher pollution rates in the industrialised world causing an increase in asthma onset.   
Globally, financial costs of asthma are high. The cost of asthma can be divided into 
direct costs – such as medication and hospital admissions and indirect costs – such as 
loss of earning caused by time away from work and premature death (GINA, 2011, 
Australia Centre for Monitoring Asthma, 2011). There is a general perception that 
the cost to control asthma is high; however, as asthma can have debilitating effects 
on the quality of life for its sufferers the cost of not treating asthma correctly is much 
higher. Understanding the molecular mechanisms that cause asthma can help provide 
key insights into designing better and more affordable therapeutic measures for 
controlling the disease.   
1.3 CLINICAL DIAGNOSIS AND DISEASE PATHOPHYSIOLOGY 
An asthma episode can be stimulated both environmentally and genetically; as such, 
asthma is considered a complex disease (Ho, 2010, Rigoli et al., 2011). A clinical 
diagnosis of asthma is given when a patient presents with symptoms of wheezing, 
breathlessness, chest tightness and coughing  (Lowhagen, 2012). A family history, 
episodic and or seasonal symptoms can also aid with diagnosis. The onset of an 
exacerbation is caused by intensified cellular events, stimulating four biological 
responses that result in the obstruction of the airways (Bousquet et al., 2000). These 
responses are: airway hyperresponsiveness, bronchial constriction, excess mucus 
production and airway inflammation (Bousquet et al., 2000).  
1.3.1 Airway Hyperresponsiveness 
The phenomenon known as airway hyperresponsiveness (AHR) is observed when 
individuals experience exaggerated decline in their ability to breathe after coming 
into contact with stimuli, such as allergens, cold air and smoke (Currie et al., 2004). 
This response causes constriction and narrowing of the airway smooth muscle 
resulting in obstruction and difficulty breathing. The stimuli that cause AHR can be 
divided into two categories: direct and indirect (Cockcroft, 2010, Anderson, 2010). 
Direct stimuli (methacholine, histamine) act directly on specific smooth muscle 
receptors and indirect stimuli (exercise, hypertonic saline) act through intermediate 
pathways which often involve release of mediators from inflammatory cells 
4 
 
(Cockcroft, 2010, Anderson, 2010). Naturally occurring AHR stimulus known to 
cause asthma exacerbations largely act through indirect mechanisms. Consequently, 
it is widely thought that the experimental use of indirect stimuli correlates better with 
the asthma phenotype than direct stimuli (Van Schoor et al., 2000). The cause of 
AHR is unknown, but traditionally it is associated with airway inflammation. 
However, recently it has been suggested that there are two components to AHR: a 
fixed and a variable component (Busse, 2010). The fixed component refers to 
structural changes in the airways known as airway remodelling. Airway remodelling 
is often observed in individuals with long standing chronic disease, and it is unlikely 
that this component can be influenced therapeutically (Brightling et al., 2012). On 
the other hand, the variable component can be influenced and altered via stimuli such 
as allergens that cause asthma exacerbations, and inhaled corticosteroids which 
prevent exacerbations (Anderson, 2010). However, the fixed/variable component of 
AHR in asthma is merely a hypothesis and, while there is evidence that these 
components exist in diseases such as Chronic Obstructive Pulmonary Disease 
(COPD) (Scichilone et al., 2006), no such experimental evidence exists for asthma. 
The relationship between asthma exacerbation, AHR and inflammation is well-
defined (Busse, 2010). By understanding the mechanisms through which AHR and 
inflammation interact, a better understanding of the asthma phenotype can be gained.  
1.3.2 Bronchoconstriction 
Bronchoconstriction refers to the narrowing of the airways as a result of tightening of 
the airway smooth muscles. Bronchoconstriction usually occurs in response to an 
external stimulus but has been known to occur spontaneously (Hayes et al., 2012, 
Anderson and Kippelen, 2012, Sheppard, 1986). Constriction of the airways occurs 
when a stimulus activates the parasympathetic nervous system; this causes the 
release of acetylcholine into the smooth muscle layer surrounding the bronchi. The 
acetylcholine activates M3 type muscarinic receptors. These receptors set off a 
cascade of cellular events that ultimately ends with the increase of intracellular Ca
2+ 
that causes contraction of the airway smooth muscle (Pelaia et al., 2008). Controlling 
the bronchoconstriction of the airways, and thus reducing airway resistance is a 
major therapeutic target in asthma treatment. Short acting β2 agonists (SABA) and 
long acting β2 agonists (LABA) are in mainstream use for both symptom relief and 
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control medications (Ortega and Peters, 2010). They operate via the β2 adrenergic 
receptors to relax smooth muscles, thus preventing constriction of the airways 
(Ortega and Peters, 2010). 
 Bronchoconstriction is considered a secondary mechanism in the asthma response, 
triggered either via airway hyperresponsiveness and or airway inflammation. 
However, given that targeting bronchoconstriction therapeutically is extremely 
effective in controlling asthma exacerbations, there are many who argue that 
uncontrolled bronchoconstriction may be the initial event that triggers the cellular 
cascade that results in obstruction of the airways (Grainge et al., 2011, Koziol-White 
et al., 2011). 
1.3.3 Excess Mucus Production 
Excessive mucus production is a dominant characteristic of chronic airway diseases 
such as asthma (Jackson, 2001). The increase of mucus in the airways is a natural 
immune response designed to protect the lungs. However, excessive production of 
mucus can be detrimental to health as hypersecretion contributes to the development 
of viscid mucus plugs that block the airways (Voynow and Rubin, 2009). Mucins — 
the major mucus proteins — are secreted via surface epithelial cells, goblet cells, and 
sub-mucosal glands (Voynow and Rubin, 2009). Normally, these mucin secreting 
cells are located in the large airways. 
In chronic respiratory diseases, goblet cell hyperplasia causes an increase in cell 
numbers. This leads to the spreading of goblet cells to the smaller airways where 
they are rarely found (Jackson, 2001). The large and small airways have different 
biological roles and, as such, have different defence mechanisms. Thus, coughing to 
remove a blockage caused by mucus hypersecretion does not effectively clear mucus 
from the small airways (Pilette et al., 2001). The build-up of mucus can cause 
occlusions which ultimately contribute to the severity of chronic respiratory diseases. 
The underlying cause of the mucus hypersecretion response is not well understood, 
but it contributes greatly to the airway obstruction observed in asthma and the 
ensuing inflammatory response.   
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1.3.4 Airway Inflammation 
Exacerbation of inflammation in response to harmless stimuli is considered the 
primary cause of the airway obstruction observed in the asthma phenotype (Kazani 
and Israel, 2012). Inflammation is a protective event that occurs in an organism to 
remove harmful pathogens and to initiate healing processes. Depending on the type 
of inflammation observed, inflammation can be classified as either acute or chronic 
(Medzhitov, 2008). Acute inflammation is the initial response to a stimulus wherein 
the injured tissue recruits plasma and leukocytes from the circulation to eradicate and 
remove invading microbes (Medzhitov, 2008). Chronic inflammation refers to a shift 
in the type of cells at the inflammation site and is characterized by both destruction 
and healing processes (Medzhitov, 2008). In asthma, both acute and chronic 
inflammation is observed (Bousquet et al., 2000). The inflammatory response largely 
occurs in the conducting airways but as the disease becomes more chronic this 
inflammation can spread proximally to the trachea and distally to the smaller airways 
(Figure 1-1) (Faul et al., 1997, Hamid et al., 1997, Balzar et al., 2002, Poutler, 
1997). The initiation and exacerbation of the inflammatory response is controlled by 
the immune system.  
 
Figure 1-1: Airway inflammation in asthma 
Adapted from: (Hoiby, 2011) 
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1.4 IMMUNE SYSTEM 
The immune system consists of a collection of cells, tissues, and proteins that 
mediate the host defence against invading microbes and pathogens. The coordinated 
reaction of the different components of the immune system makes up the immune 
response. The overall defence mechanisms and thus the immune response can be 
split into two components: innate immunity and adaptive immunity (Holgate, 2012). 
Innate immunity refers to the host defence that provides the initial protection against 
infection (Abbas, 2006). However, adaptive immunity refers to immunity that is 
acquired over time in response to invading pathogens and microbes. The latter is 
often more effective in defending the host organism (Islam and Luster, 2012). The 
inflammatory response in asthma involves both the innate and adaptive immune 
responses. However, the extent to which each contributes to the exacerbation of 
inflammation in response to relatively harmless stimuli still needs to be fully 
understood (Holgate, 2012). 
1.4.1 Innate Immunity 
The main components of the innate immune system consist of epithelial cell barriers, 
the leukocytes, neutrophils and monocytes, and natural killer (NK) cells. The 
epithelial cell barriers line the skin, respiratory tract, reproductive tract and 
gastrointestinal tract.  Neutrophils and monocytes are recruited to sites of infection to 
recognise and ingest microbes for intracellular killing. Aside from their active role in 
providing tumour immunity, NK cells also respond to microbes by eradicating 
infected cells and by producing the cytokine, interferon gamma (INFγ) to recruit 
macrophages to the site of infection.  
Respiratory Epithelium 
The respiratory epithelium has a large surface area that is exposed to the external 
environment. The airway epithelium represents the boundary between the body and 
the environment, and is the first line of defence against inhaled microbes and 
allergens (Lambrecht and Hammad, 2012). The respiratory epithelium is a mucosal 
epithelium which includes sporadically placed goblet cells that secrete mucus. Mucus 
serves a number of protective functions within innate immunity. This includes 
encapsulation of microorganisms within its viscous fluid, preventing attachment and 
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colonisation of the epithelium (Murphy, 2011). Cilia — hair like projections found 
within the epithelium — beat to expel the mucus in an outward flow in a process 
known as mucociliary clearance (Stannard and O'Callaghan, 2006). This first line of 
defence is extremely effective in clearing the airways of microorganisms.  
If mucociliary clearance fails to remove such pathogens, the epithelia is also 
protected by chemical defences, the antimicrobial enzymes and peptides which 
include the lysozymes and defensins respectively (Lambrecht and Hammad, 2012). 
Lysozymes function via breaking the chemical bonds in the bacterial cell wall. The 
sugar molecule peptidoglycan resides within bacterial cell walls and lysozymes 
cleave the peptide bridge linking the two peptidogylcan polymers N-
acetylglucosamine (GlcNAc) and N-acetylmuramic acids (MurNAc) (Lambrecht and 
Hammad, 2012). On the other hand, defensins disrupt the cell membranes of the 
invading microorganism. Either way, these biomolecules further protect the host 
from invading pathogens. 
Distinguishing between pathogenic and non-pathogenic particles that enter the 
respiratory tract is an important innate immune mechanism. Epithelial cells recognise 
harmful microbes by expressing a number of pattern recognition receptors (PRRs) 
(Lambrecht and Hammad, 2012). Microbes contain conserved sequences known as 
pathogen associated molecular patterns (PAMPs) which can be detected by PRRs. 
Alternatively, epithelial cells can also recognise damaged associated molecular 
patterns (DAMPs), which are molecules that can initiate the immune response in 
non-infectious invasions including self-damage via the host (Lambrecht and 
Hammad, 2012). PRRs are not only present in epithelial cells but also found in 
leukocytes (Lambrecht and Hammad, 2012). Bacterial lipopolysaccharide (LPS) is 
an extremely well known PAMP which is often used experimentally to investigate 
immune response pathways.   
Cells expressing PRRs rapidly respond to microbes, tissue damage, cell death and 
cellular stress (Lambrecht and Hammad, 2012). The activation of PRRs causes the 
release of biomolecules including cytokines and defensins that attract and activate 
various immune cells (Newton and Dixit, 2012).  Epithelial cell activation is a 
triggering event to activate the antigen presenting cells (APC), dendritic cells (DC) 
which further coordinate the immune response. DCs migrate to the lymph nodes and 
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present antigens to naïve T lymphocytes initiating an adaptive immune response 
(Holgate, 2012). In response to allergen stimulus, epithelial cells also release 
cytokines such as Interleukin (IL) 33, IL-1α, IL-1β and IL-36γ as well as chemokines 
that attract neutrophils, monocytes and immature DCs to the airways. In doing so, the 
epithelial cells initiate the cascade of cells and proteins observed in an inflammatory 
response (Ramadas et al., 2011, Chustz et al., 2011).  
In asthma airways the epithelial cells are fragile. The epithelium is partly shed; the 
ciliated cells, which assist in mucosal clearance, appear swollen and often lose their 
cilia, impeding their ability to function properly (Laitinen et al., 1985, Montefort et 
al., 1993). This damage to the epithelial barrier potentially leads to heightened 
airway hyperresponsiveness, altered permeability of the airway mucosa and 
increased pro-inflammatory cytokine production (Bousquet et al., 2000). Thus, it 
appears the epithelial cells may contribute to the asthma phenotype through 
inappropriate barrier protection and by heightened activation and secretion of 
inflammatory proteins. 
Neutrophils and monocytes/macrophages. 
Neutrophils and monocytes are circulating blood cells known as phagocytes that are 
recruited to sites of infection to detect and ingest microbes for intracellular killing; a 
process known as phagocytosis (Dale et al., 2008). Monocytes that enter 
extravascular tissue differentiate into macrophages. There are resident macrophages 
found in every organ of the body and serve as phagocytes (Gordon and Taylor, 
2005). On recognising invading pathogens, macrophages produce a number of 
cytokines including tumour necrosis factor alpha (TNF-α), IL-1 and IL-6 (Belardelli, 
1995). These cytokines stimulate endothelial cells to produce the adhesion molecules 
E-selectin and P-selectin. Circulating neutrophils and monocytes express surface 
carbohydrates that bind weakly to selectin. Thus, neutrophils and monocytes are 
recruited to sites of infection through weak binding interactions with these adhesion 
molecules (Ley, 2003). However, chemokines — a family of pro-inflammatory 
cytokines — have also been shown to play a major role in directing the migration of 
these phagocytes to inflamed tissue areas. Studies have shown that CXCL8 (IL-8), 
CXCL5 (epithelial cell-derived neutrophil-activating protein), CCL2 (monocytes 
chemoattractant protein-1), CCL3 (macrophage inflammatory protein-1α) and CCL5 
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(RANTES) are chemokines which are involved in the recruitment of leukocytes to 
sites of infection (Silva, 2010).   
Neutrophils are the first cell type recruited during infection, and ingest microbes and 
invading pathogens (Kumar and Sharma, 2010). The production of neutrophils is 
stimulated by cytokines known as colony-stimulating factors that are produced by a 
number of cell types including epithelial cells (Dale et al., 2008). Colony stimulating 
factors act upon the bone marrow stem cells to stimulate proliferation and maturation 
of neutrophil precursors.  
Considerable evidence implicating neutrophils in the pathogenesis of asthma exists. 
Indeed, investigators report increased prevalence of neutrophils in all severe forms of 
asthma (Ito et al., 2008, Hastie et al., 2010, Nair et al., 2012, Jatakanon et al., 1999, 
Cundall et al., 2003, Zhou et al., 2005, Mann and Chung, 2006, Kikuchi et al., 
2009). During asthma exacerbations there is a significant increase in neutrophil 
numbers recruited to the airways, with the exacerbations being associated with and 
without infections (Hastie et al., 2010, Jatakanon et al., 1999). Neutrophils are 
usually recruited via the immune system in response to bacterial and fungal 
pathogens. However, the cause of their increased presence in asthma remains largely 
unknown (Kumar and Sharma, 2010).  
Macrophages are important sentinels of immunity; they recognise invading 
pathogens and apoptotic cells. Aside from their active role in phagocytosis, 
macrophages also secrete cytokines that initiate the adaptive immune response 
(Belardelli, 1995). Two distinct sets of macrophages exist: the classical M1 
macrophages that release the cytokines and chemokines IL-12, TNF-α, CXCL10 and 
CCL3. These cytokines stimulate the TH1 lymphocytes of the adaptive immune 
system. The M2 macrophages produce the cytokines IL-4 and IL-13 which activate 
the TH2 lymphocytes causing an alternate adaptive immune response (Moreira and 
Hogaboam, 2011).  
Within the airways, macrophages occupy two different compartments of the lungs: 
the alveolar and the interstitial space. The contribution macrophages have to the 
prolonged inflammatory state of asthmatic airways is not well understood. However, 
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there is growing evidence that the release of pro-inflammatory mediators by 
macrophages may exacerbate lung injury and accelerate airway remodelling.  
Recently high levels of exhaled nitric oxide have been reported in asthmatic patients 
(Khanduja et al., 2011, Zeiger et al., 2011). Previously, Naura et al (2010) used 
animal models to demonstrate that excessive generation of nitric oxide by 
macrophages led to oxidative DNA damage, inflammation and increased mucus 
production. Furthermore, pro-inflammatory cytokines macrophages produce which 
include IL-1β and IL-6, have a direct effect on TH2 cell proliferation and also have 
been shown to promote fibroblast activation (Tang et al., 1998, Gallelli et al., 2008). 
Thus, altered macrophage pathways and cytokine/chemokine secretion in asthma 
would not only affect the innate immune response but may also alter the adaptive 
immune response.  
Natural Killer (NK) Cells  
Natural Killer (NK) cells are a key cell type in orchestrating the innate immune 
response. Natural killer cells are lymphocytes that are easily distinguishable from B 
and T cell lymphocytes as they lack the characteristic cell surface antigens of these 
adaptive immune cells (Herberman and Ortaldo, 1981). NK cells represent one of the 
first lines of the immune defence and are characterised by several important effector 
functions. These functions include their ability to randomly lyse susceptible targets 
such as cells that have dropped major histocompatability complexes (MHC) 1 
complexes, and activate alternate pathways to remove invading pathogens (Smyth et 
al., 2005). Another important function of NK cells is their ability to promptly 
produce cytokines such as INFγ and TNF-α, and chemokines such as MIP1-α/β that 
initiate other cellular responses (Maghazachi, 2010, Maghazachi, 2003). 
Interestingly, human NK cells comprise several subsets that are phenotypically and 
functionally distinct; it has been suggested that NK cells may be able to modify their 
functional attributes depending on their environmental context (Di Santo, 2006).  
NK cell development, proliferation and homeostasis are controlled by cell-intrinsic 
mechanisms and by extrinsic signals such as cytokines. One such cytokine that 
stimulates NK production is IL-15. IL-15 is a pleiotropic cytokine that is produced 
by epithelial cells, macrophages, and dendritic cells (Fehniger and Caligiuri, 2001). 
The production of IL-15 appears to be under the control of the master inflammatory 
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transcription factor nuclear factor kappa B (NF-κB) (Washizu et al., 1998). 
Interestingly, in asthma patients IL-15 is found to be increased in sputum fluid from 
patients taking steroid medication compared to those who are not (Komai-Koma et 
al., 2001). A clear relationship exists between epithelial cells, phagocytes and natural 
killer cells in initiating and regulating the innate immune response. All of these cells 
play a necessary and important role in inflammatory pathways. However, how these 
cells contribute to the uncontrolled inflammation observed in the airways of 
asthmatics still needs to be better understood.  
Dendritic Cells 
Amongst the epithelia is a population of antigen presenting cells (APCs) termed 
dendritic cells (DCs). DCs link the innate and adaptive immune systems (Hammad 
and Lambrecht, 2008). These immunological effector cells are sensitive to antigens 
and environmental signals that indicate a pathogen is present. DCs have an important 
role in determining how allergic immune responses are initiated and perpetuated. The 
conducting airways are lined with a mucociliary blanket and are composed of airway 
epithelial cells that are connected by tight junctions and proteins (Hammad and 
Lambrecht, 2008). The mucosal DCs are situated in the basolateral space; they are 
separated from the inhaled air only via the epithelium tight junction barrier. Their 
close proximity to the airway lumen enables the mucosal DCs to act in a periscope - 
like manner and extend their processes into the airway lumen to allow for sampling 
and continuous surveillance of inhaled air (Jahnsen et al., 2006). On encountering an 
antigen, DCs can then migrate to the lymph nodes and present captured antigens to 
naïve T lymphocytes where several adaptive immune responses can begin. In terms 
of asthma, a TH2 type immune response is generally observed (Hammad et al., 2004, 
Marsland et al., 2004, Raymond et al., 2009). Interestingly many of the cells 
involved in ongoing airway inflammation such as TH2 cells, eosinophils and mast 
cells produce mediators that can perpetuate DC-driven TH2 cell development (Webb 
et al., 2007). Furthermore, these cells also produce the TH2 cell associated cytokines 
IL-4 and IL-13. Interestingly, there is emerging evidence that suggests the IL-4 
receptor α (IL-4Rα) expression by resident lung DCs is an important feedback 
mechanism through which IL-4 and IL-13 producing cells promote further TH2 cell 
polarization in ongoing allergen responses (Webb et al., 2007). This increase in 
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production of TH2 cells may maintain the epithelium changes that are characteristic 
of asthma. 
1.4.2 Adaptive Immunity 
Adaptive immunity refers to immunity that occurs over time and is often the more 
effective of the two immune responses. Adaptive immunity is stimulated in response 
to pathogens and microbes that invade tissues and is controlled by the cells known as 
lymphocytes (Abbas, 2006). While morphologically similar, lymphocytes are 
extremely heterogeneous in terms of lineage, function and phenotype (Zhu and Paul., 
2008). The recognition mechanism used by the lymphocytes of the adaptive immune 
response enables detection of an almost infinite number of antigens. Thus, each 
different pathogen can be targeted specifically. On entering the bloodstream, each 
naїve lymphocyte bears antigen receptors of a single specificity. The specificity of 
these receptors is determined by a unique genetic mechanism that operates during 
lymphocyte development in the bone marrow and thymus to generate 100’s of  
millions of different variants of the genes encoding the receptor molecules (Abbas, 
2006).  Based on the proteins which the lymphocytes express, adaptive immunity can 
be classified as either humoral or cell mediated immunity. Humoral immunity 
mediated by the B lymphocytes is the immune response that mediates protection 
against extracellular pathogens. Cell mediated immunity is mediated by the T 
lymphocytes and mediates the immune response which protects against intracellular 
pathogens (Abbas, 2006). Therefore, B lymphocytes are mainly effective before 
microbes enter the cell and once the cell has been invaded it is the largely the role of 
the T lymphocytes to eliminate the microbes.   
B lymphocytes 
B lymphocytes are the cells that mediate humoral immunity. B cells produce proteins 
known as antibodies which neutralize and eliminate microbes. Antibodies, termed 
immunoglobulins (Ig), act to prevent microbes found in blood and mucosal surfaces 
from entering and colonizing host cells and tissues. There are five Ig isotypes: IgA, 
IgD, IgE, IgG and IgM. Each antibody plays a different role in protection against 
infection. In the asthma phenotype, the B lymphocytes predominantly express the 
IgE antibody (Hizawa et al., 2001, Galli and Tsai, 2012). IgE interacts with mast 
cells, basophils and macrophages, stimulating cytokine and chemokine production. 
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These interactions recruit more inflammatory cells into the airways leading to an 
intensified inflammatory response (Galli and Tsai, 2012). The critical role IgE plays 
in exacerbating inflammation is further substantiated in clinical trials investigating 
anti-IgE (omalizumab) medication. These studies show attenuation of inflammation 
in mild and severe asthma sufferers after a course of omalizumab therapy (Bousquet 
et al., 2011, Busse et al., 2011, Domingo et al., 2010, Kulus et al., 2010, Siergiejko 
et al., 2011). Of the five antibodies expressed by the B lymphocytes, IgE along with 
IgD are the least abundant. The expression of antibodies of different subclasses on B 
cells is determined by a process known as heavy chain class switching. This process 
is initiated by CD40L mediated signals, and the different classes of Igs are stimulated 
by different cytokines (Edry and Melamed, 2007). The production of IgE by B cells 
is stimulated by IL-4,  generally in response to invading environmental allergens and 
helminths (Oettgen and Geha, 2001). However, there is conflicting evidence that 
exposure to allergens during childhood and subsequent production of IgE is 
associated with an increased risk of developing asthma (Karvonen et al., 2012, Lau 
et al., 2000). Furthermore, with 40% of the western population considered to be 
atopic — where atopy is defined as an increase in IgE levels — only 7% of this 
population present with asthma (Holgate, 2008). This suggests that the cause of 
asthma, and thus its associated inflammation, may be genetically predetermined as 
well as environmentally triggered.  
T Lymphocytes 
T lymphocytes control cell-mediated immunity. T cells identify antigens produced by 
intracellular microbes or phagocytosed pathogens by recognising peptide fragments 
of protein antigens (Abbas, 2006). These fragments are bound to specialised peptide 
displaying molecules called major histocompatability complex (MHC) molecules 
which are separated into two classes: class I and II. The class I MHC molecules 
present intracellular peptides whereas the class II molecules present extracellular 
peptides (Reche and Reinherz, 2003). The peptide fragments are then displayed on 
MHC class II molecules to naїve T lymphocytes. At the same time naїve T 
lymphocytes encounter the peptide fragments, they receive additional signals from 
the innate immune system. The combination of stimuli causes the T cells to produce 
cytokines which stimulates the proliferation and recruitment of antigen-specific T 
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cells and other leukocytes to the site of invasion. This proliferation allows the naїve 
T cells to develop into active effector T cells.  
Among the T cells are the CD4
+
 cells and the CD8
+
cells. The CD4T cells are referred 
to as helper T cells as they help B lymphocytes to produce antibodies and phagocytes 
to destroy microbes. Naїve CD4 T cells are subject to a variety of fates which are 
ultimately decided by the initial interaction with an antigen. The CD4 cells can 
become TH1, TH2, TH9 TH17, TfH and induced regulatory Treg (iTreg) cells (Zhu and 
Paul., 2008).  
TH1 cells are critical in regulating immunity for intracellular microorganisms; they 
produce the cytokines IFNγ and IL-2. The production of IFNγ via TH1 cells is 
important in activating macrophages to increase their activity (Zhu and Paul., 2008). 
On the other hand, TH2 cells are responsible for the host’s defence against 
extracellular pathogens such as helminths.  TH2 cells produce a number of cytokines 
including IL-4, IL-5, IL-9, IL-10, IL-13 and IL-25. These cytokines play an 
enormous role in orchestrating and amplifying inflammatory pathways. IL-4, as well 
as being a major mediator of IgE class switching in B cells, is also a positive 
feedback cytokine for TH2 differentiation (Davies and O'Hehir, 2008). Furthermore, 
IL-5 plays a critical role in recruiting eosinophils to the site of infection while IL-9 
and IL-13 can stimulate mucin production in epithelial cells as well as recruit mast 
cells and lymphocytes (Longphre et al., 1999). Interestingly, many of the features of 
asthma such as bronchial hyperreactivity and goblet cell hyperplasia can be 
mimicked by administration of IL-13. Given the TH2 cytokines pathways, it is not at 
all surprising that the TH2 immune response is largely associated with allergy- driven 
responses and diseases such as asthma (Barnes, 2001). However, TH17 cells, 
believed to mediate immune responses against extracellular bacteria and fungi have 
also been implicated as potential mediators of the asthma response.  TH17 cells 
produce IL-17a, IL-17f, IL-21 and IL-22  (Maddur et al., 2012). Previously, IL-17 
has been shown to mediate the recruitment of neutrophils and activate airway smooth 
muscle cells and epithelial cells to induce pro-inflammatory mediators. Furthermore, 
in patients with asthma, IL-17a and IL-17f expression has been shown to be 
increased in lung: sputum, BAL fluid, and sera; these increases can also be correlated 
with the severity of airway hypersensitivity (Doe et al., 2010, Song et al., 2008, 
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Molet et al., 2001). Thus, while asthma is largely considered a TH2 driven 
inflammatory response, there is mounting evidence that TH17 cells may also 
contribute to and regulate airway inflammation.   
The TH cells play a major role in orchestrating the adaptive immune response and are 
extremely effective in protecting the host against invading pathogens. However, an 
over-stimulated TH2 and potentially TH17 immune response is observed in the 
asthma phenotype. The underlying cause of this skewed immune profile is yet to be 
determined. However, it has been hypothesised that these changes in the immune 
profile of asthmatics may be caused by environmentally influenced yet genetically 
heritable modifications known as epigenetic modifications.  
1.4.3 Airway Inflammation in Asthma 
It is clear that both the innate and adaptive immune system play crucial roles in 
stimulating the inflammatory response observed in an asthma exacerbation (Figure 1-
2). Following exposure to an allergen, individuals become sensitised. Allergens are 
detected by the epithelial cells which use mucociliary clearance techniques to prevent 
allergens from entering the host. At the same time, epithelial cells produce adhesive 
molecules (selectins) and cytokines/chemokines that recruit neutrophils and 
monocytes into the airway to act as phagocytes. Allergens that have managed to 
avoid mucociliary clearance and penetrate the epithelium are intercepted by the 
antigen-presenting cells: dendritic cells (Bousquet et al., 2000). The dendritic cells 
migrate to the regional lymph nodes and present the allergen peptides to residing B 
and T cells. IgE production is initiated by the B cells in the presence of TH2 
cytokines IL-4 and IL-13. Antigen specific IgE is released into the blood stream 
where it binds to high affinity IgE receptors (FсεR1) on mast cells and basophils, or 
low affinity IgE receptors, such as CD23, on dendritic cells, monocytes/macrophages 
and lymphocytes (Davies and O'Hehir, 2008). These cells rapidly release pro-
inflammatory mediators such as histamine, eicosanoids, and reactive oxygen species. 
These mediators act upon the airway smooth muscle to cause contraction and thus 
airway narrowing.  
It is also clear that the stimulation and continuous response of the innate and adaptive 
immune system occur via the rapid recruitment and activation of a number of pro-
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inflammatory proteins and adhesion molecules expressed by the immune cells 
themselves. The synthesis of these proteins within cells occurs via inducible gene 
expression. It has been hypothesised by researchers that the potential for these cells 
to over express inflammatory proteins may cause a heightened response to stimuli. 
Inducible gene expression is controlled through epigenetic modifications.  
 
 
Figure 1-2: Inflammation of the airways 
When allergens/stimulants enter the airway they encounter the respiratory epithelium. On 
recognition of the invading allergen, the epithelial cells produce a number of cytokines, 
chemokines, and selectins which recruit neutrophils, macrophages, and NK cells to the 
airways. If the invading allergen penetrates the epithelial barrier, they are detected by 
dendritic cells and taken to the lymph nodes. In the lymph nodes, naїve T cells recognise the 
invading allergen and the adaptive immune response is initiated. Figure was created using 
MOTIFOLIO© – Biomedical PowerPoint Tool Kits. 
 
1.5 EPIGENETICS 
Epigenetics refers to a change in a cells/organisms phenotype that is not encoded in 
the deoxyribonucleic acid (DNA) molecule itself (Cortessis et al., 2012). Despite 
identical DNA content, different cell types have distinct morphologies and functions. 
They also respond differently to external stimuli. This occurs because gene 
expression is regulated such that each cell type can determine which genes are active. 
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Furthermore, within individual cells genes are seldom expressed at constant 
unchanging levels. Rather, expression levels vary in response to environmental 
stimuli. Regulation of gene expression contributes to a cell’s phenotype (Igarashi, 
2005).  
While DNA contains the crucial instructions that make life, it does not run the 
operation of the cell. These instructions are read by a class of proteins known as the 
basal general transcriptional machinery which aid in the transcription of specific 
genes to produce complementary proteins. The entire process, from reading the DNA 
to translation of the protein, constitutes induced gene expression (Igarashi, 2005).  
Gene expression begins with enzymes and transcription factors gaining access to the 
DNA structure. Chromosomal DNA is packaged into a highly ordered structure 
known as chromatin and, as such, gaining access to DNA is tightly regulated. Thus, 
the first step in gene expression is to make the chromatin structure transcriptionally 
active (Urnov and Wolffe, 2001). Once proteins gain access to the DNA, the enzyme 
ribonucleic acid (RNA) polymerase II (pol II), can begin transcribing complementary 
RNA of the gene. When the complementary sequence is complete, the transcription 
process is terminated. The newly transcribed RNA is then further modified into 
mature messenger RNA (mRNA) prior to protein translation. This occurs through a 
number of processes which includes the addition of a Poly A tail to the RNA 
molecule. The Poly A tail consists of a stretch of adenine bases and aids in the 
protection of mRNA from degradation in the cytoplasm. Mature mRNA is then 
transported out of the nucleus and into the cytoplasm of the cell where it interacts 
with ribosomes which translates the mRNA by synthesising a complementary protein 
(Fig 1-3) (Igarashi, 2005). 
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Figure 1-3: Steps involved in gene expression 
1. Alteration in chromatin structure: RNA Pol II gaining access to the chromatin structure is 
a critical part of gene expression. 2. Initiation of transcription, 3. Transcription elongation 
4.Termination of transcription 5.Processing of RNA to mRNA; a. Capping, b. Cleavage, 
c.Polyadenylation, d. Splicing. 6. Nucleocytoplasmic transport 7. Translation to protein. 
Figure was created using MOTIFOLIO
©
 – Biomedical PowerPoint Tool Kits. 
Transcription does not occur on naked DNA but rather in the context of chromatin. 
The state and conformation of chromatin has a huge influence on the accessibility of 
transcriptional machinery to DNA (Urnov and Wolffe, 2001). Under light 
microscopy, chromatin is observed as a string of beads. The beads are an octomer of 
4 histone proteins — H2A, H2B, H3 and H4 — known as the core histone. Wrapped 
in a solenoid form around the core histone are 146 base pairs (bp) of DNA. 
Connections between each histone are made via joining DNA. Protruding from each 
histone core are N-terminal tails rich in lysines (K) that can be extensively modified 
by acetylation, methylation and phosphorylation (Strahl and Allis, 2000). 
Modifications to the N-terminal tail can affect the state and conformation of the 
chromatin making it more accessible to transcription machinery (Cortessis et al., 
2012, Igarashi, 2005). However, the transcription machineries ability to transcribe 
DNA does not solely rely on the conformation of the chromatin molecule but also on 
the methylation status of the DNA strands. Thus, DNA methylation, histone 
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modifications and chromatin remodelling are closely entwined and represent multiple 
layers of epigenetic modifications that control and modulate gene expression through 
chromatin structure.  
1.5.1 DNA methylation 
DNA methylation generally refers to the addition of a methyl group to the N5 
position of the cytosine ring of the DNA molecule. The methylation reaction occurs 
through the molecule s-adenosyl-L-methionine (SAM) which donates its methyl 
group to DNA. The reaction is catalysed by enzymes known as DNA 
methyltransferases (DNMTs). Methylation is often observed on CpG islands in 
DNA, where CpG islands refer to genomic regions with a high content of CpG sites. 
Three quarters of transcription start sites and 88% of active promoters are known as 
CpG rich sites (Tost, 2010). The hypermethylation of these sites are associated with 
gene silencing. The best known example of gene silencing is observed in females 
with the inactivation of the second X chromosome. DNA methylation patterns are 
necessary to maintain an inactive state of the second X chromosome and the 
silencing of its genes (Hysolli et al., 2012). Interestingly, studies have shown that 
methylated and silenced genes can be reactivated using DNA methylation inhibitors 
such as 5-azacytidine (Datta et al., 2009, Rao et al., 2007, Zheng et al., 2012). This 
suggests that while methylation may silence a number of genes, these genes can 
potentially be reactivated either by the cell itself or therapeutically.  
Asthma is both genetically and environmentally influenced; thus, it has been 
hypothesised that changes to the epigenetic profile of immune cells may cause the 
asthma phenotype.  DNA methylation is the most well studied area in the field of 
epigenetics. In asthma research, methylation studies have focused particularly on 
how methylation may influence TH2 driven inflammation. 
Rapidly accumulating evidence suggests that epigenetic mechanisms influence 
transcription factor binding and cytokine expression that control the TH1 and TH2 
lineage (Janson et al., 2009). In particular, extensive research into the expression of 
TH1 cytokine IFNγ and TH2 cytokines IL-4 and IL-13 uncovered DNA methylation 
as a major player in determining specific gene expression within these cells. Jones et 
al (2006) utilised mice to show that methylation of the IFNγ promoter inhibited the 
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ability of activating transcription factor 2 (ATF-2), cJun, and cAMP response 
element binding protein (CREB) transcription factors. The inhibition of ATF-2 and 
CREB lead to the suppression of IFNγ in TH2 cells (Jones and Chen, 2006). A paper 
by White et al (2006) investigated the regulation of TH1 in cord blood samples of 
children. Their results showed that CD4
+
 cells enhance the development of TH1 
through progressive demethylation of the IFNγ promoter. On the other hand, 
demethylation of IL-4 and IL-13 promoter regions has been shown to initiate a TH2 
profile (White et al., 2006). Furthermore, the loss of DNA methylation, combined 
with the increased association with activated histone marks, established an open 
chromatin configuration at the TH2 locus. This open chromatin formation allowed 
recruitment of transcriptional machinery to this locus which caused the rapid 
expression of TH2 cytokines (White et al., 2006).  
There is strong evidence that methylation of DNA plays a major role in 
differentiating naїve CD4+ cells into TH1 and TH2 cells. However, researchers 
investigating causes of asthma using human samples have been unable to identify 
significantly different methylation patterns that could potentially lead to an asthma 
phenotype.  This suggests that while methylation may be required for differentiation 
of naїve T cells into their TH1 and TH2 lineage, changes in DNA methylation of 
naїve T cells skewed towards the TH2 lineage may not be responsible for the asthma 
phenotype.   
However, DNA methylation is not the only way in which methylation influences 
gene expression within cells. Methylation of the histone tails at specific sites and 
residues can control gene expression by regulating accessibility to RNA polymerase 
II and transcription factors (Lan and Shi, 2009). Histone lysine (K) methylation has 
been found to occur at six major sites: histone 3 (H3), lysine 4 (K4), H3K9, H3K27, 
H3K36, H3K79 and H4K20 (Lan and Shi, 2009). Interestingly, lysine residues can 
be methylated to different degrees, such as, mono, di and trimethyl moieties (Lan and 
Shi, 2009). The degree of methylation in combination with which lysine is 
methylated have different functional consequences. For example trimethylation of 
H3K4 (H3K4me3) is strongly associated with transcriptional activation while 
H3K27me3 is strongly associated with gene silencing (Lan and Shi, 2009). An 
emerging paradigm for epigenetic regulation of gene expression is the relationship 
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between DNA methylation and histone modification. Previously the enzyme 
DNMT3L has been shown to bind to the N terminus of histone H3 tail (Hu et al., 
2009). DNMT3L recognises unmethylated H3 tails at lysine 4 and induces de novo 
DNA methylation by either recruiting or activating DNMT3A2 (Hu et al., 2009). The 
authors of these studies concluded that unmethylated lysine 4 at the N terminus of 
the histone H3 tail is a chromatin determinant for DNA methylation (Hu et al., 2009, 
Ooi et al., 2007). However, histone methylation doesn’t always influence DNA 
methylation. A recent study found that TGF-β2 suppresses expression of a 
disintegrin and metalloprotease 33 (ADAM33), an asthma susceptibility gene, in 
fibroblasts of healthy and asthmatic patients. This suppression occurred by altering 
chromatin structure through, deactylation of histone H3, demethylation of lysine 4 on 
H3 and hypermethyaltion of lysine 9 on H3, and not by gene silencing through DNA 
methylation as is observed in epithelial cells (Yang et al., 2012). Thus, epigenetic 
modifications can control gene expression through directly influencing DNA or via 
altering the chromatin structure through histone modifications.  While the 
relationship between DNA and histone methylation is thought to have a significant 
impact on epigenetic regulation, studies investigating the influences of these factors 
on the asthma phenotype have been inconclusive. However, there are a number of 
other epigenetic modifications that influence gene expression through altering the 
chromatin structure and these include histone acetylation.   
1.5.2 Acetylation 
Modifications to the chromatin structure affect the ability of transcription factors to 
bind to DNA. Histone acetylation is an epigenetic modification that directly alters the 
configuration of chromatin, and as such regulates transcription factor binding. 
Histone acetylation refers to the addition of an acetyl group to the protruding N-
terminal tails of the core histone (Figure 1-4). The addition of the acetyl group alters 
the formation of the chromatin structure and can turn it from heterochromatin (closed 
state) into accessible euchromatin (open state). The open state of chromatin grants 
transcriptional machinery access to the DNA, thus allowing gene expression to occur 
(Selvi and Kundu, 2009).  Acetylation of the histones is controlled by enzymes 
known as histone acetyltransferases (HATs) and histone deacetylases (HDACs).  
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Figure 1-4: HAT enzymes initiate histone acetylation pathways 
HAT enzymes acetylate lysine residues of the histones. This changes the conformation of 
heterochromatin to the transcriptionally accessible euchromatin. The open state of chromatin 
allows RNA pol II and transcription factors access to the DNA to begin gene transcription. 
Figure was created using MOTIFOLIO
©
 – Biomedical PowerPoint Tool Kits. 
 
Histone Acetyltransferases 
Histone Acetyltransferases (HATs) are enzymes that acetylate the lysine tail on 
histone proteins by transferring the acetyl group of acetyl CoA. The addition of an 
acetyl group to the lysine tails of histones result in important regulatory effects on 
chromatin structure, assembly and gene transcription. There are over 30 HATs 
identified thus far and these have been divided into five families: (1) General control 
non-depressible related acetyltransferase (GNAT) (Dyda et al., 2000), (2) MYST 
related HATs (Sapountzi and Cote, 2011), (3) p300/CBP HATs (Bedford et al., 
2010), (4) general transcription factor HATs and (5) Nuclear hormone related HATs 
(York and O'Malley, 2010). Within the core histone, there are several acetylation 
targets which HATs can acetylate: histone (H) 2A: Lysine (K) 5, on H2B: K5 and 
K12, on H3: K4, K9, K14, K23, K27 and finally on H4: K5, K8, K12 and K16 
(Strahl and Allis, 2000). Histone acetylation at H4K8 and H4K12 are a hallmark of 
inflammatory induction (Ito et al., 2000); however, the acetylation of other histone 
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lysine tails is also known to stimulate inflammatory genes (Rahman et al., 2004). 
Selective recognition of these acetylated lysines within the histone by other proteins 
containing bromodomains adds a further level of transcriptional regulation.  
There is accumulating evidence that HATs play a role in inducing and regulating 
inflammatory pathways. The HAT enzyme, CBP (Defined as: cyclic Adenosine 
Monophosphate (cAMP) responsive element binding protein (CREB), binding 
protein) is important in T cell development with the knockdown of CBP leading to a 
CD8
+
 T cell phenotype in mice (Kasper et al., 2006, Fukuyama et al., 2009). CBP 
and adenoviral protein E1A (p300) have been identified as important activators for 
initiating transcription of a number of pro-inflammatory cytokines as they interact 
with over 50 T-lymphocyte essential transcriptional regulators (Kasper et al., 2006).  
CBP and p300 belong to the same HAT family (group 3) and, as such, have been 
found to have several similar functions in initiating transcription. Interestingly, 
another HAT steroid receptor co-activator 1 (SRC-1) (group 5) has also been 
identified as a regulator of inflammatory cytokines. SRC-1 appears to have a clear 
relationship with CBP and p300 with several studies concluding that combined 
efforts of CBP, p300 and SRC-1 leads to optimal regulation of inflammatory genes 
(Sheppard et al., 1999, Sahar et al., 2007, Li et al., 2003). However, it should be 
noted that only one of the enzymes is required to utilise their HAT activity when 
found in this formation. 
HATs can influence gene expression in two ways: the first (discussed earlier) is by 
acetylating histone tails and altering the structure of chromatin which gives access to 
transcription factors; and the second is by acetylating and activating transcription-
related proteins themselves. For example, optimal binding of the inflammatory 
transcription factor nuclear factor kappa B (NF-κB) requires interactions with several 
co-activators including the HATs, SRC-1, p300, CBP and p300/CBP associated 
factor (P/CAF) (Sheppard et al., 1999). Furthermore, the HATs, GRIP1/TIF2 can 
further enhance the transcriptional activity of NF-κB (Chinenov et al., 2012). HATs 
are not only involved in the initiation of inflammatory gene transcription but are also 
required to attenuate inflammation. Kruppel-like factor 2 (KLF2) is a known 
inhibitor of the pro-inflammatory activation of monocytes. The expression of KLF2 
in monocytes is reduced by cytokine activation and differentiation. Using mice, Das 
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et al (2006) discovered KLF2 can operate via inhibiting transcriptional activity of the 
inflammatory transcription factors: NF-κB and activating protein 1 (AP-1). This 
inhibition occurred through the recruitment of the HAT, P/CAF (Das et al., 2006).   
Protein acetylation is a widespread, well-studied phenomenon among eukaryotes. 
There are two acetylation targets on proteins: the first is co-translational N
α–terminal 
acetylation. This is the most frequently observed protein modification. The second is 
acetylation on the ε-amino group of lysines. While the latter modification is less 
common, it is known to affect protein function, half-life and proteins associated with 
other molecules. It has been hypothesised that acetylation of the ε-amino group of 
lysines may have profound effects on inflammatory status (Glozak et al., 2005). 
Furthermore, as this acetylation is highly reversible it provides an attractive 
therapeutic target. One of the most effective treatments of inflammatory driven 
diseases such as asthma is the use of corticosteroids. The corticosteroid 
dexamethasone (DEX) induces acetylation of H4K5 in CD4
+
 cells. A study 
performed by Li et al (2007) utilised human peripheral blood mononuclear cells 
(PBMCs) to evaluate the cell type specific response to steroids in an effort to 
determine mechanisms of steroid insensitivity. Interestingly, when comparing CD4
+
 
and CD8
+
 cells stimulated by IL-10 and mitogen-activated protein kinase 
phosphatise (MAPKP), DEX had no effect on the expression of HATs: SRC-1, p300 
and TIP60. However, the inhibition of the HAT ATF-2 lead to inhibition of DEX 
induced transactivation in CD4
+
 cells (Li et al., 2007).  
The literature suggests that HATs play a dynamic and important role in regulating 
the immune response. Not only can they directly induce gene expression via binding 
to lysine tails of histones but they can also act indirectly via acetylating and 
activating transcription factors. Activation of the transcription factor allows the 
protein to shuttle from the cytoplasm to the nucleus where it can bind to DNA to 
begin gene transcription. HATs are also recruited by other molecules to inhibit pro-
inflammatory responses. Thus, the regulation of these enzymes within immune cells 
may have important implications on the inflammatory response.  
Histone Deacetylases (HDACs) 
Where HATs are associated with activating gene expression, histone deacetylases 
(HDACs) are associated with repression of gene expression. HDACs are the 
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enzymes that remove the acetyl group from the ε-N-acetyl lysine tails of the core 
histone. The removal of the acetyl group allows the DNA to wrap around the 
histones, transforming the open euchromatin, into its closed heterochromatin state 
(Figure 1-5). HDACs generally exist as part of a multi-subunit complex with a co-
repressor. Aside from transforming euchromatin into heterochromatin, removing the 
acetyl group from the histone lysine tails also removes the docking sites for 
transcription factors (Shakespear et al., 2011). Thus far, 18 HDAC enzymes have 
been identified and divided into four classes: Class I: HDAC 1-3 and 8; Class II: 
HDAC 4-7 and 9-10, Class III: SIRT 1-7 and Class IV: 11 (Shakespear et al., 2011). 
The class I HDACs are widely expressed but localized mainly in the nucleus whereas 
class II, although more restricted in their distribution, shuttle between the cytoplasm 
and the nucleus. Where the HDACs reside in the cell is important as they need to be 
in the nucleus to deacetylate histones. Like HATs, HDAC enzymes participate in the 
transcriptional regulation of both pro- and anti-inflammatory cytokines. The pro-
inflammatory cytokines IL-1, IL-2, IL-8 and IL-12 have been shown to be regulated 
by histone acetylation. The IL-8 promoter is rapidly acetylated by p300 and this is 
accompanied by a brief decrease in HDAC1 and HDAC5 enzymatic activity. As 
HDAC1 and HDAC5 are shortly recruited back to the promoter region after gene 
induction, evidence suggests these enzymes are involved in repressing IL-8 gene 
expression (Schmeck et al., 2008). Similar to IL-8 production, IL-12 also appears to 
be activated by p300 and deactivated by HDAC1 (Lu et al., 2005). Furthermore, 
HDACs are reported to be involved in the regulation of IL-2 which is involved in the 
differentiation and homeostasis of T cells. Interestingly, the over expression of 
HDAC1 leads to the inhibition of IL-2 production (Kametani et al., 2008, Tenbrock 
et al., 2006, Wang et al., 2009).  
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Figure 1-5: HDAC enzymes repress histone acetylation pathways 
HDAC enzymes remove the acetyl groups from the lysine tails of histones. This alters the 
conformation of the chromatin causing it to close, and thus preventing transcriptional 
machinery access to its DNA. Figure was created using MOTIFOLIO© – Biomedical PowerPoint 
Tool Kits. 
 
As well as pro-inflammatory cytokine regulation, HDACs are involved in the 
regulation of anti-inflammatory cytokines. Interleukin 10 (IL-10), a cytokine 
involved in inhibiting inflammatory responses, is regulated by HDAC11 (Villagra et 
al., 2009a).  HDAC11 down regulates IL-10 transcription in murine and human 
APCs by interacting at the chromatin level with the distal region of the IL-10 
promoter. This effect may explain, at least partially, the flexibility of the APC to 
determine T cell activation versus T cell tolerance (Villagra et al., 2009a). 
Like HATs, HDACs possess substrate specificity and accumulating evidence 
suggests that many HDACs can deacetylate non-histone proteins. In unstimulated 
cells, HDAC1 is known to bind to the p50 subunit of NF-κB to repress the 
transcription of NF-κB target genes (Elsharkawy et al., 2010). On the other hand, 
HDAC3 deacetylates the p65 subunit of NF-κB causing it to bind to IκBα leading to 
its nuclear export. This process terminates NF-κB activity and recycles protein 
components to the cytoplasm for new rounds of activation (Kiernan et al., 2003).  
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The third class of HDACs — the atypical nicotinamide adenosine dinucleotide-
(NAD)-dependent sirtuins, commonly known as SIRTs — are notable for their non-
histone protein interactions (Sauve and Youn, 2012). SIRTs have been shown to 
promote longevity in several model organisms and in mammalian cell cultures 
(Morris, 2012). The deacetylase activity of SIRTs consists of the removal of a lysine 
linked acetyl group from the target protein. During sirtuin mediated deacetylation, 
the NAD molecule is hydrolysed releasing a metabolite resulting from the 
condensation of the acetyl group with ADP-ribose of NAD. The other component of 
NAD, nicotinamide, also releases and acts as an end-product inhibitor of the 
deacetylation reaction (Sauve and Youn, 2012). There are seven members of the 
sirtuin family: SIRT 1, 6 and 7 reside in the nucleus, SIRT 2 in the cytoplasm, while 
SIRT 3, 4 and 5 reside in the mitochondria. The sirtuin enzymes are known to 
deacetylate and regulate the function of transcription factors; in particular, the 
inflammatory transcription factors NF-κB and AP-1 (Yeung et al., 2004, Gao and 
Ye, 2008, Zhang et al., 2010).  
SIRT 1 is a negative regulator of NF-κB activity through the deacetylation of p65 at 
lysine 310 (Yeung et al., 2004). This is further substantiated with the observation 
that reduction of SIRT1 leads to NF-κB dependent prolonged inflammation in 
several distinct cell lines. SIRT1 also deacetylates both dimers of the inflammatory 
transcription factor AP-1 resulting in the attenuation of an inflammatory profile (Gao 
and Ye, 2008, Zhang et al., 2010). In macrophages, SIRT1 activation decreases the 
transcription of the inflammatory protein COX-2, which is typically regulated by 
AP-1 (Zhang et al., 2010). Like SIRT1, SIRT6 also regulates NF-κB pathways; 
however, unlike SIRT1, instead of interacting directly with NF-κB, SIRT6 appears to 
interfere with its transcriptional activity. SIRT6 deacetylates H3K9 on the promoter 
of selected NF-κB target genes decreasing NF-κB accessibility to its target genes 
(Kawahara et al., 2009). Interestingly, there is evidence that the SIRT1 and SIRT6 
enzymes have compensatory roles. Schug et al (2010) demonstrated macrophages 
deficient in SIRT1, function relatively normally as SIRT6 appears to compensate for 
the loss of SIRT1 function. 
The SIRTs may also play a role in the induction of pro-inflammatory cytokine 
expression in both the innate and adaptive immune cells. A study demonstrating 
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decreased intracellular NAD levels, obtained by inhibiting enzyme activity of 
Nampt, resulted in decreased secretion of the cytokines TNF-α, IL-6 and/or IFNγ by 
immune cells. This result was considered to be SIRT mediated as the use of SIRT 
inhibitors gave reproducible results. When investigated further, SIRT6 appeared to 
positively regulate TNF-α and IFNγ production (Van Gool et al., 2009, Bruzzone et 
al., 2009). 
Histone acetylation and its associated HAT and HDAC enzymes clearly contribute to 
the immune response. A delicate balance between HAT and HDAC activity is 
believed to regulate a proportioned immune response. Thus, an imbalance between 
these enzymes during a basal state may lead to the later development of 
inflammatory diseases. 
1.5.3 Histone Acetylation and Asthma 
There is growing evidence that inflammatory cytokine and chemokine gene 
expression is induced by histone acetylation. Whether or not an imbalance in the 
expression of these cytokines contributes to an asthma phenotype is largely 
unknown. As histone acetylation is controlled by the enzymes HATs and HDACs, 
asthma research in this area largely focuses on the expression and mechanisms 
through which these enzymes operate.  
The protein expression of HDAC1 and HDAC2 are reported to be decreased in 
bronchial biopsies of individuals with asthma (Ito et al., 2002a).  However, a 
separate study reports a decrease in HDAC1 but not HDAC2 expression in alveolar 
macrophages between asthma and healthy individuals (Cosio et al., 2004). 
Surprisingly, HDAC1 expression in PBMCs between the two groups was not found 
to be significantly different. The different expression levels observed in the blood 
monocytes, and alveolar macrophages from asthma patients suggest that changes in 
HDAC1 expression may be localized to the airways (Cosio et al., 2004). Yet 
contrary to this study, Hew et al (2006) investigated steroid insensitivity in severe 
asthma and reported reduced HDAC activity in PBMCs. The reduction in HDAC 
activity is inversely correlated with cytokine expression; the lower the HDAC 
activity the greater the steroid insensitivity and the higher the cytokine expression. 
The same study also reported an increase in HAT expression after LPS induced 
30 
 
cytokine release. This HAT expression correlated strongly with the expression of 
cytokines: GM-CSF, IL-10, IL-1β, IL-6, IL-8, TNF-α and MIP-1α in PBMCs (Hew 
et al., 2006). Interestingly, despite slightly opposing results all of these studies report 
reduced HDAC activity and an increase in overall HAT activity within the airways of 
individuals with asthma when compared to healthy controls (Ito et al., 2002a, Cosio 
et al., 2004, Hew et al., 2006).  At present, evidence within humans suggests a role 
for these enzymes in the asthma phenotype, but the enzymes responsible remains 
unclear.  
HDAC expression has also been investigated as a possible cause for other airway 
inflammatory diseases such as pneumonia, cystic fibrosis and chronic obstructive 
pulmonary disease (COPD). These investigations revealed that changes were 
observed in the expression of HDAC enzyme activity and expression only in 
individuals with COPD (Ito et al., 2005). As COPD and asthma are environmentally 
influenced, the finding suggests that the expression of HDAC enzymes may also be 
influenced by external environmental stimuli which can cause individuals to present 
with disease.  HDAC activity was significantly decreased in severe forms of COPD. 
As the disease became more severe HDAC activity decreased accordingly (Ito et al., 
2005). Unlike asthma, lung tissues from COPD patients indicated reduced mRNA 
expression of several HDAC enzymes including HDAC2, HDAC5 and HDAC8. The 
development of COPD is strongly associated with chronic smoking, as is severe 
asthma.  The decreased expression of HDAC2 within the airways appears to be 
common within the two diseases.  This could suggest that HDAC2 is directly 
influenced by the external environment, whereas other HDAC enzymes such as 
HDAC1 in asthma and HDAC5 and HDAC8 in COPD maybe more disease specific. 
Greater insight into how HAT and HDAC enzymes influence molecular mechanisms 
and regulate inflammatory pathways has been gained through the use of airway cell 
lines and ‘asthma’ animal models.  One study utilising an epithelial cell line (BEAS-
2B) has shown that environmental exposure to diesel fumes causes an increase in the 
expression of the inflammatory protein COX2. The increased expression is caused by 
an increase in acetylation of H4 at the COX2 promoter region. However, while 
acetylation of H4 required increased binding of the HAT p300 and RNA pol II, 
increased expression of COX2 appeared to be due to the inhibition of HDAC 
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proteins rather than an increase in HAT activity.  Knockdown experiments reveal 
that the inhibition of HDAC1 causes increased transcriptional activity of the COX2 
gene (Cao et al., 2007). A separate study utilising human alveolar adenocarcinoma 
cells (A549 cells) investigated how the transcription factors NF-κB and AP-1 
mediated IL-1β induced TGF-β1 expression. The experiment revealed that the p65 
subunit of NF-κB and the cJun subunit of AP-1 are recruited to the TGF-β1 promoter 
region after IL-1β stimulation. Gene expression was induced by the acetylation of the 
histones H3 and H4. The addition of the HDAC inhibitor trichostatin A (TSA) 
amplified the induced TGF-β1 mRNA expression suggesting that histone acetylation 
indeed plays a key role in the induction of TGF-β1 gene expression (Lee et al., 
2006).  
In similar experiments, Clarke et al (2010) utilised human airway smooth muscle 
(HASM) cells to determine how IFNγ and TNF-α induce the expression of the 
inflammatory chemokines CXCL10. The two inflammatory cytokines synergistically 
induced the expression of the chemokine CXCL10. Despite the synergy causing 
increases in the binding of CBP to the CXCL10 promoter, no increased effect on the 
acetylation status of histone H3 or H4 was observed (Clarke et al., 2010).   These 
results are contrary to previous studies performed by the same group. Their previous 
studies showed enhanced acetylation of H4 caused an increased expression of the 
inflammatory genes CCL11 and CXCL8 (Nie et al., 2003, Zhu et al., 2003, Nie et 
al., 2005b). Increased acetylation of inflammatory genes may be caused by either 
increased HAT enzyme activity, or the inhibition of HDAC enzymes. The evidence 
thus far suggests that the latter is more likely responsible for prolonged inflammation 
in airway disease. 
Investigations into the mechanisms through which histone acetylation may contribute 
to an asthma phenotype have been studied in a number of mouse models of asthma. 
These studies have largely focused on the adaptive immune system and the role of 
HAT and HDAC enzymes in regulating TH1 and TH2 immune pathways. Studies 
focusing on the role TH2 cytokines play in asthma have determined that the TH2 
locus control region (LCR) is essential for the pathogenesis of allergic asthma, at 
least in an animal model. The expression of the TH2 cytokines, IL-4, IL-5 and IL-13 
were found to be greatly reduced in the lungs of TH2 LCR knockout mice and these 
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cytokines were regulated by H3 and H4 acetylation and methylation (Koh et al., 
2010).   
A separate study utilized a HDAC1 knockdown model to determine the effects 
HDAC1 depletion would have on T cell development (Grausenburger et al., 2010). 
While the deletion of HDAC1 had no effect on T cell development, an increase in the 
expression of HDAC2 but no other HDAC enzymes was observed in the CD4
+
 and 
CD8
+
 T cells of HDAC1 deficient mice. When exposed to ovalbumin (OVA), an 
asthma phenotype was observed in HDAC1 deficient mice; where an asthma 
phenotype was defined as an increase in inflammatory cells, mucus hypersecretion 
and airway resistance.  Furthermore, HDAC1 deficient mice showed increased T cell 
proliferation under TH2 conditions.  The swing towards the TH2 profile is potentially 
caused by HDAC1 regulation at the activated IL-4 locus. There are multiple 
recruitment sites for HDAC1 along the IL-4 gene locus and surrounding cytokine 
genes (Grausenburger et al., 2010).  
Despite the belief that deacetylases act to prevent gene expression and thus attenuate 
an inflammatory response, there is evidence that the 3
rd
 Class of HDAC enzymes 
(Sirtuins) may contribute to enhanced inflammation within the airways.  Kim et al 
(2010), using C576/BL mice, observed that after an OVA challenge SIRT1 was 
increased in the lungs and airway epithelium of sensitised mice. This increase 
production of the SIRT1 enzyme was accompanied by an inflammatory profile which 
included increased vascular endothelial growth factor (VEGF) production and 
increased TH2 cytokine levels, 72 hrs after OVA inhalation. The use of the universal 
sirtuin inhibitor sirtinol reversed SIRT1 expression and decreased the increased 
VEGF levels. The administration of  sirtinol also reduced the observed increase in 
cytokine expression, as well as reducing airway hyperresponsiveness of the OVA 
stimulated mice (Kim et al., 2010).  
It is well known that environmental triggers (pollen, dust, animals, smoking etc.) are 
major causes of asthma exacerbations. However, microbial exposures during early 
life development, particularly in farm settings, have been linked to asthma protection 
at later stages in life. It has been suggested that this protection could be potentially 
mediated by epigenetic modifications. A recent study which utilised a mouse model 
of asthma reported prenatal exposure to bacterial pathogens prevented the 
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presentation of an asthma phenotype in the progeny and this protection was mediated 
through H4 acetylation (Brand et al., 2011).  
1.5.4 Histone Acetylation as a Therapeutic Target 
Asthma can be a well-managed disease. Current therapies such as inhaled 
corticosteroids and β2 agonists have proven to be effective in improving the quality 
of life for a number of asthma sufferers (GINA, 2011). Corticosteroids and β2 
agonists target both inflammation and constriction of the airways. However, there 
exists a subset of patients who don’t respond to these therapies and, as such, effective 
management and care of these patients can be difficult (in't Veen et al., 1999, Spahn 
et al., 1997). There have been major advances in understanding the molecular 
mechanisms through which corticosteroids and β2 agonists act. Accumulating 
evidence suggests that histone acetylation pathways are key modulators of the 
effectiveness of corticosteroids in controlling inflammation and corticosteroid 
insensitivity.  
Glucocorticoids control inflammation by inducing anti-inflammatory responses and 
suppressing pro-inflammatory responses. As glucocorticoids enter the airway they 
diffuse across the cell membrane and bind to the glucocorticoid receptor (GR). When 
the ligand binds to GR, GR is released and is rapidly translocated to the nucleus. 
Once GR has entered the nucleus it binds to the glucocorticoid responsive element 
(GRE), in the promoter regions of glucocorticoid responsive genes (Barnes, 2010). 
The DNA bound GR then interacts with co-activator molecules, some of which 
possess HAT activity, to induce or suppress gene transcription. One mechanism by 
which glucocorticoids act is via inhibiting histone H4 acetylation of the 
inflammatory genes: eotaxin, IL-8 and GM-CSF (Kim et al., 2009, Nie et al., 2005b, 
Nie et al., 2005b, Ito et al., 2000). Interestingly, while there is substantial evidence 
suggesting that glucocorticoids suppresses inflammation through the inhibition of H4 
acetylation, the role of specific HATs within the pathways remain unknown. While 
researchers have hypothesized that the HATs, P/CAF and CBP may play a role in 
orchestrating glucocorticoid actions, the experimental results suggest otherwise. A 
number of studies found that CBP and P/CAF, while necessary for gene action, 
appear not to contribute to the asthma phenotype, or the effectiveness of steroid 
medication (Kasper et al., 2006, Bedford et al., 2010, Fukuyama et al., 2009, Lim et 
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al., 2011a). It is only in the absence of HDAC activity that glucocorticoids have been 
able to suppress CBP associated histone acetylation (Ito et al., 2000).  The evidence 
supports conclusions drawn from previous studies which indicate that rather than an 
increase in HAT activity the lack of HDAC activity could be causal of the 
inflammatory response.  
A major mechanism through which glucocorticoids are known to attenuate 
inflammation is via the recruitment of HDAC2 to the activated inflammatory gene 
complex which then effectively suppresses inflammatory gene expression (Figure 1-
6) (Ito et al., 2006). Decreased levels of HDAC2 expression appears to be correlated 
with steroid insensitivity (Adenuga et al., 2009, Butler et al., 2011, Li et al., 2010).  
Several studies have identified decreased HDAC2 levels to be associated with 
smoking, oxidative stress and steroid insensitivity (Meja et al., 2008, Mercado et al., 
2011, Ito et al., 2002a, Ito et al., 2005). Studies in cell lines have previously reported 
glucocorticoids as inducers of HDAC2 expression. However, animal models suggest 
that while glucocorticoids effectively suppressed HAT, NF-κB activity, and pro-
inflammatory mRNA cytokine expression, HDAC2 levels are not restored (Ito et al., 
2008).  
Reduced HDAC2 levels appear to be strongly associated with corticosteroid 
insensitivity and, as such, restoring HDAC2 levels have gained interest as a possible 
therapeutic target to improve corticosteroid sensitivity. Theophylline, a potent β2 
agonist, appears to have some ability to restore HDAC2 levels. On its own, 
theophylline has been shown to increase HDAC1 expression and overall HDAC 
activity but have no effect on HDAC2 expression (Ito et al., 2002b). However, as a 
combined therapy, theophylline/corticosteroid is effective in attenuating the 
inflammatory response in vitro. In agreement with these findings, a separate study 
found that theophylline combined with corticosteroids restored the corticosteroids 
ability to suppress H4K8 acetylation. Interestingly, despite the promising in vitro 
data, the clinical therapeutic benefits of theophylline/corticosteroids are yet to be 
observed.  
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Figure 1-6: Corticosteroids recruit HDAC2 to attenuate airway inflammation 
Corticosteroids, bind to the glucocorticoid receptor, and translocates to the nucleus. It then 
recruits HDAC2 to the active transcription site to deacetylate lysine tails, and thus prevent 
transcription of inflammatory genes. Figure was created using MOTIFOLIO© – Biomedical 
PowerPoint Tool Kits. 
 
Recently, inhibitors of Phosphoinositide 3-kinase (PI3K) (a family of enzymes that 
play an essential role in the physiological reactions of inflammatory cells) have been 
shown to reverse corticosteroid insensitivity under conditions of oxidative stress. The 
inhibition of PI3Kδ involved the restoration of HDAC2 and glucocorticoid 
sensitivity in asthma mice models (Mercado et al., 2011).  
β2 agonists also may act through histone acetylation pathways to control 
inflammation and constriction of the airways. β2 agonists activate signalling 
pathways via PPARγ which leads to the inhibition of TNF-α induced eotaxin 
production. A study has reported that when PPARγ agonists, glucocorticoids, and β2 
agonists are used in combination, they additively and transcriptionally inhibit TNF-α 
induced eotaxin expression in human airway smooth muscle (HASM) (Nie et al., 
2005a). Furthermore, it appears that all three biomolecules suppress eotaxin 
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expression via the inhibition of histone H4 acetylation and prevention of the p65 
subunit of NF-κB binding to the eotaxin promoter. 
Corticosteroids bind to the GR in the cytoplasm and then these bound complexes are 
translocated to the nucleus, to exert their effects. However, there are two GR isotypes 
— GRα and GRβ — which have quite separate functions (Pujols et al., 2007). 
Glucocorticoids bind to GRα in the cytoplasm and the complex is translocated to the 
nucleus, whereas GRβ interacts with DNA directly and does not associate with 
glucocorticoids. Thus theoretically, GRβ could inhibit the effects of glucocorticoids 
by competing with GRα binding sites.  
Studies have shown that GRβ reduces HDAC2 mRNA levels but not HDAC1 and 
silencing the GRβ levels caused significant increases in HDAC2 gene expression but 
not HDAC1 gene expression (Butler et al., 2011). Studies have revealed that GRβ is 
not highly expressed in the epithelium (Vazquez-Tello et al., 2010, Pujols et al., 
2003). The over expression of GRβ in the airway epithelium in severe asthmatics 
may be another contributor to corticosteroid insensitivity.  
There is an established role for HDAC2 in the mechanistic pathways of 
glucocorticoids. However, glucocorticoids function through a number of pathways, 
and at present the effort to restore HDAC2 levels has not been clinically beneficial to 
patients suffering from corticosteroid insensitivity.  Thus, other HAT and HDAC 
enzymes may play significant roles in the anti-inflammatory mechanisms targeted by 
glucocorticoids. Alternatively, HAT and HDAC enzymes may attenuate 
inflammatory pathways that glucocorticoids do not target. More global HAT and 
HDAC experiments need be performed in humans to determine which, if any, of the 
histone acetylation enzymes are directly involved in the asthma phenotype and 
corticosteroid insensitivity.   
HDAC Inhibitors (HDACis) 
It is clear that reduced HDAC activity is associated with increases in 
inflammatory parameters within the airways. HDAC2 is a critical component of 
corticosteroid anti-inflammatory action (Barnes, 2009a); this observation is further 
corroborated by the observation that reduced HDAC2 levels in airways are 
associated with steroid resistance in patients suffering from COPD and severe asthma 
37 
 
(Biswas and Rahman, 2008, Butler et al., 2011, Ito et al., 2000, Li et al., 2010, Meja 
et al., 2008). Thus, it is not surprising histone deacetylases have been suggested as 
possible drug targets for pulmonary cancer and inflammatory lung diseases.  
However, what is surprising is the interest and focus on the use of HDAC inhibitors 
(HDACis) as a potential therapeutic option for asthma (Royce et al., 2012b). Several 
studies have utilised animal models to investigate the effects HDACis such as: 
Trichostatin A (TSA) (inhibits Class I and II HDACs), Valproic acid (inhibits class I 
and II HDACs) and Sirtinol (inhibits Class III HDACs), have on the underlying 
pathways associated with asthma. Whether HDAC inhibition is pro or anti-
inflammatory is contestable. To date ‘asthma’ animal studies report contradictory 
results; several studies report HDACis’s as having an anti-inflammatory affect in an 
animal’s airways (Royce et al., 2012a, Dombrowsky et al., 2009, Assem el et al., 
2008, Choi et al., 2005), while other studies suggest the use of such inhibitors have 
no affect on the inflammatory response (Banerjee et al., 2012, Royce et al., 2011).  
As discussed earlier asthma is a complex disease that is caused by four major 
underlying biological responses: airway hyper responsiveness, bronchial constriction, 
excess mucus production and airway inflammation (Bousquet et al., 2000).  Airway 
inflammation is considered the primary component that causes the airway 
obstruction in asthma however; these secondary responses also play a significant role 
in causing airway obstruction. Thus, it has been suggested that a need for a new 
asthma therapy that concurrently addresses airway hyperresponsiveness, loss of lung 
function and airway inflammation is required. While the effective use of HDACis to 
target airway inflammation is debatable, there is strong evidence that HDACis can 
prevent airway hyperresponsiveness and airway remodelling in asthma.  Several 
studies utilising a variety of animal models (rat, mouse and guinea pig) have shown 
that HDACis reduce airway remodelling, airway hyper responsiveness and airway 
muscle contraction (Royce et al., 2011, Royce et al., 2012a, Banerjee et al., 2012, 
Dombrowsky et al., 2009, Assem el et al., 2008, Choi et al., 2005).  Royce et al 
(2012) demonstrated that TSA significantly reduced airway remodelling in OVA 
treated mice. Furthermore, TSA attenuated airway hyperresponsiveness in these mice 
at the highest methacholine dose received. While a separate study showed that TSA 
inhibited, methacholine induced increases in lung resistance and inhibited the 
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intracellular release of Ca
2+
 is airway smooth muscle cells in response to histamine 
(Banerjee et al., 2012). These studies suggest that the use of TSA could potentially 
prevent bronchoconstriction of the airways.  TSA is not the only HDACis that has 
been shown to influence airway remodelling. Valproic acid reduces epithelial 
thickness and sub-epithelial collagen deposition, as well as attenuates airway 
hyperresponsiveness in the airways (Royce et al., 2011).  
While increasing HDAC expression in the airways may attenuate inflammation, 
inhibiting HDAC levels in the airway may reduce airway hyperresponsiveness, 
bronchoconstriction and airway remodelling. The literature highlights the importance 
of understanding which HDACs are involved in causing specific airway responses.    
1.6 AIRWAY FLUID SAMPLING 
There are a number of techniques which are used by researchers to obtain airway 
samples to investigate the inflammatory response of asthma. Samples obtained from 
the airway include: Bronchial alveolar lavage (BAL) samples, bronchial tissue 
samples, tracheal aspirates, pleural fluid and induced sputum.  
A BAL sample is obtained by wedging a bronchoscope into the segmental or sub-
segmental bronchus. A volume of saline ranging between 100 – 400 mL is instilled 
into the airway and the fluid is then aspirated back from the airways using gentle 
suction. Bronchial biopsies are obtained usually after a BAL sample; the procedure 
involves tiny forceps (cupped fenestrated forceps) being passed down the 
bronchoscope into the segmental or sub-segmental bronchus. The patient is asked to 
breathe out slowly and a small sample of lung tissue is collected. The procedure is 
repeated several times until an appropriate amount of lung tissue is obtained (Looi et 
al., 2011).  
Tracheal aspirates are obtained via inserting a catheter into the endotracheal tube for 
a short distance. Using gentle suction, mucus and or instilled fluid is aspirated out. 
On the other hand, a pleural fluid sample is taken via a procedure known as a 
thoracentesis. This is where the pleural fluid is removed from the pleural cavity using 
a needle and syringe (McCullough and Brinson, 1999, Shields and Riedler, 2000). 
All of these airway samples are beneficial in providing key insights into the 
inflammatory processes of airway diseases. BAL samples contain inflammatory cells 
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such as macrophages, eosinophils, and a low number of neutrophils as well as large 
numbers of inflammatory cytokines. Bronchial biopsies allow investigation of the 
epithelium, basement membrane and submucosa of the airway while bronchial 
brushing allows for the thorough investigation of epithelial cells. However, these 
procedures while relatively safe are invasive and require some form of anaesthetic. 
Consequently, recruiting volunteers to participate in research studies using these 
methods can be difficult.  
Within the last twenty years, sputum samples have been utilised as a less invasive 
technique to assess airway inflammation. Induced sputum samples are obtained via 
individuals breathing in aerosolised hypertonic saline. The hypertonic saline causes 
an osmotic change in the airways that allows inflammatory cells to be easily drawn 
through the airways via coughing. The sputum samples are then expectorated from 
the patient into a specimen container (Pavord et al., 1997). Sputum samples contain 
inflammatory cells and proteins from the innate immune system and are similar to 
that of BAL fluid samples (Silkoff et al., 2003). However, it should be noted that 
there is a difference in the number of neutrophils between the two samples; with 
BAL samples typically containing lower neutrophil numbers compared to the 
moderate numbers observed in induced sputum samples (Silkoff et al., 2003). 
Furthermore, unlike bronchoscopy, airway structural information is not available for 
sputum induction, as there is no easy way to determine where exactly in the airways 
the sputum sample has come from (Jeffery et al., 2003). Nonetheless, previous 
studies have revealed that sputum samples largely come from the central airways 
(Alexis et al., 2001, Lay et al., 2011).  
Induced sputum samples are an accepted non-invasive technique to collect airway 
fluid samples. The inflammatory cells and cytokines are similar to that of BAL 
samples and the technique is less invasive which increases subject participation rates 
substantially.  
1.7 SUMMARY 
Asthma is a disease that is both environmentally and genetically driven. As the world 
becomes more industrialised, the incidence of asthma is expected to increase 
significantly. Inflammation of the airways appears to be the primary cause of airway 
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obstruction. This inflammation is controlled and regulated by both the innate and 
adaptive immune system through the expression of a number of pro-inflammatory 
cytokines and chemokines. The expression of these genes is potentially controlled by 
epigenetic modifications that have a direct influence on the chromatin structure in 
which DNA is found within the cell. As epigenetic modifications can be influenced 
by internal and external stimuli, changes to the epigenome of a gene as a possible 
cause for complex diseases has become a growing area of interest in research. While 
changes in methylation status of DNA are yet to reveal key asthma pathways, 
research into histone acetylation has produced some promising results. However, 
changes in the expression of these enzymes between healthy and asthma individuals 
are yet to be fully elucidated.   
Despite the innate immune system initiating the inflammatory response, research has 
largely focused on the role of key enzymes in regulating the adaptive immune 
response in asthma. Specifically, research focuses on the skewing of the TH1/TH2 T 
cells towards a TH2 profile and how histone acetylation may contribute to this 
phenotype. Changes in epigenetic regulation that could potentially affect the innate 
immune system are yet to be elucidated. Furthermore, as epigenetic modifications 
can be influenced via external and internal stimulants whether or not the changes 
observed within an epigenetic profile are a cause of disease or a consequence of the 
symptoms of the disease, is yet to be established. Thus, this project was designed to 
investigate changes in HAT and HDAC gene expression in induced sputum samples 
of individuals with and without asthma. Furthermore, it was designed to determine if 
induced inflammation could alter the expression of these HAT and HDAC enzymes.  
1.8 AIMS AND HYPOTHESES 
1.8.1 Hypothesis 
Increases in the production of inflammatory proteins via inflammatory cells 
contribute to the chronic inflammation observed in asthma airways. This increased 
production of inflammatory proteins is controlled in part, by histone acetylation 
pathways.  The acetylation equilibrium is mostly maintained through the physical 
and functional interplay of HAT and HDAC enzymes. As such, it is hypothesised 
that an imbalance of the acetylation equilibrium within innate immune cells is caused 
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by the dysfunction of HAT and HDAC enzymes. Furthermore, the expression and 
activity of HAT enzymes will be increased while HDAC enzyme expression and 
activity will be decreased, in innate immune cells from asthma airways. In addition it 
is hypothesised that the use of corticosteroid medication attenuates inflammation, in 
part, by altering HAT and HDAC enzyme expressions levels.  
1.8.2 Aims 
The hypothesis was addressed through the following aims: 
 Determine the mRNA expression of HATs p300, CBP, P/CAF, SRC-1, 
ATF-2, TIF-2, HDACs 1-6 and SIRT 1-6 as well as total HAT and HDAC 
activity in induced sputum samples of individuals with asthma who are 
treating with bronchodilators only, and healthy controls.  
 Determine if mRNA and protein expression of HAT and HDAC enzymes 
are differentially expressed in the airways of individuals treating their 
asthma with bronchodilators and inhaled corticosteroids.  
 Determine if induced inflammation of the airways alters the expression of 
these HAT and HDAC enzymes within the airways. 
 Determine if HAT and HDAC enzymes influence airway inflammation via 
the inflammatory transcription factors NF-κB and AP-1.  
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CHAPTER 2: MATERIALS AND METHODS 
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Throughout this project a number of molecular and cellular biology techniques 
were utilised; this chapter describes in detail the common methods used. Specific 
experimental parameters and techniques have been described in subsequent chapters. 
General laboratory items and materials were supplied by Lab Advantage (VWR, 
Murarrie, Queensland, Australia). 
2.1 SUBJECT RECRUITMENT 
2.1.1 Human Ethics Approval 
Subject recruitment for the participation in this study was approved by the 
Queensland University of Technology’s Human Research Ethics Committee 
(No.0800000179). 
2.1.2 Sample Size 
To determine the number of subjects required for detection of significant 
changes in enzyme expression between healthy and asthma individuals, sample size 
calculations were performed. Given the lack of experimental research using human 
participants in this field, data from the literature could not be used as a guide for 
these calculations. Thus, sample size calculations using the Student T-Test were 
performed adhering to general sample size guidelines, without knowledge of an 
estimated standard deviation from the mean within each group (McDonald, 2009). 
Using a Power of 80%, an effect size of 0.5, where the ratio of subjects between the 
two groups was taken as 1:1 and significance as p < 0.05 the sample size calculations 
indicated, a total sample size of 128 individuals — 64 within each cohort — were 
required for this project. As participant recruitment was performed by the author, 
rather than through a hospital or recruitment agency achieving participation and 
viable specimen samples from such a moderate sample size was deemed unlikely. 
Previous researchers investigating the inflammatory response within airway disease 
utilised 15 individuals within each cohort. These studies detected significant changes 
between the airways of individuals with and without asthma in these smaller sample 
sizes (Witten et al., 2005, Cosio et al., 2004, Ito et al., 2002a). Therefore, for the 
purpose of this project, a conservative number of 15 subjects within each cohort was 
the minimum sample size target. However, to determine how sensitive a total sample 
size of 30 subjects would be in detecting changes between the two cohorts, a 
45 
 
sensitivity test was also performed. To detect significant changes (p < 0.05) in 
enzyme expression between the asthma and healthy cohorts, a theoretical effect size 
of 1.06 was required.  
2.1.3 Subject Recruitment 
Participant recruitment for medical research is one of the most challenging and 
time consuming parts of a research project.  Recruitment refers to the communication 
that occurs between investigator and potential volunteer prior to consent of 
participation in the research project (Patel et al., 2003). The recruitment process that 
was used for this project is outlined in Figure 2-2. The retention of participants was 
an important aspect of this project; poor participant retention can be costly both 
financially and in terms of time. Thus, the timeframe (Figure 2-1) for the recruitment 
phase of this project was designed to take into account a number of factors. These 
factors included: obtaining an appropriate sputum sample from subjects. While non-
invasive the collection of an adequate sputum sample is heavily reliant on the full 
cooperation of the subject during the sputum induction session.  Thus, issues such as 
participant embarrassment during spitting, coughing and expectorating sputum, as 
well as a low tolerance for moderate saline concentrations resulted in at times the 
collection of inadequate sputum samples.  Furthermore, the failure of participants to 
show up for scheduled appointments and the postponing of these appointments 
caused further delays in the recruitment timeline.  Finally, as one of the aims of this 
project required participants involvement in repeat sessions, withdrawal from the 
project before completing the study requirements also affected the recruitment 
timeframe. 
 
Figure 2-1: Timeframe for project recruitment phase 
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Figure 2-2: Flow chart of recruitment process for participation in research project 
 
The flow chart illustrates the steps taken to recruit participants for a research project. 
The failure of volunteers to show up to sessions and inadequate specimen samples 
collected from subjects increase the recruitment phase time line. TF refers to Time 
frame 
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Individuals diagnosed with and without asthma were invited to participate in this 
project. The participants were recruited by the investigator using methods outlined in 
Table 2-1. Previous studies have shown that cigarette smoke can alter HDAC 
expression levels within the airways, as such; chronic smokers were excluded from 
participation (Adenuga et al., 2009, Liu et al., 2010, Yang et al., 2006). Furthermore, 
as the study sought to investigate changes in airway inflammation caused by asthma, 
individuals who had recently (< 2 weeks) suffered from a respiratory tract infection 
(RTI) were excluded from the study.  The exclusion criteria also included women 
who were pregnant or breastfeeding, as the hormone changes in pregnancy and 
breastfeeding could potentially influence the expression of the enzymes investigated.  
Informed written consent was obtained from all subjects prior to partaking in this 
study (Appendix A1). 
Table 2-1: Recruitment methods for participation in project 
Recruitment Method Expression of 
Interest 
Participation Asthma 
Status 
Did Not 
Participate 
Asthma 
Status 
Trial Spotting 13 0   
 
 
 
 
51 Asthma 
52 Healthy 
 
 
 
  
13   
  
  
  
22 Asthma 
32 Healthy 
24 Unknown 
  
  
  
  
Visiting U/G Class 11 5 6 
Word of Mouth 13 12 1 
Research Institutes 11 7 4 
University Newspaper 37 20 17 
City Newspaper 2 0 2 
Institute Website 1 0 1 
Flyers  4 4 0 
Conference 1 1 0 
Previous Subject 5 3 2 
Email U/G Classes 82 50 32 
Total 181 103  78  
The table depicts a sample of email responses from subjects indicating expression of 
interest to participate in this project. Expression of interest is represented in terms of 
methods used to recruit participants. U/G – Undergraduate 
2.2 CLINICAL INFORMATION 
2.2.1 Collection of Clinical Information 
Prior to participation, all subjects were asked to complete a medical health 
questionnaire which focused on allergy history, respiratory symptoms, asthma 
symptoms and history, family history and medication usage (Appendix A2 and B). 
Subjects were determined to have asthma if they had a clinical diagnosis of asthma, 
and still suffered from asthma symptoms. Asthma subjects were classified according 
to the level of asthma control as outlined in the GINA guidelines (GINA, 2011).  
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2.2.2 Pulmonary Function Tests 
Baseline Spirometry was measured using an electronic spirometer (COSMED, 
Albano Laziale, Rome, Italy) in accordance with the American Thoracic Society 
(ATS) guidelines (Miller et al., 2005). The spirometer was calibrated on a daily basis 
to ensure accurate lung measurement. Forced Expiratory Volume in 1 second (FEV1) 
and Forced Vital Capacity (FVC) measurements were taken for each subject.  Each 
subject was seated and asked to inhale to a total lung volume and then to forcefully 
exhale for 6 seconds as fast as possible; each subject’s FEV1 and FVC measurements 
were recorded. The procedure was repeated three times for each subject to ensure 
accurate pulmonary function measurements were obtained. Spirometry was taken at 
the beginning of the session, after bronchodilator treatment, during sputum induction 
and post sputum induction.  
2.2.3 Bronchodilator Administration 
After baseline spirometry all subjects were given 400 mg of salbutamol (trade 
name Ventolin: GlaxoSmithKline, Abbotsford, Vic, Australia). Salbutamol was 
administered through a metered dose inhaler and a valve holding chamber. Subjects 
were asked to press down firmly on the canister and breathe in slowly and deeply 
through the chamber four times. Subjects waited one minute before repeating the 
above procedure until a total of 400 mg of salbutamol was administered (4 times). 
After a 15 minute waiting period, spirometry measurements were repeated (Section 
2.2.2) and the FEV1 and FVC post bronchodilator values for each subject were 
recorded. Each subject’s airway response to medication was calculated using the 
following formula: (Initial FEV1/ Post Bronchodilator FEV1) x 100. All subjects 
were asked to withhold the use of any bronchodilator medication for eight hours 
prior to the testing session. 
2.2.4 Sputum Induction 
All subjects underwent sputum induction to collect an airway fluid sample. 
Sputum induction was carried out using hypertonic saline (4.5%) and a modified 
procedure of Paggiaro (Paggiaro et al., 2002). Subjects were seated throughout the 
procedure. A nose clip was applied and 4.5% hypertonic saline was administered 
using a mouthpiece and a two-way valve connected to a high output suchatzki 
ultrasonic nebulizer (Niche Medical, North Sydney, NSW, Australia). Subjects 
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inhaled the saline for two minutes before being asked to take two deep breaths of the 
saline, spit saliva from the mouth into a provided container, cough deeply from the 
chest and expectorate sputum into a specimen container provided. This procedure 
was continued for a total of 20 minutes (10 cycles). After the induction was 
completed, subjects were asked to wait for 10 minutes before completing additional 
spirometry. Subjects FEV1 measurements were recorded at two minute intervals to 
monitor lung function throughout the procedure. If the subjects FEV1 dropped below 
10% of their baseline spirometry, the procedure was stopped and bronchodilator 
medication was administered. 
2.3 SAMPLE PROCESSING 
2.3.1 Induced Sputum Processing 
All sputum samples were kept on ice and processed within 30 minutes of 
collection. Firstly, each sample was weighed and an equal amount (1:1, w:v) of 
Sputasol (0.6 mM DTT, 3 mM KCl, 0.13 M NaCl, 4 mM Na2HPO4, 2 mM KH2PO4) 
was added to each sample. The samples were then gently mixed at 37 
o
C for 15 
minutes to ensure optimal cell dispersion prior to being drawn through a 20 gauge 
needle to ensure complete homogenisation of each sample. A small portion (0.5 mL) 
of each sample was used for total leukocyte cell counts (TCC) and cytospin slide 
preparation for differential cell counts. The remainder of the sample was divided into 
two portions and centrifuged using an Allegra
®
 X-15R Benchtop Centrifuge 
(Beckman Coulter
®
, Lane Cove, NSW, Aus) at 280 x g for 15 minutes at 4 
o
C. The 
supernatant was then removed from both centrifuged portions, combined, placed into 
a separate tube, and again centrifuged (Beckman Coulter
®
) at 1060 x g for 15 
minutes at 4 
o
C. The supernatant was aliquoted and stored at 
-
80 
o
C. The 2 cell 
pellets from the initial spin, were treated as follows: 1 mL of TRIzol
®
 Reagent (Life 
Technologies Australia, Mulgrave, VIC, Aus) was added to one cell pellet and stored 
at -80 
o
C for RNA extraction; the other cell pellet was re-suspended for protein 
extraction (Section 2.5.1). 
2.3.2 Sputum Cell Counts 
Total and differential cell counts were performed on all sputum samples 
collected. Total leukocyte cell counts (TCC) were counted independently by two 
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investigators using a standard haemocytometer method. Cell counts from both 
investigators were averaged and reported as cells per millilitre. One of the 
investigators was the author.  
Cytospin slides were prepared by adding two drops of cell suspension to cytospin 
funnels (Hettich, Kirchlengern, Germany) lined with filter paper (Hettich) and 
centrifuged in a cytocentrifuge (Hettich) at 500 x g for 5 minutes. The cells were 
fixed to the slides with methanol, stained with a Kwik Diff Kit (Thermo Fisher 
scientific, Scoreby, VIC, Aus) and visualised with an Olympus BX41 light 
microscope (Olympus, Center Valley, PA, USA). Cell counts (200 non squamous 
cells) were performed by one investigator (the author) blinded to the subjects tested. 
Cells were classified as macrophages, neutrophils, eosinophils, columnar epithelial, 
squamous epithelial and lymphocytes using standard morphological criteria (Figure 
2-3) (Bain, 2006).  
 
Figure 2-3: Representative cytospin slide of a subject’s sputum sample 
The image represents sputum cytology at x 400 magnification. The red arrow indicates a 
neutrophil. The blue arrow indicates a macrophage, while the green arrow indicates a 
squamous epithelial cell. The black arrow indicates a columnar epithelial cell. 
2.4 REVERSE TRANSCRIPTASE (RT) POLYMERASE CHAIN 
REACTION (PCR) 
2.4.1 RNA extraction 
Total RNA extraction was performed using a combined TRIzol
®
 Reagent (Life 
Technologies Australia) and an RNeasy Mini Kit (QIAGEN, Chadstone, VIC, Aus) 
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method. TRIzol
®
 samples were gently thawed from -80 
o
C to room temperature (RT). 
Each sample then received 200 µL of chloroform and was gently mixed via 
inversion. Samples were left at RT for 7 minutes and then centrifuged at 12,000 x g 
for 15 minutes at 4 
o
C. The aqueous (top) phase of the samples was removed and 
placed into a separate microcentrifuge containing an equal volume of ice cold 70 % 
ethanol and gently mixed by inversion. A 600 µL aliquot of each sample was placed 
into an RNeasy spin column (QIAGEN) and RNA was extracted following the 
manufacturer’s instructions. Briefly, the RNA samples were eluted through the 
column at 10,000 x g for 30 seconds. Then, the samples were washed with 700 μL of 
RW1 buffer (stringent wash buffer - provided in kit), and RPE buffer (mild wash 
buffer - provided in kit), twice. Afterwards the RNA was then eluted with 60 µL of 
RNase free water (provided in kit). The RNA samples were checked for quantity and 
quality using the NanoDrop ND-1000 spectrophotometer (NanoDrop, Wilmington, 
DE, USA.) A 260/280 value of less than 1.8 was considered low quality. The RNA 
was then stored at -80 
o
C until further use. 
2.4.2 Complementary cDNA sequencing and Polymerase Chain Reaction (PCR) 
A total of 100 ng or 500 ng of total RNA was reverse transcribed to 
complementary DNA (cDNA) using SuperScript
®
 III RT kit (Life Technologies 
Australia) following the manufacturer’s instructions. Briefly, the samples were made 
to a volume of 10 uL as follows: X µL of total RNA (equivalent to 100 ng or 500 ng 
of total RNA) was added to 1 µL of 10 mM dNTP mix and 1 µL of 10 mM Random 
Hexamers. DEPC H2O was added to make up a final volume of 10 uL. The samples 
were incubated at 65 
o
C for 5 minutes before being rapidly chilled on ice. The 
following master mix (Table 2-2) was then prepared and 10 µL of master mix was 
added to each sample. 
Table 2-2: cDNA Master Mix 
Component Volume Per Reaction 
10x RT PCR 2 µL 
50mM MgCl2 4 µL 
0.1M DTT 2 µL 
2x Superscript®  III 1 µL 
2x RNAse OUT 1 µL 
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The samples were placed on a DNA Engine
®
 Peltier Thermal Cycle (PTC–200) (Bio 
Rad, Gladesville, NSW, Aus) and heated as follows: 25 
o
C for 10 minutes, 50 
o
C for 
50 minutes, 85 
o
C for 5 minutes and cooled to 4 
o
C. After this cycle 1 unit of 
Ribonuclease H (Life Technologies Australia) was added to each sample, and the 
samples were heated at 37 
o
C for 20 minutes before being stored at -80 
o
C. 
2.4.3 Creating Standards for Quantitative Reverse Transcriptase PCR (Q-RT-
PCR) 
Standard PCR was performed on a DNA Engine
®
 Peltier Thermal Cycle (PTC–
200) (Bio Rad) to develop gene standards for real time RT PCR. The PCR reactions 
were made to a volume of 20 µL with 2 µL of cDNA, and 0.2 µM of forward and 
reverse primer (Sigma Aldrich, Castle Hill, NSW, Aus) (Table 2-3) and the PCR 
master mix (Table 2-4). 
Table 2-3: HAT and HDAC primers for PCR reactions 
Gene Fwd Primer Reverse Primer Gene 
Sequence 
18s rRNA 5’ GATCCATTGGAGGGCAAGTCT 5’ CCAAGATCCAACTACGAGCTTTT  
HDAC 1 5’ TGGGGACCTACGGGATATCGGG 5’ AAGACCACCGCACTAGGCTGGA NM_004964.2 
HDAC 2 5’ AACTGGCGGTTCAGTTCGTGGA 5’ CCTCAAGTCTCCTGTGCCAGGA NM_001527.3 
HDAC 3 5’ TCAGCCCCACCAATATGCA 5’ TGTAACGCGAGCAGAACTCAAA NM_001527.3 
HDAC 4 5’ GGCTCGGCGCGCTTGAACGTCT 5’ TCTCGGCCAGAAAGTCCATCTGGA NM_006037.3 
HDAC 5 5’ CTCTGCATCGCTATGACAACG 5’ AGGTACTCCACGTCTCCAATGG NM_001015053.1 
HDAC 6 5’ CCTAGCTGCCTGGCATCGCC 5’ AGGGTCAGCAGGGGTGGTGG NM_006044.2 
SIRTUIN 1 5’ ACTCCAAGGCCACGGATAGGTCC 5’ AGGTGGAGGTATTGTTTCCGGCA NM_012238.4 
SIRTUIN 2 5’ CAGAGCAGTCGGTGACGGGAC 5’ CAGAGGGTGAGAGGGGTCTGGCTC NM_012237.3 
SIRTUIN 3 5’ GCCGGGTAGTTGAACGGGTCG 5’ TTTAATAATCGTCCCTGCCGCCAAG NM_012239.5 
SIRTUIN 4 5’ CCAGCGGTACTGGGCGAGAA 5’ ACAGGACCCTGTCCATGCATCCG NM_012240.2 
SIRTUIN 5 5’ TCGGGACACAGCGCCTCTAGG 5’ CCATTTACTTGGGCCCCGCAC NM_012241.4 
SIRTUIN 6 5’ CATGTTTGTGGAAGAATGTGCC 5’ TAGGATGGTGTCCCTCAGCTCT NM_016539.2 
CBP 5’ GCTCGCTCCCGCATTGTCGAA 5’ TGCACAATGGGCAACTTGGCAG NM_004380.2 
PCAF 5’ TCGGCCCGAATCGCCGTGAA 5’ ACAAGACTCCTCGGCCTTGCAG NM_003884.4 
P300 5’ GCCGAGAATGTGGTGGAACCGG 5’ GAGAGCCAAAATCTGTGCCATCGCT NM_001429.3 
SRC1 5’ GATGGAACCCAGCAGGTGCAA 5’ GGGTCTGTGGTCCTGACGTGG NM_003743.4 
TIF2 5’ TATGTCACCCCGAATGGCA 5’ CCTGCGCCCATCCATTTAT NM_006540.2 
ATF2 5’GCCTGGATGTGGCCAGCGTTT 5’ TTGGTGTTGGGGTCTGATCAGCC NM_001256090.1 
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Table 2-4: PCR Master Mix 
Component Volume per Reaction 
10x RT PCR 2.0 µL 
50mM MgCl2 0.6 µL 
10mM dNTPs 0.2 µL 
Platinum
®
Taq 
DNA Polymerase 
0.2 µL 
DEPC H2O 14.5 µL 
 
The PCR cycle was as follows; 
94
o
C - 5 min   
94
o
C -  45 sec 
} 36 cycles 60oC -  1 min 
72
o
C -  1 min 30  
72
o
C -  10 min   
4
o
C - Finish   
 
PCR products were then electrophoresed using a Mini-Sub
®
 Cell GT Cell (Bio Rad) 
on an ethidium bromide (Bio Rad) stained 2 % agarose gel and visualized by UV 
illumination (ChemiDoc TM MP System (Bio Rad)) to ensure primers were specific 
for each gene. PCR products were then purified and quantified at 260/280 nm using a 
NanoDrop ND-1000 spectrophotometer (NanoDrop) and 1 x 10
8
 standards were 
made for each gene. The 1 x 10
8
 standards were then stored at -80 
o
C to be used in 
Q-RT-PCR where 10 fold serial dilutions were prepared. 
2.4.4 Q-RT-PCR 
Q –RT-PCR was performed for a number of Histone acetyltransferase (HAT) 
enzymes and histone deacetylase (HDAC) enzymes genes. A master mix (Table 2-5) 
for the PCR reactions was set up as follows: each reaction held 2.5 µL of diluted 
cDNA and each reaction was performed in triplicates. 
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Table 2-5: Quantitative RT-PCR Master Mix 
 
Component Volume Per Reaction 
SYBR green 10 µL 
Forward Primer 0.7 µL 
Reverse  Primer 0.7 µL 
DEPC H20 7.3 µL 
 
For PCR parameters, refer to individual result chapters. All primer sets (Sigma 
Aldrich) were tested prior to any use on the prepared samples to ensure performance 
and accuracy. 18s rRNA was used as the normalising gene as it is ubiquitously 
expressed in the airways and is not differentially expressed as a function of asthma.  
2.5 PROTEIN ANALYSIS 
2.5.1 Cytosol and Nuclear Protein Extraction 
Cell pellets were obtained from sputum samples as previously outlined 
(Section 2.3.1). The nuclear and cytoplasmic proteins were extracted from the cell 
pellet using an NE-PER Nuclear and Cytoplasmic Extraction Kit (ThermoFisher 
Scientific) following the manufacturer’s instructions. Briefly, after centrifugation at 
500 x g for 3 minutes using an Allegra
®
 X-15R Benchtop Centrifuge (Beckman 
Coulter
®
) the volume of the packed cells was established using visual aids. The 
corresponding amount of ice cold CER I buffer (provided within kit) was added to 
each pellet (Table 2-6). 
Table 2-6: Buffer volumes required for packed cell volumes 
Packed Cell Volume (μL) CER I (μL) CER II (μL) NER (μL) 
10 100 5.5 50 
20 200 11 100 
50 500 27.5 250 
100 1000 55 500 
Table taken from NE-PER protocol (ThermoFisher Scientific) 
Each sample was then vigorously mixed using a vortex mixer V1 Plus (BOECO, 
Hamburg, Germany) on the highest setting, before being left on ice for 10 minutes. 
Samples were then mixed and the corresponding amount of CER II reagent (provided 
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within kit) was added, samples were then incubated on ice for another minute. The 
samples were then centrifuged (Beckman Coulter) for five minutes at 16,000 x g at 4 
o
C 
after which the supernatant was removed and placed in pre-chilled microcentrifuge 
tubes. The appropriate amount of NER I buffer (provided within kit) was added to 
the cell pellet and mixed using a vortex (BOECO) at the highest setting. The samples 
were then placed on ice for 10 minutes before again being mixed for several seconds. 
The mixing and cooling process was repeated for 40 minutes. After 40 minutes, the 
sample was centrifuged (Bechman Coulter) at 16,000 x g for 10 minutes and the 
supernatants were transferred to labelled pre-chilled microcentrifuge tubes. Both 
cytoplasmic and nuclear protein fractions were stored at -80 
o
C until further use.  
2.5.2 Protein Quantification with Bicinchoninic Acid (BCA) assay 
Protein concentrations were quantified using a BCA Protein assay kit (Thermo 
Fischer Scientific) following the manufacturer’s instructions. A bovine serum 
albumin (BSA) protein standard curve ranging from 0.015 mg/mL to 2 mg/mL was 
generated for the measurement of unknown protein samples.  Duplicate reactions of 
10 µL for each standard and sample were added to the individual wells of a 96-well 
plate. Subsequently, 200 μL of BCA working reagent (provided within kit) was then 
added to each well. The samples were then mixed by gentle rocking and incubated at 
37 
o
C for 30 minutes. The plate was read at 562 nm on a UV-Visible Plate Reader 
(Bio-Rad).  
2.6 ACTIVITY ASSAYS 
2.6.1 Histone Acetyltransferase (HAT) Activity assays 
HAT activity in sputum samples were measured using the EpiQuik™ HAT 
Activity/Inhibition assay kit (Sapphire Bioscience, Waterloo, NSW, Australia) 
following manufacturer’s instructions. The HAT activity/inhibition kit used in this 
project works as an ELISA-like reaction. Active HATs within the experimental 
sample bind to an acetylate histone substrates within each strip well. The acetylated 
substrate is then recognized by an anti-acetylated histone antibody. The amount of 
HAT activity is determined via the ratio of acetylated histone to unacetylated histone. 
All reagents except the nuclear extract were provided within the kit. Briefly, 50 μL of 
diluted (1:50) HAT substrate was added to each sample well. To the standard curve 
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wells 50 μL of diluted (1:10) wash buffer was added, followed by 1 μL of the HAT 
assay standard in serial dilutions. The wells were then covered with Parafilm and 
incubated at RT for 45 minutes. After which the wells were aspirated and washed 
three times with 150 μL of diluted (1:10) wash buffer. To each sample well 26 μL of 
HAT assay buffer, 2 μL of diluted (1:20) Acetyl-CoA buffer and 3.5 – 5 μg of 
nuclear extract from subject samples were added.  Samples were tested in duplicates. 
To each standard well 28 μL of HAT assay buffer and 2 μL of Acetyl-CoA buffer 
was added. The wells were then gently mixed and incubated at 37 
o
C for 60 minutes. 
All wells were then aspirated and washed three times with 150 μL of diluted (1:10) 
wash buffer. After the wash step 50 μL of diluted capture antibody (1:100) was 
added to each well and the wells were incubated at RT for 60 minutes on an orbital 
shaker (75 rpm).  The wells were then aspirated and washed 4 times with diluted 
(1:10) wash buffer. Following this wash step, 50 μL of diluted (1:1000) detection 
antibody was added to each well and the wells were incubated at RT for 30 minutes.  
Each well was then aspirated and washed 5 times with 150 μL of diluted (1:10) wash 
buffer. To each well 100 μL of developing solution was then added and the wells 
were incubated at RT away from light for 2-10 minutes or until the standard wells 
turned a medium blue. Once the standard wells had turned blue, 50 μL of stop 
solution was added to the wells to stop the enzymatic reaction. The absorbance 
reading from the wells was measured at 450 nm, using a micro-plate reader (Bio-
Rad).  Enzyme activity was calculated using the standard curve.  
2.6.2 Histone Deacetylase (HDAC) Activity assays 
HDAC activity from sputum samples was measured using the EpiQuik™ 
HDAC Activity/Inhibition assay kit (Sapphire Bioscience, Waterloo, NSW, 
Australia) following manufacturer’s instructions. The HDAC Activity/Inhibition 
assay kit used within this project works as an ELISA-like reaction. Acetylated 
histone substrate is stably caputured on strip wells to which active HDACs within the 
experimental sample can then bind to and deacetylate. The remaining undeacetylated 
substrate is then recognized by an acetylated histone antibody. The amount of HDAC 
activity is then determined via the ratio of undeacetylated histone to the original 
acetylated histone substrate using colourmetric quantification.  
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All reagents, except nuclear extract were provided within the kit. Briefly, 50 μL of 
diluted (1:50) biotinylated HDAC substrate was added to each sample well. To the 
standard curve wells 49 μL of diluted (1:10) wash buffer was added, followed by 1 
μL of the HDAC assay standard in serial dilutions. The wells were then covered with 
Parafilm and incubated at RT for 45 minutes. After which the wells were aspirated 
and washed three times with 150 μL of diluted (1:10) wash buffer. To each sample 
well 28 μL of HDAC assay buffer and 3.5 – 5 μg of nuclear extract from subject 
sputum samples were added.  Samples were tested in duplicates. To each standard 
well 30 μL of HDAC assay buffer was added. The wells were then gently mixed and 
incubated at 37 
o
C for 60 minutes. All wells were then aspirated and washed three 
times with 150 μL of diluted (1:10) wash buffer. After the wash step 50 μL of diluted 
capture antibody (1:100) was added to each well and the wells were incubated at RT 
for 60 minutes on an orbital shaker (75 rpm).  The wells were then aspirated and 
washed 4 times with diluted (1:10) wash buffer. Following this wash step, 50 μL of 
diluted (1:1000) detection antibody was added to each well and the wells were 
incubated at RT for 30 minutes.  Each well was then aspirated and washed 5 times 
with 150 μL of diluted (1:10) wash buffer. To each well 100 μL of developing 
solution was then added and the wells were incubated at RT away from light for 2-10 
minutes or until the standard curve wells turned a medium blue. Once the standard 
wells had turned blue, 50 μL of stop solution was added to the wells to stop the 
enzymatic reaction. The absorbance reading from the wells was read at 450 nm, 
using a micro-plate reader (Bio-Rad). Enzyme activity was calculated using the 
standard curve. 
2.6.3 Sirtuin (SIRT) Activity assays 
SIRT activity from sputum samples was measured using the EpiQuik™ SIRT 
Activity/Inhibition assay kit (Sapphire Bioscience, Waterloo, NSW, Australia) 
following manufacturer’s instructions. SIRT activity/inhibition assay kit used in this 
study works as an ELISA-like reaction. Each kit contained strip wells coated with 
acetylated histone SIRT substrate. Active SIRTs within an experimental sample can 
bind to the substrate and deacetylate the substrate. The deacetylated products are 
recognised with a specific antibody. The ratio of deacetylated to acetylated SIRT 
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substrate is then proportionally calculated using colorimetric analysis to determine 
SIRT activity.   
All reagents, except the nuclear extract were provided within the kit. Briefly, 42 μL 
of SIRT assay buffer, 1 μL of SIRT substrate, 1 μL of TSA, 1 μL of NAD and 3.5 μg 
of nuclear extract from subject sputum samples was added to each sample well. 
Samples were tested in duplicates. To the standard curve wells 49 μL of SIRT assay 
buffer was added, followed by 1 μL of the SIRT assay standard in serial dilutions. 
The wells were then covered with adhesive films and incubated at 37 
o
C for 90 
minutes. After which the wells were aspirated and washed three times with 150 μL of 
diluted (1:10) wash buffer. To each well 50 μL of diluted capture antibody (1:1000) 
was added and the wells were incubated at RT for 60 minutes on an orbital shaker 
(75 rpm).  The wells were then aspirated and washed 4 times with 150 μL of diluted 
(1:10) wash buffer. Following this wash step, 50 μL of diluted (1:2000) detection 
antibody was added to each well and the wells were incubated at RT for 30 minutes.  
Each well was then aspirated and washed 4 times with 150 μL of diluted (1:10) wash 
buffer. To each well 100 μL of developing solution was then added and the wells 
were incubated at RT away from light for 2-10 minutes or until the standard wells 
turned a medium blue. Once the standard wells had turned blue, 50 μL of stop 
solution was added to stop the enzymatic reaction. The absorbance readings from 
each well were then measured at 450 nm, using a micro-plate reader (Bio-Rad).  
Enzyme activity was calculated using the standard curve. 
2.7 DATA ANALYSIS 
Data was analysed using IBM SPSS 19.0 (IBM Corporation, Armonk, New 
York, USA) and GraphPad Prism 5.0 (GraphPad Software Inc, San Diego, CA, USA). 
Specific data analysis is described in subsequent chapters. All data was tested for 
parametric and non-parametric distribution. Furthermore, all data was tested for 
equality of variance between the cohorts using Levene’s test for equality of variance.  
For comparisons between two groups, Mann Whitney U tests was used for analysis 
of non-parametric data, and the Student T-Test was used for analysis of parametric 
data. For correlations between two groups, Spearmans Rho test was used for non-
parametric data, and the Pearson test was used for parametric data analysis.  For the 
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comparison and analysis of 3 or more samples, linear mixed models were used. 
Linear mixed models allowed for the comparison within and between cohorts, over 
the time course of the study. Furthermore, they were also used to establish 
relationships between measurable variables. Results were considered statistically 
significant when p < 0.05.  
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CHAPTER 3:                                                                                                        
EXPRESSION OF HAT AND HDAC ENZYMES IN ASTHMA AIRWAYS 
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3.1 INTRODUCTION 
Asthma is a chronic inflammatory disease of the airways. The exacerbated 
inflammatory response to an external stimulus is initiated by the innate and adaptive 
immune system. Despite the initial breach and signalling from the innate immune 
system, the continuum of inflammation is thought to be largely driven by an over 
active TH2 immune response (Barnes, 2001). In recent years, it has become evident 
that epigenetic modifications are a determinant for T cell fate, and that histone 
acetylation contributes to a pre-established TH1/TH2 immunity in humans (Su et al., 
2008, Durham et al., 2011). To date, the bulk of information we possess in terms of 
epigenetic modifications and immunity comes largely from murine models. While 
these studies are beneficial in ascertaining and understanding epigenetic regulation of 
immunity, how this relates to a heterogeneous immune response in humans is not yet 
understood.  
Histone acetylation is an epigenetic modification that alters the state of chromatin to 
allow transcription factors access to DNA and gene transcription to occur. The 
process is controlled by enzymes known as histone acetyltransferases (HATs) which 
cause an open chromatin state, and histone deacetylases (HDACs) that returns 
chromatin to its basal closed state. Within the last decade it has become evident that 
transcriptional co-activators possess intrinsic HAT activity and utilise this HAT 
activity to influence gene transcription pathways (Bedford et al., 2010, Kasper et al., 
2006, Sheppard et al., 1999). The transcriptional co-activators: activating 
transcription factor -2 (ATF-2), CBP (cAMP Response Element Binding Protein 
(CREB) Binding Protein), p300, p300/CBP associated factor (P/CAF), steroid 
receptor co-activator (SRC-1) and transcription initiating factor 2 (TIF-2) have not 
only been shown to possess HAT activity but are also instrumental in the regulation 
and activation of a number of inflammatory pathways. Studies utilising murine 
models and cell systems have demonstrated the ability for these HAT enzymes to 
influence gene expression in two ways: directly, via acetylating the histone lysines of 
DNA and indirectly, via acetylating and thus activating known inflammatory 
transcription factors (Bedford et al., 2010, Kasper et al., 2006, Sheppard et al., 1999, 
Li et al., 2007, Sahar et al., 2007). Despite these discoveries, whether or not changes 
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in the expression of these enzymes contribute to the intensified inflammatory 
phenotype of asthma remains to be seen.  
Since being highlighted as significant regulators of immune pathways, the role 
HDACs play in inflammatory diseases has become a burgeoning area of research, 
particularly in asthma. A study performed by Ito et al (2002) found a decrease in the 
protein expression of HDAC1 and HDAC2 in bronchial biopsies of individuals with 
asthma compared to healthy controls. Interestingly, a follow-up study from the same 
group identified decreases in HDAC1 but not HDAC2 protein expression in alveolar 
macrophages from asthmatics (Cosio et al., 2004). It has been suggested that the 
expression of HDAC2 is influenced by, and contributes to, the effectiveness of 
corticosteroid medication. In vivo and in vitro experiments show significant increases 
of HDAC2 expression after treatment with dexamethasone (Ito et al., 2000, Ito et al., 
2002a, Ito et al., 2006). Furthermore, studies have shown that the decreased 
expression of HDAC2 in severe asthmatic airways strongly correlate with an increase 
in a patients resistance to corticosteroid therapy (Butler et al., 2011, Ito et al., 2008, 
Li et al., 2010, Meja et al., 2008). Similarly, decreased levels of HDAC2 expression 
have been reported in the airways of individuals suffering from Chronic Obstructive 
Pulmonary Disease (COPD); an inflammatory airway disease that is largely 
unresponsive to corticosteroid therapy (Adcock et al., 2005, Adenuga et al., 2009, 
Malhotra et al., 2011). Despite promising in vitro data, the therapeutic benefits of 
increasing HDAC2 levels in the airways to improve corticosteroid sensitivity is yet 
to be observed clinically (Choy et al., 1999, Ito et al., 2002b, Marwick et al., 2007, 
Usami et al., 2006, van Mastbergen et al., 2012). Interestingly, due to the findings of 
these earlier studies (Ito et al. 2002; Cosio et al. 2004) research into this field has 
largely focused on unravelling and understanding the cellular pathways that HDAC1 
and HDAC2 influence within the airways (Grausenburger et al., 2010, Yang et al., 
2006, Butler et al., 2011). As such, the extent to which the other HDAC enzymes 
contribute to the inflammation observed in asthma airways remains largely unknown.  
The sirtuins (SIRTs) possess similar deacetylase properties to the other members of 
the HDAC family. However, while HDAC class I and II require a water molecule to 
deacetylate their protein target, SIRTs rely on the amount of nicotinamide adenine 
dinucletodies (NAD) present in the cell (Morris, 2012). SIRTs are key enzymes 
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involved in the aging process (Finkel et al., 2009) however; recently interest has 
turned toward their role in “inflammaging”. Inflammaging is a term referring to a 
progressive increase in the pro-inflammatory status that is a major characteristic of 
the aging process (Rahman et al., 2011). Studies have indicated SIRT1 and SIRT6 as 
enzymes that activate and regulate the master inflammatory transcription factor NF-
κB and inflammatory cytokines TNF-α and IL-1β (Kawahara et al., 2009, Minagawa 
et al., 2011, Gao and Ye, 2008, Yeung et al., 2004, Zhang et al., 2010). Interestingly, 
unlike HDAC1 and HDAC2, it has been suggested that increases in SIRT1 
expression may cause an overactive inflammatory response. A study investigating 
the role of SIRT1 in the pathogenesis of allergic airway diseases found significant 
increases in the expression of SIRT1 protein in mice airways after OVA inhalation. 
The use of sirtinol (a universal SIRT inhibitor) attenuated the observed increase in 
inflammation. Thus, the authors concluded that SIRT1 regulated pro-inflammatory 
pathways within the airways (Kim et al., 2010). However, a separate study 
investigating the function of SIRTs in COPD observed a decreased expression of 
SIRT1 in the airways; this led the authors to conclude that the suppression of SIRT1 
caused increased inflammation in the airways (Rajendrasozhan et al., 2008). Thus, 
the literature suggests both a pro and anti-inflammatory role for SIRT1; how the 
SIRTs influence the asthma phenotype is yet to be clearly defined.  
Despite the initial breach of the innate immune defences, the continuum of the 
inflammatory response in asthma is thought to be largely driven by an overactive 
TH2 immune response.  However, it has been suggested that increased signalling 
from inflammatory proteins expressed by cells of the innate immune system may 
influence the over active TH2 response (Lambrecht and Hammad, 2012). As such, the 
response of innate immune cells to invading stimuli may be more influential in 
causing an exacerbated inflammatory response in the airways than originally thought. 
Thus, here it was hypothesised that an increased expression of HAT enzymes, 
indicating increased inflammatory cytokines and chemokines production, would be 
observed in airway samples of the innate immune system from asthmatic individuals. 
Furthermore, this increase in HAT expression would coincide with a decrease in the 
expression of HDAC enzymes. Consequently, it was the aim of this study to 
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determine if the mRNA expression of HAT and HDAC enzymes were differentially 
expressed in airway samples of individuals with and without asthma.    
3.2 MATERIALS AND METHODS 
3.2.1 Subject Recruitment and Characteristics 
Thirty – six subjects, nineteen with asthma and seventeen healthy controls, 
participated in this study. Subjects were considered to be asthmatic if they had a 
previous diagnosis of asthma from their physician and still experienced asthma 
episodes.  All asthma subjects were taking short acting β2 agonists only at the time of 
study and had not received corticosteroid medication for at least 3 months prior to 
participation. Subject participation involved a single visit where they gave written 
informed consent (Appendix A1), filled out a medical health questionnaire inquiring 
about asthma history (Appendix A2), underwent spirometry testing, and airway fluid 
collection via sputum induction. Subjects were excluded from the study if they had a 
pre-existing medical condition other than asthma, smoked, were pregnant or breast 
feeding, or had a respiratory tract infection two weeks prior to participation. 
3.2.2 Sputum Induction 
Sputum collection was performed as outlined in chapter 2, section 2.2. 
3.2.3 Sample Processing 
Sputum samples were processed as outlined in chapter 2, section 2.3.  
3.2.4 RNA Isolation and Reverse Transcriptase PCR 
Total RNA was isolated using a combined method of TRIzol
®
 Reagent (Life 
Technologies Australia) and an RNeasy Mini Kit (QIAGEN) as outlined in chapter 2, 
section 2.4. A total of 500 ng, of total RNA from each subject sputum sample was 
transcribed into cDNA using a SuperScript
®
 III RT kit (Life Technologies Australia). 
The resulting cDNA products were used in real time PCR amplification. 
3.2.5 Quantitative RT-PCR 
The enzyme expression of 16 HAT, HDAC and SIRT enzymes in sputum cell 
pellets was determined using the primer sequences shown in Table 2-3.  All PCR 
amplifications were normalised to the housekeeping gene 18s rRNA. A total of 12.5 
ng of reverse transcribed cDNA was subjected to real time PCR, using SYBR green 
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master mix (Life Technologies Australia). Each reaction consisted of 1X SYBR 
green Master Mix, 0.2 μm of the appropriate sense and anti-sense primer (Sigma 
Aldrich)  and 12.5 ng of cDNA, DEPC H2O to a volume of 20 μL. Each sample 
reaction was performed in triplicates. Quantitative RT-PCR was performed on an 
ABI PRISM® 7000 Sequence Detection System (Applied Biosystems, Carlsbad, 
California, USA) under the following PCR conditions;  
95
o
C - 2 mins 
}  40 cycles 
95
o
C - 15 sec 
60
o
C - 1 min 30 sec 
72
o
C - 30 sec 
72
o
C – 95oC - Melt Curve analysis 
 
Amplification of each specific product was determined by melt curve analysis. The  
2
-ΔΔCt
 method was used to analyse and interpret the data.  
3.2.6 Cytoplasmic/nuclear extraction and separation 
Cytoplasmic and nuclear protein extraction of sputum cell pellets was 
separated using the NE-PER kit (Thermo Fisher Scientific) following manufacturer’s 
instructions. Full details are described in chapter 2, section 2.5.  
3.2.7 HAT and HDAC activity assays 
HAT and HDAC activity of nuclear protein extracts of asthma and healthy 
sputum samples was determined using the EpiQuik™ HAT Activity/Inhibition Assay 
Kit (Sapphire Bioscience) and the EpiQuik™ HDAC Activity/Inhibition Assay Kit 
(Sapphire Bioscience) as per the manufacturer’s instructions. Full details are 
described in chapter 2, section 2.6. A total of 5 μg of nuclear extract from each 
sample was used and samples were assayed in duplicates.   
3.2.8 Statistical Analysis 
Data is expressed as the mean ± the standard error of the mean (SE) of n 
determinants, unless otherwise specified. N is stated in individual figure legends. 
Statistical analysis was performed using IBM SPSS 19.0 (IBM Corporation) and 
GraphPad Prism 5.0 (GraphPad Software Inc). Parametric and non-parametric tests 
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were used to determine significance of the data depending on the distribution of the 
results. All data sets were tested for between cohort variations using Levene’s test for 
equality of variance. Between cohort comparisons were made using the Mann 
Whitney U test for non-parametric data and the student T-test for parametric data. 
Correlation and regression analysis for subject characteristics and gene expression 
was determined using Pearson and Spearmen’s correlations as indicated. Statistical 
significance was accepted where p<0.05. 
Practical vs. Statistical Significance 
In research the P (probability) value is used to accurately assess if differences 
observed between the means of two populations are significant. However, while 
using probability measurements help researchers to ascertain differences in their 
collected data, this measurement does not allow for interpretation of the practical 
significance of the data obtained. Despite a lack of statistical significance the 
apparent difference between two populations may be great enough (positive or 
negative) that the difference in expression levels of a gene or protein could 
potentially has a mechanistic effect in causing disease. With a larger sample size this 
practical significance may be considered statistically significant. Thus, using a 
method described by Hopkins (Hopkins, 2000), the real time PCR data collected in 
this study was assessed for both statistical and practical significance. Practical 
significance was determined using confidence limits and a pre-determined threshold 
for chance. Confidence limits define a range representing the uncertainty in the true 
value of a statistic, where the true value is defined as the value that would be 
obtained in a very large sample size. Confidence limits are established by 
determining the variation between subjects and then estimating how these variations 
translate into the calculated statistic. The threshold value for chance is defined as the 
smallest clinically important positive and negative value that is likely to have a 
practical effect. Threshold values are chosen by the researcher based on experience 
and understanding. For the purpose of this study the threshold value was set at 0.25 
Ct units as this equates to about a 20% difference in gene expression between the two 
cohorts. The likelihood that the reported results would have a practical/mechanistic 
affect on cellular pathways is reported as a percentage. Using the following scale 
(Figure 3-1), whether or not the true magnitude of the effect was substantially 
68 
 
positive or negative was determined. If both chances (positive/negative) were too 
high, the effect was deemed unclear.   
 
Figure 3-1: Scale for chance of practical significance 
3.3 RESULTS 
3.3.1 Subject Characteristics 
Thirty-six subjects participated in the study, nineteen with asthma (8 females) 
and seventeen healthy controls (9 females). Asthma subjects were intermittently 
treating their asthma with the inhaled β2-adrenergic agonist salbutamol at the time of 
the study and had not used corticosteroid medication for at least three months prior to 
participation. Subject characteristics are outlined in Table 3-1; a detailed subject 
characteristic table can be found in Appendix C. Compared to the healthy controls, 
the asthma cohort showed a higher occurrence of self-reported allergies (p < 0.05). In 
addition, the asthma cohort recorded a significantly lower FEV1/FVC% (p < 0.0001). 
Coinciding with this result, the asthma cohort also showed a greater airway response 
(reversibility) to β2-adrenergic agonist treatment compared to the healthy controls (p 
< 0.05). 
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Table 3-1: General subject characteristics 
Characteristic Study Cohort P Value 
 
Asthma(n=19) Healthy (n=17) 
 
Gender (no.)                                                  Male 11 8 
0.53 
Female 8 9 
Age (yr) 26.68 ± 2.17 26.65 ± 1.94 0.99 
Respiratory Tract Infection (Mths) 3.93 ± 0.99 7.71 ± 1.74 0.05 
Height (cm) 175.47 ± 2.51 168.94 ± 1.93 0.05 
Weight (kg) 76.02 ± 4.43 72.57 ± 4.09 0.57 
BMI 24.52 ± 1.16 25.42 ± 1.38 0.62 
Allergy –Self-Reported                                         Yes 11 3 
0.01
*
 
No 8 14 
Family History                                                        Yes 14 6 
0.22 No 3 10 
Unsure 2 1 
Asthma Medication 
Time of Participation                                β2 agonist 10 --- N/A 
Past Medication                                         β2 agonist 10 --- N/A 
Corticosteroids ICS - 9, OCS - 1 --- N/A 
Pulmonary Function 
FEV1(L) 3.53 ± 0.23 3.65 ± 0.16 0.68 
FVC (L) 4.57 ± 0.29 4.13 ± 0.19 0.23 
FEV1/FVC% 78.12 ± 2.10 88.56 ± 0.76 <0.0001
*
 
Post FEV1(L) 3.72 ± 0.26 3.64 ± 0.17 0.80 
Reversibility (% of FEV1/Post FEV1) 5.01 ± 2.19 -0.4 ± 1.13 0.04
*
 
Smoking                                                                                                                        Yes     --- 1 
N/A 
No 19 16 
Smoked past 12 Mths 5 3 N/A 
Sputum Volume (mL) 4.4 ± 0.65 4.42 ± 0.44 0.99 
Abbreviations: Yr- Year, Mths – Months, cm – Centimetres, kg – kilograms, L – Litres, mL – 
millilitres, FEV1 – Forced Expiratory Volume in 1 second, FVC – Forced Vital Capacity, ICS – 
Inhaled Corticosteroids, OCS – Oral Corticosteroids. Plus-minus values are means ± SE. Reversibility 
refers to the overall change in FEV1, 15 minutes after the administration of β2 agonists. Significant 
differences between the two cohorts were determined using a Student T-test, results were considered 
significant where p <0.05*. 
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3.3.2 Inflammatory Cell Counts 
To determine if an inflammatory state existed in the asthma airways at rest, 
total and differential cell counts were performed on sputum samples of all healthy 
and asthma subjects.  Average counts are shown in Table 3-2. No significant change 
in sputum cell population was observed between the healthy and asthma cohorts. 
Thus, the result indicated that at a resting state the inflammatory status, at least in 
terms of leukocytes numbers, did not differ between healthy and asthma airways.  
Table 3-2: Inflammatory cell counts 
 
Asthma 
(n=19) 
Healthy 
(n=17) 
P Value 
Total Cell Count x10
6
/mL 2.33 ± 0.27 2.40 ± 0.54 0.90 
Neutrophils % 37.7± 3.70 36.8± 2.99 0.86 
Neutrophils x 10
6
/mL 0.93 ± 0.21 0.92 ± 0.12 0.96 
Eosinophils % 2.55 ± 1.08 1.77 ± 1.10 0.61 
Eosinophils x 10
4
/mL 7.24 ± 3.91 7.14 ± 4.90 0.99 
Macrophage % 54.7 ± 4.12 58.9 ± 2.90 0.42 
Macrophage x 10
6
/mL 1.34 ± 0.28 1.46 ± 0.14 0.72 
Lymphocytes % 5.09 ± 2.72 2.46 ± 0.86 0.40 
Lymphocytes x 10
4
/mL 5.63 ± 2.30 5.44 ± 2.03 0.95 
Columnar Epithelial Cells % 9.23 ± 2.60 9.41 ± 1.45 0.96 
Columnar Epithelial Cells x 10
4
/mL 0.27 ± 0.11 0.22 ± 0.03 0.69 
Squamous Cells % 22.58 ± 2.51 20.73 ± 1.72 0.52 
Abbreviations: mL – millilitres, % - percentage. Changes in leukocytes counts between the study 
cohorts were determined using the Student T-Test. Plus-minus values are the mean ± SE.  Results 
were considered significant where p < 0.05. 
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3.3.3 A decrease in CBP expression within the asthma airways is likely to 
influence inflammatory pathways.  
Asthma is primarily considered an inflammatory disorder of the airways. 
Previous studies have implicated HAT enzymes as regulators of inflammatory 
pathways (Bedford et al., 2010, Kasper et al., 2006, Sheppard et al., 1999). Thus, to 
investigate if expression of the HAT enzymes — ATF-2, CBP, p300, P/CAF, SRC-1 
and TIF-2 — differed in healthy and asthma airways Q-RT-PCR was performed on 
heterogeneous cell populations isolated from asthma and healthy airways. The gene 
expression of the HAT enzymes observed within each cohort is shown in Figure 3-2. 
Interestingly, the cohort individual data plots show a greater variability in gene 
expression in the healthy cohort compared to the asthma cohort. The significance of 
this observation is reflected in analysis for the equality of variance between the two 
cohorts. The variation between the two cohorts was significantly different for the 
HAT enzymes: ATF-2 (p< 0.001) (Fig 3-2A), P/CAF (p < 0.05) (Fig 3-2D), SRC-1 (p 
< 0.05) (Fig 3-2E) and TIF-2 (p < 0.001) (Fig 3-2F). However, despite the lack of 
equality of variance between the healthy and asthma populations, no statistically 
significant difference in the level of expression of these HAT enzymes was observed 
between the two cohorts.  
As well as statistical significance the data was also assessed for practical 
significance. Table 3-3 reports the average differences in gene expression between 
the two cohorts in terms of fold difference. The fold difference was determined by 
directly comparing the ΔCt values (Gene expression normalised to 18s rRNA) of 
asthma subjects to ΔCt values of healthy subjects. As such, Table 3-3 also reports the 
mean Ct value ± SD of each enzyme investigated for each cohort, the 90% 
confidence interval of where the true effect lies and the level of significance (p 
value) of the difference in enzyme expression. Table 3-4 reports the likelihood that 
the difference between the two means is of practical significance. While not 
statistically significant there appears to be an 82.6% chance that the decreased 
expression of CBP observed in the sputum cell populations of the asthma cohort 
influences cellular pathways.  
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Figure 3-2: Distribution of HAT mRNA expression within asthma and healthy 
cohorts. 
Q-RT-PCR was performed on mRNA extracted from sputum samples of healthy and asthma subjects. 
Gene expression was normalised to housekeeping gene 18s rRNA where ΔCt = gene – 18s rRNA. 
Each point represents one subject and the horizontal bars represent the mean ± SE. Equality of 
variance between the two cohorts was determined using the Levene’s test for equality of variance.  
Data for ATF-2 (A) n = 15 asthma subjects (A) and 14 Healthy subjects (H), CBP (B) n = 14 A and 14 
H, p300 (C) n = 15A and 14H, P/CAF (D) n = 16A and 14 H, SRC-1 (E) n = 16A and 16H, and TIF-2 
(F) n = 14A and 15 H. *p<0.05 and **p<0.001 
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Table 3-3: Fold difference and confidence limits for mRNA expression of HAT enzymes in asthma and healthy airways. 
 
Gene 
Asthma vs. Healthy  
P 
Value 
Average ΔCt 
±  SD 
Asthma 
Cohort 
Average ΔCt 
±  SD Healthy 
Cohort 
Value of effect 
statistic 
(Difference 
between means of 
Ct Values) 
Degrees 
of 
freedom 
Level 
(%) for 
conf. 
limits 
Threshold values 
for... 
Outcome 
expressed as 
value, with 90% 
confidence 
interval 
2
-ΔΔCt 
Fold Difference ± 
SD +ive -ive 
ATF-2 2.18 ±  2.82  0.3 17.39 ±  0.72 17.41 ±  2.06 0.02 27 90 0.25 -0.25 0.02, -1.3 to 1.4 
CBP 0.95 ± 0.75 0.19 19.70 ±  1.42 18.85 ±  1.89 0.86 26 90 0.25 -0.25 0.86, -0.23 to 1.9 
P300 1.20 ± 0.25 0.71 15.41 ±  0.82 15.26 ±  1.34 0.15 27 90 0.25 -0.25 0.15, -0.53 to 0.83 
P/CAF 0.73 ± 0.96 0.55 18.82 ±  0.69 18.55 ±  1.44 0.27 28 90 0.25 -0.25 0.27, -0.45 to 0.99 
SRC-1 1.15 ± 0.85 0.55 20.17 ±  0.86 20.00 ±  1.70 0.16 30 90 0.25 -0.25 0.16, -0.62 to 0.94 
TIF-2 1.26 ± 1.22 0.33 17.75 ±  0.58 17.53 ±  1.65 0.22 27 90 0.25 -0.25 0.22, -0.55 to 0.99 
 
Table 3-4: Practical Significance of observed changes in mRNA HAT expression. 
 
Gene 
Chances that the true value of the effect statistic is…     
substantially +ive 
negligible or 
trivial 
substantially -ive 
Odds ratio 
benefit/harm Mechanistic Inference 
ATF-2 38.70% Possibly 24.60% Unlikely 36.80% Possibly 1 UC - More Data Required 
CBP 4.70% Very Unlikely 12.70% Unlikely 82.60% Likely 96 Likely Negative 
P300 40.20% Possibly 43.50% Possibly 16.30% Unlikely 3 UC - More Data Required 
P/CAF 51.90% Possibly 36.60% Possibly 11.50% Unlikely 8 UC - More Data Required 
SRC-1 42.30% Possibly 38.70% Possibly 19.00% Unlikely 8 UC - More Data Required 
TIF-2 47.40% Possibly 37.30% Possibly 15.40% Unlikely 5 UC - More Data Required 
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3.3.4 A tendency towards an increased mRNA expression of HDAC enzymes is 
observed in asthma airways. 
Changes in HAT enzyme expression may contribute to the exacerbated 
inflammatory response in asthma airways. However, it is hypothesised that the 
imbalance of HAT and HDAC enzyme expression within the airways contributes to a 
chronic inflammatory status. Thus, in order to determine if changes in the expression 
of HDAC enzymes are equal and opposite to changes observed in the expression of 
the HAT enzymes, Q-RT-PCR was used to determine the mRNA expression of 
HDAC enzymes in sputum samples from the healthy and asthma cohorts. Unlike the 
HAT enzymes investigated, the variation in HDAC enzyme expression was equally 
distributed amongst the 2 cohorts (Figure 3-3).  
Interestingly, despite the anticipated decrease in HDAC expression, analysis of the 
results suggests an increase in the mRNA expression of HDAC1, HDAC2 and 
HDAC3 in the asthma cohort compared to the healthy cohort. Table 3-5 reports the 
calculated fold difference in the mRNA expression levels of these HDACs. The fold 
difference was determined by directly comparing the ΔCt values (Gene expression 
normalised to 18s rRNA) of asthma subjects to ΔCt values of healthy subjects. Of the 
HDACs investigated only HDAC5 showed a decreased expression level in the 
asthma cohort compared to the healthy cohort. Table 3-6 reports the likelihood that 
the differences observed between the two cohorts has a practical influence on cellular 
pathways within the airways. The increase in HDAC1 expression and the decrease in 
HDAC5 expression observed in the asthma airways compared to the healthy cohort; 
is 81.8% and 86.1% likely (respectively) to be of practical importance.  
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Figure 3-3: mRNA Expression of HDAC Enzymes (Class I and II) is equally 
distributed within healthy and asthma cohorts. 
Q-RT-PCR was performed on mRNA extracted from samples of healthy and asthma subjects. Gene 
expression was normalised to the housekeeping gene 18s rRNA where ΔCt, gene – 18s rRNA. Each 
point represents one subject and the horizontal bars represent the mean ± SE. Equality of variance 
between the two cohorts was determined using the Levene’s test for equality of variance. HDAC1 (A.) 
n = 19A and 17 H, HDAC2 (B.) n = 19A and 17H, HDAC3 (C.) n =19A and 16H, HDAC4 (D.) n = 
19A and 17H and HDAC5 (E.) n = 17A and 16H.  
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Table 3-5: Fold difference and confidence limits for mRNA expression of HDAC enzymes in asthma and healthy airways. 
 
Gene 
Asthma vs. Healthy  
P 
Value 
Average ΔCt 
±  SD 
Asthma 
Cohort 
Average ΔCt 
±  SD 
Healthy 
Cohort 
Value of effect 
statistic (Difference 
between means of 
Ct Values) 
Degrees 
of 
freedom 
Level 
(%) for 
conf. 
limits 
Threshold values 
for... 
Outcome 
expressed as 
value, with 90% 
confidence 
interval 
2
-ΔΔCt 
Fold Difference ± SD 
+ive -ive 
HDAC1 1.95 ±  0.59 0.14 15.20 ±  1.20 15.84 ± 1.31 0.64 34 90 0.25 -0.25 0.64, -0.076 to 1.4 
HDAC2 2.42  ±  1.61 0.33 16.14 ± 1.86 16.81 ± 2.17  0.67 34 90 0.25 -0.25 0.67, -0.48 to 1.8 
HDAC3 1.88  ±  0.56 0.43 15.74 ± 1.38 16.13 ± 1.52 0.39 33 90 0.25 -0.25 0.39, -0.44 to 1.2 
HDAC4 1.11  ±  0.31 0.6 18.31 ± 1.42 18.06 ± 1.38 -0.25 34 90 0.25 -0.25 0.25, -1 to 0.55 
HDAC5 0.81 ±  0.37 0.15 18.54 ± 2.20 17.56 ± 1.55 -0.99 31 90 0.25 -0.25 0.99, -2.1 to 0.5 
 
Table 3-6: Practical Significance of observed changes in mRNA HDAC expression. 
 
Gene 
Chances that the true value of the effect statistic is… 
  
substantially +ive 
negligible or 
trivial 
substantially -ive 
Odds ratio 
benefit/harm 
Mechanistic Inference 
HDAC1 81.80% Likely 16.00% Unlikely 2.20% Very Unlikely 204 Likely Positive 
HDAC2 73.00% Possibly 17.80% Unlikely 9.20% Unlikely 27 UC - More Data Required 
HDAC3 61.20% Possibly 28.90% Possibly 9.90% Unlikely 14 UC - More Data Required 
HDAC4 14.90% Unlikely 35.10% Possibly 50.00% Possibly 14 UC - More Data Required 
HDAC5 3.70% Very Unlikely 10.20% Unlikely 86.10% Likely 0 Likely Negative 
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3.3.5 Q-RT-PCR analysis suggests SIRT6 mRNA is expressed at lower levels 
asthma airways. 
Previous studies have suggested both pro and anti-inflammatory roles for the 
SIRT enzymes in airway disease. However, their precise role in the asthma 
phenotype is yet to be understood. Thus, to determine if the SIRT enzymes were 
differentially expressed in asthma airways, Q-RT-PCR was performed on sputum 
samples collected from healthy and asthma subjects. Similar to the HDAC enzymes, 
the variation in enzyme expression amongst the SIRT family was considered to be 
evenly distributed between the two cohorts (Figure 3-4). 
Interestingly, of all the enzymes investigated difference in the expression of the SIRT 
enzymes between the two cohorts were the closet to being statistically significant. 
Table 3-7 reports the difference in the expression levels of the SIRT enzymes as a 
fold difference between the asthma and healthy cohorts. The fold difference was 
determined by directly comparing the ΔCt values (Gene expression normalised to 
18s rRNA) of asthma subjects to ΔCt values of healthy subjects.  Table 3-8 reports 
the likelihood that the perceived decreases in SIRT5 and SIRT6 enzyme expression 
observed in the asthma cohort would influence cellular pathways. There is an 87.2% 
and 89.7% chance that the decreased expression levels of SIRT5 and SIRT6 
(respectively) is of practical significance. 
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Figure 3-4: mRNA expression of Sirtuins (Class III HDAC) do not vary significantly 
between healthy and asthma sputum samples. 
Q-RT-PCR was performed on mRNA extracted from sputum samples of healthy and asthma subjects. 
Gene expression was normalised to housekeeping gene 18s rRNA, ΔCt refers to the mRNA expression 
of the gene – 18s rRNA. Each point represents one subject and the horizontal bars represent the mean 
± SE. Equality of variance between the two cohorts was determined using the Levenes test. SIRT1 
(A.) n = 14 A and 15 H, SIRT3 (B.) n = 18 A and 16 H, SIRT4 (C.) n = 14 A and 16 H, SIRT5 (D.) n = 
16 A and 16 H, and SIRT6 (E.) n = 17 A and 16 H. 
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Table 3-7: Fold difference and confidence limits for mRNA expression of SIRT enzymes in asthma and healthy airways. 
 
Gene 
Asthma vs. Healthy 
P 
Value 
Average ΔCt ±  
SD Asthma 
Cohort 
Average ΔCt ±  
SD Healthy 
Cohort 
Value of effect 
statistic 
(Difference 
between means 
of Ct Values) 
Degrees 
of 
freedom 
Level (%) 
for conf. 
limits 
Threshold 
values for... Outcome expressed as 
value, with 90% confidence 
interval 
2
-ΔΔCt 
Fold 
Difference ± SD 
+ive -ive 
SIRT1 4.39 ± 6.13 0.24 18.04 ± 3.46 19.31 ± 2.15 1.27 27 90 0.25 -0.25 1.3,-0.54 to 3.1 
SIRT3 1.23 ± 0.65 0.68 19.94 ± 1.27 19.73 ± 1.67 -0.21 32 90 0.25 -0.25 -0.21,-1.1 to 0.64 
SIRT4 2.19 ± 2.14 0.93 22.14 ± 2.67 22.23 ±  2.57 0.08 28 90 0.25 -0.25 0.08,-1.5 to 1.7 
SIRT5 0.63 ± 0.16 0.09 20.76 ± 1.17 20.00 ± 1.35 -0.77 30 90 0.25 -0.25 -0.77, -0.01 to -1.5 
SIRT6 0.59 ± 0.10 0.06 18.92 ± 1.19 18.16 ± 1.11 -0.77 31 90 0.25 -0.25 -0.77, -1.4 to -0.09 
 
Table 3-8: Practical Significance of observed changes in mRNA SIRT expression. 
 
Gene 
Chances that the true value of the effect statistic is…     
substantially +ive negligible or trivial substantially -ive 
Odds ratio 
benefit/harm Mechanistic Inference 
SIRT1 82.60% Likely 9.10% Unlikely 8.30% Unlikely 53 UC - More Data Required 
SIRT3 18.40% Unlikely 34.70% Possibly 46.90% Possibly 4 UC - More Data Required 
SIRT4 43.20% Possibly 20.30% Unlikely 36.50% Possibly 1 UC - More Data Required 
SIRT5 1.50% Unlikely 11.30% Unlikely 87.20% Likely 450 Likely Negative 
SIRT6 0.80% Unlikely 9.50% Unlikely 89.70% Likely 0 Likely Negative 
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3.3.6 No change in HAT or HDAC activity is observed in mild asthma. 
To determine if changes in mRNA expression could be attributed to the 
acetylation status of the airways, the overall HAT and HDAC activity of nuclear 
protein fractions from sputum samples were measured (Figure 3-4). Although a 
slight increase in HAT activity was observed in the asthma cohort (Figure 3-4A), this 
difference was not considered statistically significant. No difference in HDAC 
activity between the two cohorts was observed. These results suggest that in the 
airways of asthmatics at rest and healthy controls, there is no difference in the 
enzymatic activity of HAT and HDAC enzymes. However, it should be noted that 
the HDAC activity assay kits, do not measure the activity of the SIRT family of 
enzymes and, as such, SIRT activity within the airways was not measured.  
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Figure 3-5: HAT and HDAC activity in sputum samples of healthy and asthma 
individuals 
HAT and HDAC activity was measured in duplicate samples of 5μg of nuclear protein extracted from 
sputum samples. Results represent average activity observed ± SE where n=15. Average HAT activity 
(A) was measured at 120 ± 6.70 OD/hr/mg in the asthma cohort and 105.6 ± 6.20 OD/hr/mg in the 
healthy cohort (p = 0.13). Average HDAC activity (B) was measured at 1.31 ± 0.20 OD/hr/ml in the 
asthma cohort and 1.30 ± 0.18 OD/hr/ml in the healthy cohort (p = 0.97). 
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3.3.7 Is there a relationship between mRNA expression levels and subject 
characteristics? 
To determine if changes in the expression of HAT and HDAC enzymes could 
reflect an asthma phenotype, correlation analysis was used to assess if relationships 
existed between the expression of these enzymes and classical features of asthma. 
The correlation analysis between enzymes and asthma characteristics that were 
considered significant or close to significant are reported in Table 3-9. Pearson 
Product moment correlation indicated a loose, yet significant negative association 
between the expression levels of CBP and FEV1/FVC% (p < 0.05) (Figure 3.6A). As 
a decreased FEV1/FVC% ratio is often observed in asthma, this result suggests that 
changes in CBP expression could potentially influence lung function. While not 
statistically significant, the expression levels of HDAC5 also indicated a potential 
relationship with FEV1/FVC% (p < 0.1) (Figure 3.6B). Interestingly, the correlation 
analysis for HDAC5 also indicated other characteristics associated with asthma, such 
as reversibility, allergy and smoking, may be associated with its expression levels 
within the airways. However, these relationships were not considered to be 
statistically significant (Table 3-9).  
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Figure 3-6: Significant relationship between the expression of CBP and 
FEV1/FVC%. 
Abbreviations - CBP: CREB binding protein, FEV1: Forced expiratory volume in 1 second, FVC: 
Forced vital capacity, ΔCt: (CBP Ct – 18s rRNA Ct). (A). N= 14 A and 14H for CBP and (B) n = 17 A 
and 16 H for HDAC5 analysis. 
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Table 3-9: Correlation analysis of HAT and HDAC mRNA expression and general 
subject characteristics 
Gene Subject Characteristic Correlation Test R DF P Value 
ATF-2 Sample Volume Spearmans Rho -0.382 26 0.05 
SRC-1 Sample Volume Spearmans Rho -0.411 30 0.02
*
 
P300 Reversibility Spearmans Rho -0.326 27 0.08 
CBP Reversibility Pearson +0.342 26 0.09 
HDAC5 Reversibility Pearson +0.267 31 0.13 
HDAC5 Allergy Pearson -0.335 31 0.06 
HDAC5 Smoking in past 12mths Pearson +0.294 31 0.10 
SIRT1 Gender Pearson -0.402 27 0.03
*
 
SIRT1 Height Pearson -0.415 27 0.03
*
 
 
Abbreviations – DF: Degrees of Freedom, R: Correlation coefficient. Statistical tests used to 
determine relationships between gene expression and subject characteristics are indicated in the table. 
A significant relationship was deemed to exist where p < 0.05
*
. 
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3.4 DISCUSSION 
Epigenetic modifications, such as histone acetylation is a growing area of interest in 
asthma research. This investigation sought to determine if, the mRNA expression of 
HAT and HDAC enzymes was differentially expressed in asthma airways compared 
to healthy controls. HAT and HDAC enzymes regulate the dynamic process known 
as histone acetylation which has been shown to control the gene expression of a 
number of inflammatory proteins (Villagra et al., 2009b). Gene expression within an 
individual cell does not generally occur at a constant unchanging rate but rather, in 
response to internal and external stimulus gene expression constantly changes. For 
example, the TH2 cytokine, IL-13 is expressed at relatively low levels in asthma 
airways during a stable phase; however, during an asthma exacerbation the 
expression of this cytokine is found to be markedly increased in the airways 
(Calderon et al., 2009). Increases in protein expression can occur either by increased 
translation of existing mRNA or via increased transcription and translation of IL-13; 
a process that requires HAT and HDAC activity (Yamashita et al., 2002, Kaneko et 
al., 2007). Thus, the grouped expression levels of HAT enzymes observed in the 
asthma cohort (Figure 3-2) could potentially be interpreted as a consequence of 
chronic inflammation and the ongoing transcription of inflammatory proteins in 
asthma airways.  Furthermore, the HAT enzymes ATF-2 is known to be involved in 
the transcription of pro-inflammatory proteins such as TNF-α (Kuo et al., 2012, 
Bickford et al., 2011, Hall et al., 2005). TNF-α is a cytokine that is found to be in 
increased levels in airways of asthmatics (Russo and Polosa, 2005). However, no 
difference in inflammatory cell counts between the two cohorts was observed. Thus, 
this suggests that at least at a leukocyte level, the inflammatory status between the 
two cohorts remained the same.  An alternate hypothesis is that the observed 
grouping of the expression levels for these HAT enzymes in the asthma cohort may 
be caused via bronchial hyperresponsiveness.  
Asthma, although primarily thought to be an inflammatory disease, has three other 
major biological components; one of which is bronchial hyperresponsiveness – an 
exacerbated sensitivity to a stimulus. Hypertonic saline has previously been reported 
as an indirect stimulus that causes bronchial hyperresponsiveness which can lead to 
inflammation (Joos et al., 2003). Deterioration of FEV1 in response to hypertonic 
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saline over an induction period reflects an airways hypersensitivity to the 
administered saline.  Although deterioration of lung function during sputum 
induction was not observed within the cohorts of this study, the hypersensitivity of 
the asthma airways may have caused the hypertonic saline to initiate the immune 
pathways within the airways. Thus, the grouped expression level of HAT enzymes 
(Figure 3-2) observed in the asthma cohort may reflect the hypersensitivity of asthma 
airways.  
Contrary to HAT expression, the HDAC expression levels indicate a normal 
distribution of mRNA expression between the two cohorts (Figure 3-3). Previously 
studies have shown decreases in the protein expression of the enzymes HDAC1 and 
HDAC2 in asthma airways.  This decreased expression coincided with a decrease in 
overall HDAC activity (Cosio et al., 2004, Ito et al., 2002a). Here, rather than a 
decrease in HDAC expression, an increase in HDAC expression is observed within 
the asthma cohort. Although not statistically significant, the overall mRNA 
expression of HDAC1, HDAC2 and HDAC3 appeared to be increased in sputum 
samples from individuals with asthma compared to healthy controls (Table 3-5). 
Furthermore, while not statistically significant the increase in HDAC1 expression 
was considered to be 81.8% likely to influence cellular pathways. This data is clearly 
contradictory to the findings of the literature, however; the conflicting results are 
likely explained through two major differences between studies. Here, sputum 
samples (heterogeneous cell populations), were utilised to measure HAT and HDAC 
expression in the airways while previous studies have used a cell specific approach. 
Thus, the results of this study reflect a global expression of these enzymes in the 
airways. Decreases or increases, in the expression of enzymes such as HDAC1 and 
HDAC2 observed in a single cell population are likely to be masked by greater and 
more global changes in HDAC enzyme expression in a heterogeneous cell 
population.  
Another key difference between this study and Ito et al (2002a) and Cosio et al 
(2004) is the use of β2 agonists prior to the collection of the sputum sample (Cosio et 
al., 2004, Ito et al., 2002a). Studies have shown that potential pathways through 
which β2 agonist function involve suppressing NF-κB mediated inflammatory gene 
expression through the inhibition of histone acetylation (Nie et al., 2005b, Pang and 
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Knox, 2001). As such, there is some evidence that β2 agonists may influence the 
expression levels of HAT and HDAC enzymes.  Unfortunately, the ethical clearance 
for this study did not permit the performance of sputum induction without the prior 
use of β2 agonists.  While both cohorts received β2 agonists, whether or not the 
medication would have the same affect at a cellular level on asthma and healthy 
airways undergoing sputum induction is unknown. The use of β2 agonists may 
explain the increased HDAC expression but more so, it may also explain why a 
decreased expression of CBP is observed in asthma airways. Previous research has 
suggested that CBP is a key enzyme involved in the transcription of a number of pro-
inflammatory proteins (Clarke et al., 2010, Liu et al., 2004, Mantelingu et al., 2007, 
Reber et al., 2009, Zerfaoui et al., 2008) and, as such, it was expected that CBP 
levels would be increased in the asthma airways. However, while not statistically 
significant CBP was found to be slightly decreased in the asthma cohort, this 
decrease may be a direct result of the use of β2 agonists. Therefore, there is some 
ambiguity as to whether or not the perceived increases in HDAC expression and 
decreases in HAT expression are caused by a difference in expression levels between 
healthy and asthma airways or whether the prior use of β2 agonists have influenced 
these enzyme levels. 
Interestingly, while not significant, HDAC5 was the only class I/II enzyme that 
appeared to have decreased expression levels in the airways of asthmatics. Moreover 
this decrease appeared to be of some practical significance (Table 3-5).  Adding to 
this observation, correlation analysis revealed potential relationships between the 
expression levels of HDAC5 and classic asthma characteristics such as lower 
FEV1/FVC%, reversibility of the airways and a history of allergies. HDAC5 has 
previously been implicated as a key enzyme in muscle regulation (Yamashita et al., 
2002). A major biological cause behind asthma symptoms is the excessive 
bronchoconstriction of the airway smooth muscle. Thus, a potentially important 
relationship exists between HDAC5 and pulmonary function. However, despite these 
observed relationships, the correlation analysis and comparisons between the two 
cohorts for HDAC5 expression were not considered statistically significant. This may 
be due to a lack of HDAC5 expression in leukocytes. The mRNA expression of 
HDAC5 for both healthy and asthma cohorts was at the lower end of detection 
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(Figure 3-3E). The class II HDACs (including HDAC5) are known to be expressed 
in a tissue specific manner (Martin et al., 2009). Previously, Kankaankata et al 
(2010) investigated the role of HDAC inhibitors in inducing apoptosis. Kankaankata 
reported very low mRNA expression levels of HDAC5 in neutrophils and eosinophils 
(Kankaanranta et al., 2010). As the majority of cells in sputum samples are 
macrophages and neutrophils, it is reasonable to conclude that sputum samples are 
not the best sample for investigating the function and expression of HDAC5 in 
asthma. Thus, the reduced expression levels of HDAC5 observed in this study and its 
relationship to the asthma phenotype may be more pronounced in a more suitable 
tissue type, such as human airway smooth muscle.  
The final group of enzymes investigated in this study were the third class of HDACs: 
the SIRTs. SIRT1 is the most widely researched enzyme of the SIRT family. It has 
known roles in the aging process (Rahman et al., 2011, Morris, 2012). It has been 
difficult to establish a specific role for SIRT1 in airway disease, studies report both 
an anti – and pro – inflammatory role for the enzyme within the airways (Morris, 
2012), (Kim et al., 2010). As an explanation for the contrary findings, it has been 
proposed that SIRT1 potentially plays a protective role in inflammatory disorders 
where the T cell response is caused by an innate mechanism. These disorders include 
aging, oxidative stress and metabolic dysfunction. However, where an adaptive 
immune response is observed, in cases such as allergy driven inflammation, SIRT1 
may play a pro-inflammatory role (Legutko et al., 2011).  Here, the expression of 
SIRT1 was measured in sputum samples which largely reflect cells of the innate 
immune system. Although not significant, an increase in SIRT1 levels was observed 
in this asthma cohort and as such could reflect a pro-inflammatory role in asthma. 
However, this perceived increase in expression level is the result of high levels of 
SIRT1 expression in four samples from the asthma cohort (Figure 3-4A). As asthma 
is both environmentally and genetically stimulated, it is possible that SIRT1 may 
play both a protective and inflammatory role in this disease. For this study, subjects 
were recruited on the basis of their medication use rather than the causes of an 
asthma exacerbation (allergic/non-allergic). As such, it is possible that the variation 
in SIRT1 levels observed in the asthma cohort may be caused by a difference in the 
type of asthma individual’s experience (allergic/non-allergic).  Thus, the obtained 
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data may indicate different expression levels of SIRT1 in asthma compared to 
healthy controls, however; a more appropriate experiment where asthma subjects are 
recruited according to their type of asthma rather than control of asthma is required 
to determine if SIRT1 is increased or decreased in the airways.  
Unlike SIRT1, the mRNA expression levels of SIRT5 and SIRT6 indicate a decrease 
in gene expression in asthma airways. Interestingly, SIRT3, SIRT4 and SIRT5 are 
mitochondrial proteins which can act in coordination with SIRT1 (Gertz and 
Steegborn, 2009). Furthermore SIRT1 has been known to enhance SIRT6 expression 
and can regulate mitochondrial activity thus, influencing the production of metabolic 
intermediates (Gertz and Steegborn, 2009). Very little is known about SIRT5 and its 
function within leukocytes therefore, interpretation of the influence that decreased 
expression levels of this enzyme has on the asthma phenotype is difficult.  However, 
there is potential that SIRT1, SIRT5 and SIRT6 may act in concert with each other, 
and as such, a change in the expression of one enzyme may influence pathways of 
the others.  
While, not statistically significant (p = 0.06), further analysis of SIRT6 revealed that 
the decreased levels of SIRT6 in the asthma airways is likely to be of practical 
importance. SIRT6 first gained interest amongst scientists when it was discovered 
that SIRT6 knockout mice aged prematurely. Born healthy, the mice died 
prematurely almost a month later due to profound complications involving every 
bodily system (Mostoslavsky et al., 2006). The researchers concluded that SIRT6 
suppresses genomic instability in mouse cells. Interestingly, SIRT6 has also been 
suggested to regulate cellular senescence and inflammatory pathways (Minagawa et 
al., 2011). Kawahara et al (2009) have demonstrated the ability of SIRT6 to 
attenuate NF-κB signalling via H3K9 deacetylation at the chromatin level (Kawahara 
et al., 2009) and, as such, SIRT6 can influence the production of inflammatory 
cytokines within a cell. Thus, it appears SIRT6 may be a key regulator in controlling 
and attenuating inflammation. In this study, a lower expression level of SIRT6 (Table 
3-7) was observed in asthma airways compared to healthy controls. Given the 
important role that SIRT6 plays in regulating genomic stability, a reduction in its 
expression may lead to hyperactive inflammatory states.  
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Although results from this study detected moderate differences in enzyme expression 
levels between healthy and asthma individuals, these results were not considered 
statistically significant. Sample size calculations and sensitivity tests were performed 
for this project to determine, the sample size required to detect a difference in gene 
expression of 50% between the two cohorts (chapter  2, section 2.1). However, due 
to logistical constraints, a conservative number of 15 subjects within each cohort 
were used rather than the predicted 64 subjects. Sensitivity calculations suggested an 
effect size of 1.06 would be required to detect significant changes in enzyme 
expression between two cohorts of 15 subjects. Thus, the lack of significance within 
the study may be caused by this reduced cohort population. Furthermore, despite the 
initial subject cohorts of 19 asthma and 17 healthy subjects, the actual number of 
subjects able to be analysed for each target enzyme, varied depending on the amount 
of cDNA available for each experiment. As the total amount of sputum collected 
varies between subjects, so does the amount of RNA extracted from the samples. 
Although equivalent amounts of RNA were used in each experiment, the 
confinements of the procedure meant that subjects, who provided low volume 
sputum samples, could not be used in all Q-RT-PCR experiments and therefore the n 
value for these experiments was decreased.   
Overall, the study isolated the HAT and HDAC enzymes CBP, HDAC1, HDAC5, 
SIRT1, SIRT5 and SIRT6 as enzymes that are potentially expressed at different 
levels in the airways of individuals with asthma. Further investigations are required 
to determine how these enzymes may regulate underlying characteristics of the 
disease. The study also revealed a difference in the variation of the expression levels 
of HAT enzymes between the two cohorts. This raises a question in to how HAT 
enzymes are regulated within the airways. The airway epithelium is constantly 
protecting the body from potentially harmful stimuli, breathed in from an individual. 
As part of this protection process these enzymes may be expressed at varying levels 
within an individual’s airway. Thus, before establishing differences in expression 
levels between the two cohorts, it would be an advantage to determine whether or not 
a stable level of expression exists for these HAT and HDAC enzymes within the 
airways. Furthermore, previous studies have concluded that decrease in HDAC 
enzymes levels within the airway leads to an exacerbated inflammatory response 
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(Cosio et al., 2004, Ito et al., 2002a, Tirumurugaan et al., 2007, Ito et al., 2005). 
While there have been in vitro and in vivo animal studies that show decreased 
production of these enzymes leading to heightened inflammation (Grausenburger et 
al., 2010, Cao et al., 2007) thus far, no human study exists which shows the effect 
that induced inflammation has on the expression levels of these enzymes. Whether or 
not changes in HAT and HDAC levels are a precursor to an exacerbated 
inflammatory response or are merely a function of inflammation is yet to be observed 
in human airways.  While this investigation has highlighted some enzymes that may 
be of importance to the asthma phenotype, further studies are required to determine 
how these enzymes are regulated within the airways and how they respond to and 
influence inflammation.  
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CHAPTER 4:                                                                                                                  
THE MRNA EXPRESSION OF HAT AND HDAC ENZYMES IN 
RESPONSE TO INFLAMMATION IN THE AIRWAYS 
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4.1 INTRODUCTION 
The respiratory tract has a large epithelial surface area that is exposed to the external 
environment.  It is the barrier between the body and the external environment and 
provides the first line of defence against inhaled microbes, allergens and other 
particles (Lambrecht and Hammad, 2012). While asthma is often viewed and, as 
such, investigated as an allergy driven disease, it has been suggested that the 
interaction between respiratory epithelium and environmental triggers maybe more 
involved with the cause of disease, than merely the induction of an exacerbation 
(Lambrecht and Hammad, 2012). Particularly the disruption to the epithelium barrier 
explains why asthma patients are more susceptible to respiratory viruses and 
furthermore, why air pollution can cause an asthma exacerbations.  Thus, it has been 
postulated that asthma is primarily caused by defects within the barrier protection 
provided by the respiratory epithelium.    
In the past decade the role that epigenetic modifications play in the stimulation and 
control of inflammatory genes has become of great interest. There are numerous 
reviews which suggest alterations to histone acetylation pathways cause an increased 
recruitment of inflammatory proteins and cells to the airways (Barnes, 2006, Adcock 
et al., 2007, Barnes, 2010, Barnes, 2011, Durham et al., 2011, Adcock et al., 2005, 
Barnes, 2009b, Barnes, 2009a, Barnes et al., 2005, Barnes et al., 2004, Bhavsar et 
al., 2008, Chen and Greene, 2003, Clifford et al., 2011, Dekker and Haisma, 2009, 
Ho, 2010, Rigoli et al., 2011). The data from chapter 3 of this thesis has shown a 
difference in the variability of HAT enzyme mRNA expression levels between 
healthy and asthma airways. The disruption to the airway epithelium that is observed 
in asthma may cause prolonged activation of inflammatory pathways and, as such, 
result in the constant activation of HAT enzymes within the airways.  
While external environmental influences may alter the expression levels of HAT and 
HDAC enzymes within the airways the internal environment of the airways may also 
influence their expression levels. Previous research has shown decreased HDAC 
expression levels within the airways of individuals with asthma and other chronic 
inflammatory respiratory diseases (Ito et al., 2002, Ito et al., 2005). It has been 
hypothesised that the decreased HDAC expression levels lead to a heightened 
inflammatory response of the airways. However, the expression of HAT and HDAC 
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enzymes in response to a chronic inflammatory response has not been investigated in 
human airways. As such the observed decrease reported in these previous studies 
may be the result of chronic inflammation within the airways caused by dysfunction 
of the respiratory barrier, rather than a decrease in enzyme expression leading to an 
exacerbated inflammatory response. Thus, whether HAT and HDAC expression 
levels contribute to the homeostasis of the airways and respond to inflammation 
needs to be determined. 
Naturally occurring stimuli that cause asthma exacerbations do so via indirect 
mechanisms. Hypertonic saline - used during sputum induction - is not only a known 
indirect stimulant that causes bronchial hyperresponsiveness but also induces mild 
inflammation in the airways. Increases in neutrophil population numbers is observed 
within the airways post sputum induction using hypertonic saline, with the highest 
neutrophil numbers observed about six hours after the initial induction (Nightingale 
et al., 1998, van der Vaart et al., 2006).  The increase in neutrophil numbers after 
hypertonic saline treatment, coupled with the observed increase in neutrophils 
numbers during an asthma exacerbation provides further credibility to the idea that 
inflammation caused by hypertonic saline is reflective of an inflammatory response 
during an asthma exacerbation (Cockcroft, 2010). As such repeat sputum induction 
should be a viable method to determine how HAT and HDAC enzymes respond to an 
inflammatory response similar to that observed during an asthma exacerbation. 
Glucocorticoids are the anti-inflammatory therapy of choice in treating asthma. They 
control chronic inflammation and significantly minimise exacerbations of the 
disease. Within recent years, there have been major advances in understanding the 
molecular mechanisms through which glucocorticoids exert their effects. 
Glucocorticoids utilise transcriptional, translational and post translational pathways 
to reduce inflammation. They can activate anti-inflammatory genes and inactivate 
pro-inflammatory genes. Glucocorticoids have been shown to influence gene 
regulation via histone acetylation, and particularly the acetylation of histone 4 (H4). 
Administered glucocorticoids bind to the glucocorticoid receptor (GR), within the 
cytoplasm and translocates to the nucleus of the cell. Interaction between the DNA 
bound GR and transcriptional co-activators such as CBP causes acetylation of H4 
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which induces the expression of a number of anti-inflammatory proteins (Holownia 
et al., 2008, Barnes, 2011).  
An alternate action of glucocorticoids is through switching off pro-inflammatory 
gene transcription. Several studies have shown this can occur through the interaction 
of GR with the transcription factors NF-κB and AP-1. These inflammatory 
transcription factors are responsible for the initiation and production of a large 
number of inflammatory cytokines, chemokines, and adhesion molecules. 
Importantly, studies have shown that the specific recruitment of HDAC2 to the 
activated inflammatory gene complex by activated GR largely contributed to the 
switching off of these genes (Ito et al., 2000, Mukaida et al., 1994, Nie et al., 2005b, 
Ito et al., 2006). Patients who are known to be resistant to glucocorticoid therapy 
have been shown to have reduced HDAC2 levels in their airways, leading some 
researchers to believe that lower levels of HDAC2 may be the cause of their poor 
response to this medication (Li et al., 2010, Bartling and Drumm, 2009).  
Accumulating evidence suggests that histone acetylation plays a role in asthma, and 
this pathway can be exploited therapeutically to control an exacerbated inflammatory 
response. However, whether histone acetylation contributes to a state of chronic 
inflammation observed in asthma airways is unknown. Furthermore, whether or not 
or glucocorticoids influence HAT and HDAC expression directly is also unknown.  
To date, there is no study that examines the baseline expression levels of HAT and 
HDAC mRNA in the airways, or if the expression of these enzymes can be altered by 
a controlled inflammatory response. Thus, the aim of this study was to investigate 
whether several HAT and HDAC enzymes are differentially expressed in the airways 
of asthma individuals treating with short-acting bronchodilators and inhaled 
corticosteroids. Furthermore, this study aims to determine how these enzymes 
respond to induced inflammation caused by an external stimulus (hypertonic saline) 
that initiates similar inflammatory pathways observed during an asthma 
exacerbation.   
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4.2 MATERIALS AND METHODS 
4.2.1 Study Subjects 
Healthy individuals and individuals suffering from asthma were asked to 
participate in this study. Subjects who participated within this study met the 
following criteria: otherwise healthy, no respiratory tract infection for at least two 
weeks prior to participation, non-smoker, and not pregnant or breastfeeding. Asthma 
subjects were separated into two cohorts: those treating their symptoms with short 
acting beta2 agonists (Asthma β2), and those who used a daily regime of inhaled 
corticosteroids to treat their asthma (Asthma ICS). This investigation was approved 
by the university’s human research ethics committee; all subjects provided written 
informed consent prior to participation (Appendix A). 
4.2.2 Study Design 
The study timeline is shown in Figure 4-1. To determine whether, a stable 
expression level for HAT and HDAC enzymes existed in the airways and if induced 
inflammation altered HAT and HDAC gene expression levels, subjects were asked to 
participate in three separate sessions. Initial assessment included a medical health 
questionnaire (MHQ) (Appendix B), spirometry measurements and airway fluid 
sampling via sputum induction. A minimum of seven days passed before subjects 
were required to complete two consecutive visits six hours apart. During the 2
nd
 and 
3
rd
 visits, subjects performed spirometry, and sputum induction. Comparisons 
between samples collected at the first (time point 1 (TP1)) and second session (time 
point 2 (TP2) — baseline) were used to establish a stable phase level for HAT and 
HDAC enzymes within an individual’s airway. Comparison between samples 
collected at TP2 and the third session (time point 3 (TP3)), were used to determine if 
HAT and HDAC enzymes levels are altered in response to inflammation within the 
airways, as repeat sputum induction has previously been shown to cause 
inflammation of the airways (Nightingale et al., 1998, van der Vaart et al., 2006). 
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Figure 4-1: Study timeline 
The figure represents the study timeline. At TP1 subjects, filled out a MHQ, underwent spirometry 
and sputum induction followed by a waiting period of at least seven days.  Subjects then completed 
two consecutive sputum inductions held six hours apart (TP2 and TP3 respectively). 
4.2.3 Sputum Induction 
Sputum collection was performed as outlined in chapter 2, section 2.2. 
4.2.4 Processing Sputum sample 
Sputum samples were processed as outlined in chapter 2, section 2.3. 
4.2.5 RNA isolation and reverse transcription PCR (RT-PCR) 
Total RNA was isolated using a combined method utilising TRIzol
®
 Reagent 
(Life Technologies Australia) and an RNeasy Mini Kit (QIAGEN) as outlined in 
chapter 2, section 2.4. A total 100 ng of RNA was transcribed into cDNA using 
SuperScript
®
 III RT kit (Life Technologies Australia). The resulting cDNA products 
were used for Q-RT-PCR amplification.  
4.2.6 Quantitative Reverse Transcriptase Polymerase Chain Reaction (Q-RT-
PCR).  
The expression of HAT and HDAC enzymes within sputum cell populations 
were determined using specific primer sequences outlined in Table 4-1.  HAT and 
HDAC expression was normalised using 18s rRNA as a housekeeping gene control. 
A total of 20 ng of reverse transcribed cDNA was utilised in each real time PCR 
experiment. Each reaction consisted of 1X SYBR green Master Mix (Life 
Technologies Australia), 0.2 μm sense and anti-sense primer, 20 ng of cDNA and 
DEPC H2O to a volume of 20 μL. Triplicate reactions for each sample were 
performed on a Rotor Gene Q PCR machine (QIAGEN) under the following PCR 
conditions;  
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 Visit (TP3) 1
st
 visit (TP1) 
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Table 4-1: Q-RT-PCR Primers 
Gene Fwd Primer Reverse Primer Gene Sequence   
18s rRNA 5’ GATCCATTGGAGGGCAAGTCT 5’ CCAAGATCCAACTACGAGCTTTT  
E
a
sy
 O
li
g
o
, 
S
ig
m
a
 
A
ld
ri
ch
, 
N
S
W
 HDAC 1 5’ TGGGGACCTACGGGATATCGGG 5’ AAGACCACCGCACTAGGCTGGA NM_004964.2 
HDAC 2 5’ AACTGGCGGTTCAGTTCGTGGA 5’ CCTCAAGTCTCCTGTGCCAGGA NM_001527.3 
SIRTUIN 1 5’ ACTCCAAGGCCACGGATAGGTCC 5’ AGGTGGAGGTATTGTTTCCGGCA NM_012238.4 
SIRTUIN 6 5’ CATGTTTGTGGAAGAATGTGCC 5’ TAGGATGGTGTCCCTCAGCTCT NM_016539.2 
CBP 5’ GCTCGCTCCCGCATTGTCGAA 5’ TGCACAATGGGCAACTTGGCAG NM_004380.2 
SRC1 5’ GATGGAACCCAGCAGGTGCAA 5’ GGGTCTGTGGTCCTGACGTGG NM_003743.4 
ATF2 5’ GCCTGGATGTGGCCAGCGTTT 5’ TTGGTGTTGGGGTCTGATCAGCC NM_001256090.1 
4.2.7 Statistical Analysis 
Data is expressed as mean ± SE of n determinants as specified in figure 
legends. All statistical analysis was performed using IBM SPSS 19.0 (IBM 
Corporation) and GraphPad Prism 5.0 (GraphPad Software Inc). Data was analysed 
to determine: differences in enzyme expression levels between cohorts (Healthy, 
Asthma β2, Asthma ICS), differences in enzyme expression over time (TP1, TP2, 
and TP3), and if enzyme expression differed between the cohorts over the time 
course of the study (interaction between cohort and time). Furthermore, as sputum 
cell populations are heterogeneous the data was also analysed to determine if 
changes in expression levels could be attributed to a particular cell type within the 
sputum sample. Thus, analysis of pulmonary function, differential cell counts and Q-
RT-PCR, data was performed using linear mixed models. Time of induction was 
used as both a fixed effect and random effect in nested individuals. Significant 
difference between cohort characteristics was determined via a one way ANOVA 
and Tukey’s Post Hoc test.  Statistical significance was accepted where p < 0.05.  
Genes within a cell may or may not be expressed at constant unchanging 
levels. As the airway epithelium is constantly protecting the body from invading 
microbes and other harmful stimuli there is the potential that HAT and HDAC 
enzymes are expressed at varying levels within an individual’s airways. As such, 
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linear regression analysis was also used to determine if a stable phase for these 
enzymes existed within the airways. To determine if a stable phase existed subject’s 
HAT or HDAC TP2 (baseline) gene level (ΔCt gene) was plotted on the X axis 
against its TP1 gene level (ΔCt gene), which was plotted on the Y axis. If the enzyme 
is expressed at a stable level within each subject’s airways a relatively linear 
relationship (r
2
 =1) between TP1 and TP2 (baseline) intercepting at the origin of the 
graph, should be observed. This would suggest a controlled expression of these 
enzymes within the airways. In addition, the subject gene levels at (ΔCt gene) at TP3 
were also plotted on the Y axis against the TP2 (X axis) gene levels. If induced 
inflammation within the airways alters the levels of this enzyme in a proportional 
controlled manner, a linear relationship distinct from TP1 and TP2 should be 
observed between TP3 and TP2 gene expression (Figure 4-2). 
 
 
 
 
 
 
 
 
 
The figure represents the linear regression analysis performed for each HAT and HDAC gene 
investigated in this study. HAT or HDAC gene expression levels at TP2 (ΔCt) are plotted on the X 
axis, while the HAT or HDAC gene expression levels (ΔCt) at TP1 and TP3 are plotted on the Y axis. 
If stable levels of HAT or HDAC genes exist within the airways, the relationship between TP1&TP2 
expression levels should form a relatively straight line (r
2
 =1) intercepting at the origin on the graph. If 
induced inflammation alters (increases or decreases) the expression of these enzymes, in a controlled 
and proportional manner within the airways, the relationship between TP3& TP2 should form a 
relatively straight line (r
2
 =1), that does not intercept at the origin of the graph.  
Figure 4-2: Example of linear regression analysis – TP2 vs. TP1&TP3  
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4.3 RESULTS: 
4.3.1 Subject Characteristics 
A total of 44 subjects participated in this study, 15 healthy controls (10 
females), 15 asthma β2 (9 females) and 14 Asthma ICS (10 females). General subject 
characteristics are outlined in Table 4-2; pulmonary function of each cohort is 
outlined in Table 4-3. A more detailed description of cohort characteristics and 
pulmonary function can be found in Appendix C and D. In terms of general 
characteristics, the cohorts are alike in all recorded aspects except for self reported 
family history of asthma where both asthma cohorts indicate a significantly higher (p 
< 0.01) occurrence of hereditary asthma compared to the healthy controls. Pulmonary 
function was also recorded at each study time point. Interestingly, the FVC and 
sputum volume across all three cohorts is significantly reduced at TP3 compared to 
TP2. As expected, the airways response to β2 agonists (reversibility) is significantly 
higher (p < 0.01) in the asthma β2 cohort compared to the healthy controls and the 
asthma ICS cohort.  
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Table 4-2: Subject characteristics 
 Healthy  
n=15 
Asthma – β2  
n=15 
Asthma - ICS  
n= 14 
P Value 
H vs.β2 / H vs. ICS/ β2 vs. ICS 
Gender    
0.82 
ns/ns/ns 
Male 5 6 4 
Female 10 9 10 
Age (yrs) 25.3 ± 1.6 23.1 ± 1.6 27.4 ± 2.7 
0.32 
ns/ns/ns 
Height (cm) 170.7 ± 2.6 173.2 ± 2.9 170.6 ± 2.1 
0.71 
ns/ns/ns 
Weight (kg) 70.6 ± 3.7 69.0 ± 3.7 71.4 ± 3.3 
0.89 
ns/ns/ns 
BMI 24.2 ± 1.1 22.9 ± 1.0 24.6 ± 1.2 
0.54 
ns/ns/ns 
RTI (mths) 4.4 ± 1.5 2.6 ± 0.8 5.7 ± 1.3 
0.16 
ns/ns/ns 
Medication TS 
   
--- β2 agonists --- 11 14 
ICS --- --- 13# 
Medication > 6mths 
   
--- β2 agonists --- 11 14 
ICS --- 9 13# 
Allergy Self-Reported 
   0.94 
ns/ns/ns 
Yes 9 10 10 
No 6 5 4 
Smoker 
   0.13 
ns/ns/ns 
No 14 15 11 
Ex 1 --- 3 
Smoked > 12mths --- 3 --- --- 
Family History Asthma 
   
0.0084* 
s/s/ns 
Yes 2 11 9 
No 13 3 5 
Unsure --- 1 --- 
Family History DBTs 
   
0.33 
ns/ns/ns 
Yes 2 4 5 
No 13 8 9 
Unsure --- 3 --- 
Family History CVD 
   
0.78 
ns/ns/ns 
Yes 2 4 1 
No 12 9 12 
Unsure 1 2 1 
Family History  Cancer 
   
0.19 
ns/ns/ns 
Yes 4 2 8 
No 10 11 4 
Unsure 1 2 2 
Abbreviations: Yr - Year, Mths – Months, cm – Centimetres, kg – kilograms, BMI – Body Mass Index, 
β2 – Short acting beta agonists, ICS – Inhaled Corticosteroids, CVD – Cardiovascular Disease,  DBT – 
Diabetes, TS - Time of Study, ns – not significant, s – significant. Plus-minus values are means ± SE of 
the mean. Significant difference between cohort characteristics was detected via a one way ANOVA 
and Tukey’s Post Hoc test (ns/ns/ns). Significance* is considered when p < 0.05. 
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Table 4-3: Subject pulmonary function 
 
Healthy 
n= 15 
Asthma -β2 
n = 15 
Asthma - ICS 
n= 14 
P Value* 
P Value 
CohortxTime 
FEV1 (L)    0.402 
0.461 
TP2 (Baseline) 3.66 ± 0.18 3.29 ± 0.25 3.55 ± 0.15 
0.523 TP1 3.71 ± 0.21 3.42 ± 0.25 3.48 ± 0.14 
TP3 3.61 ± 0.19 3.26 ± 0.27 3.53 ± 0.16 
FVC (L)    0.551 
0.955 
TP2 (Baseline) 4.31 ± 0.24 3.92 ± 0.34 4.25 ± 0.20 
0.005
*
 
(TP2 vs. TP3) 
TP1 4.35 ± 0.25 3.97 ± 0.33 4.22 ± 0.20 
TP3 4.24 ± 0.23
*
 3.84 ± 0.33
*
 4.12 ± 0.19
*
 
FEV1/FVC %    0.874 
0.571 
TP2 (Baseline) 85.0 ± 0.01 85.0 ± 0.02 84.0 ± 0.02 
0.097 TP1 85.0 ± 0.01 84.0 ± 0.02 83.0 ± 0.02 
TP3 86.0 ± 0.02 85.0 ± 0.02 86.0 ± 0.02 
Reversibility %  *  0.025 (H vs. β2 ) 
0.877 
TP2 (Baseline) 0.74 ± 1.23 4.40 ± 1.37 2.29 ± 1.34 
0.153 TP1 1.07 ± 0.93 4.06 ± 1.69 3.07 ± 2.00 
TP3 2.18 ± 1.04 6.07 ± 1.85 4.01 ± 1.07 
S. Volume (mL)    0.918 
0.644 
TP2 (Baseline) 3.42 ± 0.51 3.40 ± 0.60 3.52 ± 0.42 
0.035
*
 
(TP2 vs.TP3) 
TP1 3.58 ± 0.32 3.52 ± 0.46 3.78 ± 0.37 
TP3 3.32 ± 0.49
*
 2.99 ± 0.51
*
 3.36 ± 0.43
*
 
Abbreviations: FEV1 - Forced expiratory Volume in 1 second, FVC - Forced Vital Capacity, L - 
Litres, mL - millilitres, S. Volume - Sputum Volume and Reversibility is defined as the percent 
change in FEV1 after short acting Bronchodilators are given.  
 
The table represents the pulmonary function of the cohorts at each time point of the 
study. Plus or minus values are the mean ± SE. Significance was determined using a 
linear mixed model and accepted where p < 0.05
*. The first column denoted ‘p 
Value’, reports significant difference in pulmonary function between cohorts (orange 
value) exist, the white p value reports significant differences within cohorts 
influenced by the time the session occurred. The final column (P Value – 
Cohort*Time), reports significant relationships caused by changes in pulmonary 
function over the time course, within a particular cohort.  
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4.3.2 Inflammatory Cell Counts 
To induce an inflammatory response within the airways, subjects participated 
in three sputum induction sessions. The sample collected at TP1 was collected at 
least one week prior to the baseline sample, and the TP3 sample was collected six 
hours after the baseline collection. To determine if repeat sputum induction (TP2 and 
TP3) caused inflammation within subject airways differential cell counts were 
performed on all samples collected. The subsequent counts were compared between 
and within subject cohorts. A detailed description of the differential cell counts can 
be found in Table 4-4. A significant decrease in macrophage concentration (p < 0.01) 
is observed within all cohorts six hours after baseline collection (TP3, Figure 4-2A). 
However, no significant difference in macrophage concentration is observed between 
cohorts at any time point during the study. Similarly, a significant increase in 
neutrophil numbers is observed within all cohorts six hours after baseline collection 
(p < 0.01) (TP3, Figure 4-2B) but, no difference in neutrophils numbers is observed 
between cohorts at any time point during the study.  
Unlike the neutrophils and macrophages, the concentration of eosinophils, which 
appear to have been unaffected via the inflammatory stimulus, is significantly higher 
in sputum samples collected from the asthma β2 cohort compared to the healthy 
cohort (p < 0.05) (Figure 4-2D). Furthermore, a significant increase in the 
concentration of epithelial cells is observed in the asthma ICS cohort compared to 
both the asthma β2 and healthy cohorts (p < 0.05) (Table 4-4). No significant 
difference in lymphocyte concentration was observed over the time course of the 
study or between cohorts (Figure 4-2C).  Finally, the overall total cell count was 
found to be significantly decreased across all cohorts at TP3 when compared to TP2 
and TP1 samples (p < 0.01) (Table 4-4). This result coincides with a significant 
decrease in sample volume observed in all cohorts at TP3 (p < 0.05) (Table 4-3). 
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Table 4-4: Differential cell count 
 
Healthy 
n =15 
Asthma - β2 
n=15 
Asthma – ICS 
n=14 
P Value* 
P Value 
Cohort*Time 
Total Cell Counts x 10
6
/mL 
   
0.742 
0.352 
TP2 (Baseline) 1.8 ± 1.6 1.9  ± 1.4 2.1 ± 1.5 
0.001* 
(TP2 vs. TP3) 
TP1 1.8 ± 1.3 1.8  ± 1.0 2.4 ± 1.4 
TP3 1.6 ± 1.2 1.6  ± 1.3 1.8 ± 1.6 
Neutrophils % 
   
0.700 
0.410 
TP2 (Baseline) 37.1 ± 23.1 40.8 ± 18.9 43.5 ± 16.4 
0.001* 
(TP2 vs. TP3) 
TP1 30.5 ± 22.6 39.4 ± 15.7 36.1 ± 21.8 
TP3 52.2 ± 25.4
*
 49.6 ± 22.3
*
 55.4 ± 18.0
*
 
Neutrophils x 10
4
/mL 
   
0.984 
0.412 
TP2 (Baseline) 23.3 ± 28.5 25.0 ± 16.1 23.1 ± 10.2 
0.009* 
(TP2 vs. TP3) 
TP1 17.6 ± 22.2 22.7 ± 15.5 22.5 ± 18.7 
TP3 30.5 ± 29.4
*
 27.1 ± 17.8
*
 28.3 ± 19.4
*
 
Eosinophils % 
 
* 
 
0.061 (H. Vs. β2) 
0.417 
TP2 (Baseline) 0.4 ± 0.8 8.1 ± 16.2 1.6 ± 4.0 
0.328 TP1 0.2 ± 0.6 3.0 ± 4.2 1.4 ± 3.5 
TP3 0.5 ± 0.8 7.6 ± 17.9 1.5 ± 3.3 
Eosinophils x 10
4
/mL 
 
* 
 
0.043* (H. Vs. β2) 
0.366 
TP2 (Baseline) 0.2 ± 0.3 3.8 ± 7.1 1.0 ± 2.8 
0.500 TP1 0.1 ± 0.2 1.3 ± 1.8 1.1 ± 3.3 
TP3 0.2 ± 0.3 2.7 ± 4.8 0.8 ± 2.0 
Macrophage % 
   
0.271 
0.835 
TP2 (Baseline) 60.8 ± 22.9 47.3 ± 20.1 51.0 ± 17.4 
0.001* 
(TP2 vs. TP3) 
TP1 64.7 ± 24.9 54.6 ± 16.7 54.9 ± 22.3 
TP3 45.4 ± 24.9
*
 40.5 ± 24.3
*
 40.0 ± 17.8
*
 
Macrophages x 10
4
/mL 
   
0.975 
0.241 
TP2 (Baseline) 28.4 ± 14.8 27.8 ± 17.7 28.5 ± 15.2 
0.001* 
(TP2 vs. TP3) 
TP1 30.5 ± 16.2 27.4 ± 10.0 31.8 ± 14.3 
TP3 18.1 ± 9.91
*
 24.3 ± 25.8
*
 16.7 ± 5.11
*
 
Lymphocytes % 
   
0.313 
0.541 
TP2 (Baseline) 1.7 ± 2.0 3.8 ± 4.6 3.8 ± 5.0 
0.065 TP1 4.5 ± 10.1 3.0 ± 2.7 7.6 ± 13.2 
TP3 1.9 ± 2.4 2.3 ± 1.8 3.0 ± 2.2 
Lymphocytes  x 10
4
/mL 
   
0.084 
0.187 
TP2 (Baseline) 0.69 ± 1.1 2.5 ± 3.6 2.0 ± 2.3 
0.086 TP1 1.41 ± 2.1 1.6 ± 1.6 6.3 ± 12.5 
TP3 0.88 ± 0.9 1.3 ± 1.3 1.6 ± 1.6 
C. Epithelial Cells % 
  
* 0.031 
0.059 
TP2 (Baseline) 6.4 ± 5.3 7.5 ± 5.4 9.2 ± 7.1 
0.109 TP1 7.2 ± 8.8 8.0 ± 6.9 18.5 ± 15.4
*
 
TP3 7.0 ± 5.6 8.6 ± 8.1 10.8 ± 8.3 
C. Epithelial Cells  x 10
4
/mL 
  
* 0.022 (ICS vs. H & β2) 
0.002* 
TP2 (Baseline) 3.2 ± 3.1 4.5 ± 4.0 4.8 ± 3.3 
0.078 TP1 3.0 ± 2.5 4.0 ± 3.4 10.6 ± 8.1
*
 
TP3 3.3 ± 3.2 5.2 ± 5.7 4.7 ± 3.9 
Squamous Cells % 
   
0.989 
0.060 
TP2 (Baseline) 19.6 ±   9.5 21.5 ± 11.6 20.3 ± 9.1 
0.988 TP1 19.8 ± 10.8 19.3 ±    9.8 22.0 ± 8.6 
TP3 21.3 ± 10.4 21.3 ± 10.7 18.6 ± 10.7 
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TABLE 4-4: DIFFERENTIAL CELL COUNTS 
The table represents the differential cell counts of the different study cohorts 
over the time course of the study, where plus or minus values are the mean ± SD. 
Significance was determined using linear mixed models and accepted where p < 
0.05*. The first column denoted ‘P Value’, reports whether a significant 
difference in cell populations between cohorts (orange value) exists.  The white 
value in the column reports the significance that time of induction had on cell 
populations within the sputum samples. The final column (P Value – 
Cohort*Time), reports whether a significant relationships exists between cell 
populations within a particular cohort at different time points of the study. 
Interestingly, there appears to be a significantly higher population of c. epithelial 
cells in the ICS asthma cohort at TP1 compared to baseline and TP3 collections.  
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Figure 4-3: Changes in differential cell counts compared to baseline samples 
The figure represents the changes in inflammatory cell counts, when compared to their baseline measurements. Change between TP1 and TP3 cell types to baseline 
measurements were compared by subtracting the calculated cells/ml from the baseline measurements for each subject. The mean change within each cohort is shown ± SE.  
Significance was determined using linear mixed models. Results were considered significant where p<0.05. * denotes a significant result observed due to time of induction, # 
denotes significant changes between cohorts.  
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Q-RT-PCR 
HAT and HDAC enzymes are of considerable interest in asthma and it is 
hypothesised that their expression and regulation may contribute to the asthma 
phenotype. However, whether or not these enzymes are expressed at a stable level 
within the airways that is influenced by external stimulus that causes an 
inflammatory response is unknown. In this study, in order to determine if 
inflammation could induce or influence the expression of these enzymes, mRNA was 
isolated from sputum samples from asthma individuals treating with short acting β2 
agonists and individuals treating with ICS, as well as healthy controls. The mRNA 
levels for the HAT and HDAC enzymes were quantified using Q-RT-PCR and fold 
change was determined using the 2
-ΔΔCt 
method. 
4.3.3 Expression of ATF-2 is unaffected by inflammatory stimulus and the 
asthma phenotype. 
Q-RT-PCR was used to determine changes in mRNA expression of ATF-2 
after induced inflammation. The first observation worthy of note is that there appears 
to be no difference in the variability of gene expression between and within cohorts 
over time (Figure 4-4A, C&E). Furthermore, it appears that the expression of ATF-2 
mRNA is tightly regulated within each individual. Linear regression analysis reveals 
a significant and clear relationship in terms of the expression of this enzyme within 
airway samples over the time course of the study (Figure 4-4B, D &F).   
As ATF-2 is a HAT enzyme, it was expected that an elevated ATF-2 mRNA 
expression would be observed in the asthma cohorts compared to the healthy 
controls. However, although not statistically significant, the analysis suggests a lower 
ATF-2 expression in both asthma cohorts when compared to healthy controls (Figure 
4-5A).  
The induced inflammatory response, caused by repeat sputum induction, had no 
statistically significant effect on the overall expression of ATF-2 within and between 
cohorts (Figure 4-5B).  
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Figure 4-4: Gene expression of ATF-2 within and between each cohort over the time 
course of the study. 
Figure 4-4A, C and E illustrate the variability of ATF-2 gene expression within each cohort 
throughout the study. ΔCt is defined as a subject’s ATF-2 Ct value (gene level) normalised to their 
respective 18s rRNA Ct value. Each point represents one subject, and the horizontal bar represents the 
mean. There is no significant variation in the expression of ATF-2 within and between cohorts over 
the time course of the study. Figure 4-4B, D and F illustrates the relationship of subject’s, ΔCt 
baseline levels to their respective TP1 and TP3 values. r
2
 reflects the coefficient of determination. As 
is clearly demonstrated in the figure, there is a strong relationship (p < 0.0001) within each cohort 
between subject’s baseline ATF-2 levels and their TP1 and TP3 levels. This suggests a controlled and 
stable regulation of ATF-2 within the airways. Data is representative of n=15 Healthy (H), n=15 
asthma β2 (β2), n=14 asthma ICS (ICS). 
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Figure 4-5: Differences in mRNA expression of ATF-2 
Figure 4-5A: Difference in gene expression of ATF-2 between study cohorts. The figure represents 
the difference between expression level of the asthma β2, asthma ICS and healthy cohorts over the 
time course of the study. A lower ΔCt value is interpreted as a higher level of gene expression within 
a particular cohort. ΔCt refers to a subject’s ATF-2 Ct value normalised to its respective 18s rRNA 
value. The clear separation of the 3 cohorts would suggest that ATF-2 is expressed at different levels 
in asthma airways compared to healthy controls, however this observation is not considered 
significant (p = 0.678). Data is representative of the mean ± SE where n= 15 H, n = 15 β2, n = 14 ICS. 
Figure 4-5B: Gene expression of ATF-2 after induced inflammation. This figure illustrates how 
ATF-2 levels responded to inflammation within the airways. TP1 and TP3 fold changes were 
determined via comparing subject’s ATF-2 ΔCt (gene level) at TP1 and TP3 to their baseline levels 
using the 2
-ΔΔCt
 method. The data is representative of the mean fold change observed within each 
cohort ± SE, where n= 15 H, n = 15 β2, n = 14 ICS. Overall, inflammation within the airways appears 
to have no effect on the expression levels of ATF-2 within each cohort (p = 0.731).  
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4.3.4 Induced Inflammation increases mRNA CBP expression 
Previous research has suggested that CBP is involved in the initiation of a 
number of inflammatory pathways (Clarke et al., 2010, Liu et al., 2004, Mantelingu 
et al., 2007, Reber et al., 2009, Zerfaoui et al., 2008).  Similar to ATF-2 there is no 
difference in the variability in mRNA expression of CBP within and between 
cohorts. Likewise, linear regression analysis also shows a controlled and stable 
regulation of CBP within an individual’s airways (Figure 4-6B, D & F).    
As CBP is a HAT enzyme it was expected that an increase in CBP expression would 
be observed in the asthma β2 cohort compared to the healthy cohort. Furthermore, as 
ICS’s attenuate inflammation it was expected that similar expression levels would be 
observed in the healthy and ICS cohorts.  These differences were observed in the 
expression of CBP (Figure 4-7A) between the cohorts however, despite this the 
differences in expression levels between the three cohorts was not statistically 
significant.  
In response to the inflammatory stimulus, the expression of CBP was increased 
across all cohorts at TP3, six hours after baseline collection (p < 0.05).  However 
suffering from asthma, and/or treating asthma with ICS appears to have no 
significant effect on the expression levels of CBP during an induced inflammatory 
response (Figure 4-7B).  
Sputum samples are a heterogeneous cell population and, as such, there is the 
potential that an increase or decrease in a particular cell type, such as neutrophils, 
over the time course of the study may influence the expression levels of CBP within 
the airways. Thus, linear mixed models were used to determine if a particular cell 
type within the sputum samples could be associated with an increase in CBP levels in 
the airways. Time of induction was used as both a fixed and random effect nested in 
individuals. The analysis suggested an association between CBP mRNA levels, and 
the concentration of lymphocytes within the sputum samples (p < 0.05). A separate 
analysis was also performed to determine if expression levels of CBP were 
associated with pulmonary function. While not statistically significant (p < 0.15), 
there appeared to be some association between CBP levels within the airways and 
Post FEV1 over the time course of the study.  
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Figure 4-6: Gene expression of CBP within and between each cohort over the time 
course of the study. 
 
Figure 4-6A, C and E illustrate the variability of CBP gene expression within each cohort throughout 
the study. ΔCt is defined as a subject’s CBP Ct value (gene level) normalised to their respective 18s 
rRNA Ct value. Each point represents one subject, and the horizontal bar represents the mean. There is 
no significant variation in the expression of CBP within and between cohorts over the time course of 
the study. Figure 4-6B, D and F illustrates the relationship between subject’s, ΔCt baseline values to 
their respective TP1 and TP3 values. r
2
 reflects the coefficient of determination. As is clearly 
demonstrated in the figure, there is a strong relationship (p < 0.0001) within each cohort between 
subject’s baseline CBP levels and their TP1 and TP3 levels. This suggests a controlled and stable 
regulation of CBP within the airways. Data is representative of n=15 H, n=15 β2, n=14 ICS. 
 
T P 2 T P 1 T P 3
8
1 2
1 6
2 0
2 4
(B a s e lin e )

C
t
C
B
P
1 2 1 6 2 0 2 4
1 2
1 6
2 0
2 4
TP1
TP3
r
2
= 0 .9 4
r
2
= 0 .9 3
p < 0 .0 0 0 1
p < 0 .0 0 0 1
B a s e lin e ( C t C B P )

C
t
C
B
P
T P 2 T P 1 T P 3
8
1 2
1 6
2 0
2 4
(B a s e lin e )

C
t
C
B
P
1 2 1 6 2 0 2 4
1 2
1 6
2 0
2 4
TP1
TP3
r
2
= 0 .9 6
r
2
= 0 .9 4 p < 0 .0 0 0 1
p < 0 .0 0 0 1
B a s e lin e ( C t C B P )

C
t
C
B
P
T P 2  T P 1 T P 3
8
1 2
1 6
2 0
2 4
(B a s e lin e )

C
t
C
B
P
1 2 1 6 2 0 2 4
1 2
1 6
2 0
2 4
TP1
TP3
r
2
= 0 .8 2
r
2
= 0 .8 9 p < 0 .0 0 0 1
p < 0 .0 0 0 1
B a s e lin e ( C t C B P )

C
t
C
B
P
A . B .
C . D .
E . F .
H e a lth y
A s th m a  2
A s th m a  IC S
113 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-7: Fold change in mRNA expression of CBP 
Figure 4-7A: Difference in gene expression of CBP between study cohorts. The figure represents 
the difference between CBP expression levels in the airways of the healthy, asthma β2 and the asthma 
ICS cohorts over the time course of the study. A lower ΔCt value is interpreted as a higher level of 
gene expression within a particular cohort.  ΔCt is defined as a subject’s CBP Ct value (gene level) 
normalised to their respective 18s rRNA Ct value. Despite, the higher CBP levels observed in the 
asthma cohort compared to the healthy cohort there is no statistically significant difference in CBP 
expression levels within healthy and asthma airways (p = 0.900). Data is representative of the mean ± 
SE where, n = 15 healthy, n = 15 β2, n = 14 ICS. Figure 4-7B: Gene Expression of CBP after 
induced inflammation.  This figure illustrates how CBP levels responded to inflammation within the 
airways. The fold change of CBP levels at TP1 and TP3 was determined via comparing subject’s CBP 
ΔCt level at TP1 and TP3 to their baseline levels using the 2-ΔΔCt method. The data is representative of 
the mean fold change within each cohort ± SE where, n = 15 H, n = 15 β2, n = 14 ICS. In response to 
inflammation within the airways CBP levels are increased (p = 0.02*). However, the asthma 
phenotype appears to have no influence on CBP expression levels within the airways during an 
inflammatory response.   
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4.3.5 Induced Inflammation causes an increase in SRC-1 expression in Healthy 
Airways. 
As was the case for ATF-2 and CBP, no difference in variability of SRC-1 
expression between and within cohorts was observed. However, unlike ATF-2 and 
CBP the linear regression analysis of the relationship between baseline, TP1 and TP3 
levels for SRC-1 reveal a less dynamic interaction. In the healthy and asthma β2 
cohort, a strong relationship in the expression of SRC-1 within subject’s airways is 
observed over the time course of the study (Figure 4-8B & D). However, within the 
ICS cohort there appears to be only a moderate relationship between baseline and 
TP1 levels of SRC-1 (r
2 
= 0.44 and p<0.05). This relationship dissociates when 
comparing baseline and TP3, SRC-1 levels (r
2
=0.27 and p < 0.10) (Figure 4-8F). This 
result suggests that the use of inhaled corticosteroids may affect the regulation and 
stability of SRC-1 within the airways. However, within the asthma ICS TP3 data set, 
there is an outlier; if this subject is removed the relationship between baseline and 
TP3 levels within ICS subject airways become significant and slightly stronger than 
the baseline/TP1 relationship (r
2
=0.61, p < 0.01).  
Interestingly SRC-1 appears to be expressed at lower levels within the asthma ICS 
cohort compared to the healthy and asthma β2 cohorts (Figure 4-8A). However, 
despite this observation the differences in expression levels within the airways are 
not considered statistically significant.  
Unlike CBP levels, SRC-1 levels were not increased in the airways of all the cohorts 
in response to the inflammatory stimulus. Rather, an increase in SRC-1 levels at TP3 
was observed only in the healthy cohort (p < 0.01). The lack of increase in SRC-1 
levels in the asthma cohort may suggest that the response of SRC-1 to an 
inflammatory stimulus is impacted upon by the asthma phenotype (Figure 4-9B).  
To determine if a particular cell type might be responsible for an increased 
expression of SRC-1 observed in the healthy airways, further data analysis was 
performed using a linear mixed model. Time was used as both a fixed effect and a 
random effect nested in individuals. The analysis did not associate the expression 
levels of SRC-1 with any one particular cell type.   
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Figure 4-8: Gene expression of SRC-1 within and between each cohort over the time 
course of the study. 
Figure 4-8A, C and E illustrates the variability of SRC-1 gene expression within each cohort 
throughout the study. ΔCt is defined as the subject’s SRC-1 Ct value (gene level) normalised to their 
respective 18s rRNA Ct value.  Each point represents one subject, and the horizontal bar represents the 
mean. There appears to be no significant variation in SRC-1 levels within and between cohorts over 
the time course of the study. Figure 4-8B, D and F illustrates the relationship of subject’s SRC-1 ΔCt 
baseline values to their respective TP1 and TP3 values. r
2
 reflects the coefficient of determination. As 
is clearly demonstrated in the figure, there is a strong relationship (p < 0.0001) within the healthy and 
asthma β2 cohort between subject’s baseline SRC-1 levels and their TP1 and TP3 levels. This suggests 
a controlled and stable regulation of SRC-1 within the airways. However, in the ICS cohort the 
regulation of SRC-1 appears to be less controlled. If the outlier is removed (black arrow) the 
relationship improves in strength but does not reach that of the other cohorts. Data is representative of 
n=15 H, n=15 β2, n=14 ICS. 
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Figure 4-9: Fold change in mRNA expression of SRC-1 
Figure 4-9A: Difference in Gene expression of SRC-1 between study cohorts. The figure 
represents the difference between expression levels of SRC-1 in the airways of the healthy, asthma β2 
and asthma ICS cohorts over the time course of the study. A low ΔCt is interpreted as a high level of 
gene expression within a particular cohort. ΔCt is defined as a subject’s SRC-1 Ct value (gene level) 
normalised to their respective 18s rRNA Ct value. There appears to be lower SRC-1 expression levels 
in the airways of the asthma ICS cohort in comparison to the asthma β2 and healthy cohort, however 
this difference is not considered to be statistically significant (p=0.639). Data is representative of the 
mean ± SEM where, n = 15 H, n = 15 β2, n =14 ICS. Figure 4-9B: Gene Expression of SRC-1 after 
induced inflammation. This figure illustrates how SRC-1 levels responded to inflammation within 
the airways. The fold changes of SRC-1 at TP1 and TP3 were determined via comparing subject’s 
SRC-1 ΔCt levels at TP1 and TP3 to their baseline levels using the 2-ΔΔCt method.  Data is 
representative of the mean fold change observed within each cohort ± SE where, n = 15 H, n = 15 β2, 
n =14 ICS. A significant increase in SRC-1 expression is observed in the healthy cohort at TP3 (p = 
0.007). However, no increase in SRC-1 levels is observed at TP3 in the asthma cohorts.  
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4.3.6 Inflammatory stimulus has no effect on HDAC1 mRNA expression 
Similar to the HAT enzymes, no difference in the variability of HDAC1 
expression was observed within and between cohorts. However, unlike the clear and 
definite relationships observed for the HAT enzymes within each individual’s 
airways, the linear regression analysis reveals a less controlled and stable expression 
of HDAC1 in asthma airways.  In particular, the relationship between subject’s 
baseline levels and HDAC1 levels at TP1 appear to have only a moderate relationship 
(r
2 = 0.65, β2 and 0.62, ICS) within asthma airways. However, comparison between 
baseline level and TP3 level indicate a stronger relationship for HDAC1 expression 
in these cohorts (r
2=0.81, β2 and 0.82, ICS) (Figure 4-10).   
In the previous study (chapter 3), HDAC1 mRNA expression was increased in the 
asthma β2 cohort compared to healthy controls. However, instead of observing a 
similar increase in HDAC1 expression, HDAC1 appears to be expressed at lower 
levels in the asthma β2 and ICS cohort compared to the healthy cohort. Despite, the 
perceived difference in expression levels between cohorts, the lower HDAC1 level in 
the asthma cohorts were not considered statistically significant (Figure 4-11A). 
In response to the inflammatory stimulus, no change in HDAC1 expression was 
observed between and within cohorts. However, somewhat unexpectedly the 
expression of HDAC1 appears to be significantly increased at TP1 compared to the 
baseline (p<0.05). This increase in HDAC1 expression at TP1 is observed across all 
cohorts (Figure 4-11B). This suggests that the expression levels of HDAC1 within 
the airways may fluctuate on a daily basis.  
As an increase in HDAC1 gene expression was observed at TP1, whether or not this 
increase could be associated with a particular cell type was also investigated. Linear 
mixed model analysis was used to determine if a particular cell type was associated 
with changes in HDAC1 levels. Time was used as both a fixed effect and a random 
effect nested in individuals. The models suggest an association between HDAC1 
levels and the concentration of columnar epithelial cells within the sample; however, 
this relationship is not considered significant (p = 0.094).  
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Figure 4-10: Gene expression of HDAC1 within and between cohorts over the time 
course of the study. 
Figure 4-10A, C and E illustrate the variability of HDAC1 gene expression within each cohort 
throughout the study. ΔCt is defined as the subject’s HDAC1 Ct value (gene level) normalised to their 
respective 18s rRNA Ct value. Each point represents one subject, and the horizontal bar represents the 
mean.  There is no significant variation in the expression of HDAC1 within and between cohorts over 
the time course of this study. Figure 4-10B, D and F, illustrates the linear relationship of the subjects 
HDAC1 ΔCt baseline values to their respective TP1 and TP3 values. r2 reflects the coefficient of 
determination. As is clearly demonstrated in the figure there is a strong relationship (p < 0.0001) 
within the healthy cohort between subject’s HDAC1 baseline, TP1 and TP3 levels. However, only a 
moderate relationship exists between baseline and TP1 HDAC1 levels within the asthma cohorts. Data 
is representative of n=15 healthy, n= 15 β2, n = 14 ICS. 
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Figure 4-11: Fold change in mRNA expression of HDAC1 
Figure 4-11A: Difference in gene expression of HDAC1 between study cohorts. The figure 
represents the difference between expression levels of HDAC1 in the airways of the healthy, asthma 
β2 and asthma ICS cohorts. A low ΔCt value is interpreted as a high level of gene expression within a 
particular cohort. ΔCt is defined at subject’s HDAC1 Ct value (gene level) normalised to their 
respective 18s rRNA Ct value. Despite, what appears to be a low expression of HDAC1 in the asthma 
ICS and β2 airways, compared to the healthy controls, this observation is not considered statistically 
significant (p = 0.618).  Data is representative of the mean ± SE where, n = 15 H, n = 15 β2, n= 14 
ICS. Figure 4-11B: Gene expression of HDAC1 after induced Inflammation. This figure illustrates 
how HDAC1 levels responded to inflammation within the airways. The fold change of HDAC1 at TP1 
and TP3 was determined via comparing subject’s HDAC1 levels to their baseline levels using the 2-
ΔΔCt 
method.  Data is representative of the mean fold change observed within each cohort ± SE, n = 15 
H, n = 15 β2, n= 14 ICS. Interestingly, the observed increased in HDAC1 levels at TP3 were not 
considered statistically significant. However, a significant increase in HDAC1 levels at TP1 is 
observed across all cohorts (p = 0.024*).  
H e a lth y A s th m a   2 A s th m a  IC S
0 .0
1 .0
2 .0
3 .0
4 .0
5 .0
6 .0
T P 1
T P 3
*
*
*
B a s e lin e  (T P 2 )
H
D
A
C
1
 F
o
ld
 C
h
a
n
g
e
A .
B .
T P 1 T P 2  (B a s e lin e ) T P 3
1 5
1 6
1 7
1 8
1 9
2 0
H ea lthy
A s th m a 2
A s th m a  IC S

C
t
H
D
A
C
1
120 
 
4.3.7 Inflammatory Stimulus has no effect on HDAC2 mRNA expression 
Unlike the previous enzymes investigated, the regulation in expression and 
control of HDAC2 within individuals appears to be less finite. The equality of 
variances tests within the healthy controls shows a significant variation in HDAC2 
expression within the cohort over the time course of the study (p < 0.05). Previous 
linear regression analysis revealed relatively strong baseline, TP1 and TP3 
relationships in HAT and HDAC enzymes within the airways of subjects. Here, the 
regression analysis for HDAC2 expression within each individual suggests the 
regulation of this enzyme is less controlled. Within the healthy cohorts, a moderate 
relationship is observed between the baseline and TP1 HDAC2 levels (r
2 
= 0.57); a 
weaker relationship is observed when comparing baseline and TP3 levels (r
2 
= 0.39). 
Interestingly, the asthma β2 and ICS cohorts also show a moderate relationship 
between baseline and TP1 HDAC2 levels within the airways (r
2 
= 0.62 and 0.51 
respectively). However, unlike the healthy cohort, the relationship between baseline 
and TP3 levels for HDAC2 appears to be improved in the asthma ICS cohort 
(r
2
=0.77, p = 0.0002). This result possibly reflects the known pathway in which ICS 
utilise HDAC2 to attenuate inflammation (Figure 4-12F).  
Similar to HDAC1, it was expected that an increase in HDAC2 would be observed in 
the asthma β2 cohort compared to the healthy controls. Furthermore, as inhaled 
corticosteroids have been shown to influence HDAC2 expression levels, it was 
expected that the ICS cohort would have similar expression levels to the healthy 
cohort. However, while no difference was observed between the HDAC2 levels in 
the healthy and asthma β2 cohorts, the results, although not significant, suggest lower 
HDAC2 levels in the ICS cohort compared to the asthma β2 and healthy cohorts 
(Figure 4.13A). 
Similar to HDAC1, induced inflammation had no effect on the expression levels of 
HDAC2. However, significant increases in HDAC2 mRNA levels were observed at 
TP1 when compared to the HDAC2 baseline levels (p<0.001). Having an asthma 
phenotype and/or treating with ICS appear to have no significant influence on these 
increased expression levels observed at TP1. Thus, it appears that like HDAC1, the 
mRNA expression levels of HDAC2 may be quite variable within the airways 
(Figure 4-13B).  
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As an increase in gene expression was observed over the time course of the study, a 
linear mixed model analysis was used to determine if a particular cell type within the 
sputum sample was potentially responsible for the increased expression of HDAC2. 
Time was used as both a fixed and a random effect nested in individuals. The model 
suggest an association between with the expression levels of HDAC2, and the 
concentration of columnar epithelial cells within the sample (p <0 .01).   
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Figure 4-12: Gene expression of HDAC2 within and between each study cohort over 
the time course of the study. 
Figure 4-12A, C and E illustrate the variability of HDAC2 gene expression within each cohort 
throughout the study. ΔCt is defined as the subject’s HDAC2 Ct value (gene level) normalised to their 
respective 18s rRNA Ct value. Each point represents one subject, and the horizontal bar represents the 
mean. There is a significantly different variation in the expression of HDAC2 within the healthy 
cohort (p = 0.01) over the time course of the study. Figure 4-12B, D and F illustrates the linear 
relationship of the subject’s HDAC2 ΔCt baseline values to their respective TP1 and TP3 values. r2 
reflects the coefficient of determination. Interestingly, unlike the previous enzymes only moderate 
relationships exist in the airways at TP1 and baseline HDAC2 levels. Interestingly the strongest 
relationship for HDAC2 was observed in the ICS cohort between baseline and TP3 levels, this 
possibly reflects the effect ICS have on the expression of HDAC2. Data is representative of n = 15 H, 
n = 15 β2, n = 14 ICS. 
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Figure 4-13: Fold changes in mRNA expression of HDAC2. 
Figure 4-13A: Difference in gene expression of HDAC2 between study cohorts. The figure 
represents the difference between expression levels of HDAC2 in the healthy, asthma β2 and ICS 
cohorts. A low ΔCt value is interpreted as a higher level of gene expression within a particular cohort. 
ΔCt is defined as a subject’s HDAC2 Ct values (gene level) normalised to their respective 18s rRNA 
Ct value. Despite, what appears to be a lower HDAC2 expression level in the ICS airways, there is no 
significant difference in the expression levels of HDAC2 between the study cohorts (p=0.465). Data is 
representative of the mean observed within each cohort ± SE where, n = 15H, n = 15 β2, n = 14 ICS. 
Figure 4-13B: Gene expression of HDAC2 after Induced Inflammation. This figure illustrates how 
HDAC2 levels responded to inflammation within the airways. The fold change of HDAC2 at TP1 and 
TP3 was determined via comparing subject’s HDAC2 levels at these time points to their baseline 
levels using the 2
-ΔΔCt 
method.  Data is representative of the mean fold change observed within each 
cohort ± SE where, n = 15 H, n = 15 β2, n = 14 ICS. The induced inflammation appears to have no 
effect on the expression levels of HDAC2; however, a higher level of HDAC2 within the airways, 
across all cohorts is observed at TP1 compared to the baseline (p=0.006*).  
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4.3.8 Expression of SIRT1 is increased in asthma airways in response to 
inflammation. 
While no difference in the variability of the SIRT1 mRNA is observed between 
the cohorts, the regulation of SIRT1 mRNA expression within the airways appears to 
be influenced by the asthma phenotype. The healthy cohort shows a strong regulated 
mRNA expression within their airways over the time course (p<0.0001). However, 
there appears to be no relationship between the expression levels of SIRT1 at baseline 
level and TP1 and TP3 in the airways of the asthma β2 cohort (r2 =0.24 and 0.28 
respectively). This suggests that SIRT1 may not be expressed at a stable and 
controlled level within asthma airways. Interestingly, the asthma ICS cohort, report a 
moderate relationship between baseline levels and TP1 and TP3 (r
2
 = 0.50 and 0.53). 
Thus, the use of inhaled corticosteroids may influence the expression levels of SIRT1 
within the airways (Figure 4-14D&F).  
As the sirtuins belong to the third class of HDACs, it was expected that a decrease in 
the SIRT1 mRNA levels would be observed in the asthma cohorts compared to the 
healthy controls. The results indicate that SIRT1 mRNA levels are expressed at lower 
levels in asthma airways; however this lower expression level is not considered 
statistically significant (Figure 4-15A).  
In response to the inflammatory stimulus, the expression of SIRT1 is significantly 
increased in the asthma β2 (p < 0.05) but not in the healthy and ICS cohort. 
However, while induced inflammation has caused an increase in the expression of 
SIRT1 in the asthma β2 cohort, the ICS cohort has a significantly increased 
expression level of SIRT1 at TP1 compared to the baseline session (p<0.05). This 
suggests that mRNA expression of SIRT1 is increased in the asthma phenotype in 
response to an inflammatory stimulus and that this increase may be controlled by ICS 
medication (Figure 4-15B).  
As an increase in gene expression was observed over the time course of the study, a 
linear mixed model analysis was used to determine if a particular cell type within the 
sputum sample may have been responsible for the increased expression of SIRT1 
levels. Time was used as both a fixed effect and a random effect nested in 
individuals. The models suggest a strong correlation with the expression of SIRT1 
and the concentration of columnar epithelial cells within the sample (p < 0.01).   
125 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-14: Gene expression of SIRT1 within and between each study cohort over 
the time course of the study. 
Figure 4-14A, C and E illustrate the variability of SIRT1 gene expression within each cohort 
throughout the study. ΔCt is defined as the subject’s SIRT1 Ct value (gene level) normalised to their 
respective 18s rRNA Ct value. Each point represents one subject, and the horizontal bar represents the 
mean.  There appears to be no significant variation in the expression of the SIRT1 within and between 
cohorts over the time course of the study. Figure 4-14B, D and F illustrates the linear relationship of 
the subjects SIRT1 ΔCt baseline values to their respective TP1 and TP3 values. r2 reflects the 
coefficient of determination. While the expression of SIRT1 shows a strong linear relationship in the 
healthy cohort, this same relationship is not observed in the asthma β2 cohort. Data is representative 
of n = 15 H, n = 15 β2, n = 14 ICS. 
 
T P 2  T P 1 T P 3
1 0
1 2
1 4
1 6
1 8
2 0
2 2
2 4
(B a s e lin e )

C
t
S
IR
T
1
1 2 1 5 1 8 2 1
1 2
1 5
1 8
2 1
2 4
TP1
TP3
r
2
= 0 .7 7
r
2
= 0 .8 7 p < 0 .0 0 0 1
p < 0 .0 0 0 1
B a s e lin e  (T P 2 ) ( C t S IR T 1 )

C
t
S
IR
T
1
T P 2  T P 1 T P 3
1 0
1 2
1 4
1 6
1 8
2 0
2 2
2 4
(B a s e lin e )

C
t
S
IR
T
1
1 2 1 5 1 8 2 1
1 2
1 5
1 8
2 1
2 4
TP1
TP3 r
2
= 0 .2 8
r
2
= 0 .2 4
p = 0 .0 7 4 4
p = 0 .0 4 8 3
B a s e lin e  (T P 2 ) ( C t S IR T 1 )

C
t
S
IR
T
1
T P 2 T P 1 T P 3
1 0
1 2
1 4
1 6
1 8
2 0
2 2
2 4
(B a s e lin e )

C
t
S
IR
T
1
1 2 1 5 1 8 2 1
1 2
1 5
1 8
2 1
2 4
TP1
TP3
r
2
= 0 .5 0
r
2
= 0 .5 3
p = 0 .0 0 4 4
p = 0 .0 0 3 0
B a s e lin e  (T P 2 ) ( C t S IR T 1 )

C
t
S
IR
T
1
A . B .
C . D .
E . F .
H e a lth y
A s th m a  2
A s th m a  IC S
126 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-15: Fold changes in mRNA expression of SIRT1. 
Figure 4-15A: Difference in gene expression of SIRT1 between study cohorts. The figure 
represents the difference between expression levels of SIRT1 in the healthy, asthma β2 and ICS 
cohorts. A low ΔCt value is interpreted as a higher level of gene expression within a particular cohort. 
ΔCt is defined at the subject’s SIRT1 Ct value (gene level) normalised to its respective 18s rRNA 
value. Interestingly, the data shows 3 distinct levels of SIRT1 within the airways of each cohort, with 
lower expression observed in the ICS cohort however, despite this distinction, there appears to be no 
significant difference in the expression levels of SIRT1 between these cohorts (p = 0.116).   Data is 
representative of the mean ± SE where, n = 15 H, n = 15 β2, n = 14 ICS.  Figure 4-15B: Gene 
expression of SIRT1 after Induced Inflammation. This figure illustrates how SIRT1 levels 
responded to inflammation within the airways. The fold change of SIRT1 at TP1 and TP3 was 
determined via comparing subject’s SIRT1 levels at these time points to their baseline levels using the 
2
-ΔΔCt 
method.  Data is representative of the mean fold change observed within each cohort ± SE, n = 
15 H, n = 15 β2, n = 14 ICS. There is a significant increase in SIRT1 levels at TP3 in the asthma β2 
cohort and a significant increase in SIRT1 levels at TP1 in the asthma ICS cohort (p < 0.05).  
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4.3.9 Induced Inflammation has no effect on the mRNA expression of SIRT6. 
Parallel to SIRT1 expression, no change in the variability of SIRT6 mRNA 
expression is observed. Interestingly, similar relationships between baseline and TP1 
and TP3 levels that were observed in SIRT1 expression within the airways are also 
observed within SIRT6 expression. The healthy cohort showed a strong relationship 
in SIRT6 expression levels over the time course of the study. This indicates a stable 
and controlled regulation of SIRT6 mRNA within the airways of healthy individuals 
(p < 0.0001) (Figure 4-16B). However, only a moderate relationship in SIRT6 
expression exists in the asthma β2 cohort when comparing baseline and TP1 and TP3 
levels (r
2
=0.48 and r
2
=0.44 respectively, Figure 4-16D). A similar relationship is 
observed in the ICS cohort at TP1 (r
2
=0.40) but this relationship is significantly 
improved when comparing baseline levels of the ICS cohort to the TP3 levels 
(r
2
=0.74) (Figure 4.16F). Thus, it is possible that the use of inhaled corticosteroids 
may influence SIRT6 expression during an inflammatory response in the airways. 
Previously, a lower SIRT6 expression was observed in the asthma β2 airways 
compared to healthy controls. Thus, it was expected a similar expression level would 
be observed in this study. However, a higher expression of SIRT6 mRNA was 
observed in the asthma β2 cohort compared to healthy cohort, furthermore a lower 
SIRT6 level is observed in the asthma ICS cohort compared to the healthy cohort.  
However, the differences between the three cohorts are not considered statistically 
significant (Figure 4.17A).  
The induced inflammatory response in the airways appeared to have no effect on the 
expression of SIRT6 in the healthy, asthma β2 or ICS cohorts.  Thus, if the use of 
inhaled corticosteroids influences SIRT6 regulation during an inflammatory response 
if may not do so through increasing or decreasing its expression levels within the 
airways, but may activate or recruit available SIRT6 enzyme to anti-inflammatory 
machinery (Figure 4.17B).  
As the data suggests that changes in gene expression between cohorts may exist, a 
linear mixed model analysis was used to determine if a particular cell type within the 
sputum sample could be responsible for the differences in SIRT6 expression observed 
between each cohort. Time was used as both a fixed effect and a random effect 
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nested in individuals. The models suggest an association between SIRT6 mRNA 
levels and the concentration of columnar epithelial cells within samples (p<0.05).   
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Figure 4-16: Gene expression of SIRT6 within and between each cohort over the time 
course of the study. 
Figure 4-16A, C and E illustrate the variability of SIRT6 gene expression within each cohort 
throughout the study. ΔCt is defined as the subject’s SIRT6 Ct value (gene level) normalised to their 
respective 18s rRNA Ct value. Each point represents one subject, and the horizontal bar represents the 
mean.  There appears to be no significant difference in variation in the expression of SIRT6 within and 
between cohorts over the time course of the study. Figure 4-16B, D and F illustrates the linear 
relationship of the subjects SIRT6 ΔCt baseline values to their respective TP1 and TP3 values. r2 
reflects the coefficient of determination. While a strong relationship for the expression of SIRT6 exists 
in healthy airways only a moderate relationship between SIRT6 expression levels within the airways 
exists in the asthma cohorts. Data is representative of n = 15 H, n = 15 β2, n =14 ICS. 
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Figure 4-17: Fold changes in mRNA expression of SIRT6. 
Figure 4-17A: Difference in gene expression of SIRT6 between study cohorts. The figure 
represents the difference between expression levels of the healthy, asthma β2 and ICS cohorts. A low 
ΔCt value is interpreted as a higher level of gene expression within a particular cohort. ΔCt is defined 
as a subject’s SIRT6 Ct value (gene level) normalised to their respective 18s rRNA value. Like SIRT1, 
there appears to be a clear distinction between the expression levels of SIRT6 in the airways between 
the 3 cohorts. SIRT6 appears to have a higher level of expression in asthma β2 cohort in comparison to 
the healthy and asthma ICS cohorts.  However, the difference in expression of SIRT6 between cohorts 
is not considered statistically significant (p=0.085). Data is representative of the mean ± SE, n = 15 H, 
n = 15 β2, n = 14 ICS. Figure 4-17B: Gene expression of SIRT6 after Induced Inflammation. This 
figure illustrates how SIRT6 levels responded to inflammation within the airways. The fold change for 
SIRT6 at TP1 and TP3 was determined via comparing SIRT6 levels at these time points to their 
baseline levels using the 2
-ΔΔCt 
method. The data is representative of the mean fold change observed 
within each cohort ± SE where, n = 15 H, n = 15 β2, n =14 ICS. The level of SIRT6 within the airways 
appear to be unaffected by inflammation.  
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4.4 DISCUSSION 
The influences epigenetic modifications like histone acetylation have on 
complex diseases are of great interest to researchers. Studying the expression of the 
enzymes that influence these disease pathways can help define to what magnitude 
certain modifications contribute to disease onset and cause. Thus, the aims of this 
study were to determine if: HAT and HDAC enzymes are expressed at constant, 
regulated levels within an individual’s airway and whether these enzymes are 
expressed at different levels in healthy and asthma airways. Finally the study also 
investigated whether or not the expression of these enzymes could be altered under 
induced inflammatory conditions.  
Airway inflammation was induced by repeat sputum induction sessions held six 
hours apart. Coinciding with previous studies (Nightingale et al., 1998, van der Vaart 
et al., 2006), an induced inflammatory response was achieved by repeat sputum 
induction, as evident by the increase in neutrophil numbers observed in all cohorts at 
TP3 (Figure 4-2B). However, the results also suggest a decrease in the concentration 
of macrophages at TP3 (Figure 4-2A). It is important to note that while a decrease in 
macrophage concentration is observed, this should not be interpreted as a decreased 
recruitment of these cells to the airways. Rather, due to the confinements of the 
differential cell count procedure increases in one cell type will have a direct effect on 
the concentration of other cell types. Changes in cell population between the cohorts 
highlight the different environments of the airways. The observed increase in 
eosinophil numbers in the asthma β2 cohort reflects a potentially allergy driven 
asthma phenotype within this cohort. Interestingly severe asthma is associated with 
the thickening and lining of the airway walls and proliferation of epithelial cells 
(Cohen et al., 2007). An increased epithelial concentration in sputum samples from 
the asthma ICS cohort compared to the asthma β2 and healthy cohorts was observed 
within this study. Thus, as expected it is likely that the subject’s recruited who were 
treating their asthma with ICS suffered from a more severe form of asthma.    
An increase in the expression of HAT enzymes was expected to be observed amongst 
all the cohorts at TP3. This would indicate an increased production of inflammatory 
cytokines in the airways; coinciding with an increase number of inflammatory cells 
to the airways however, this was rarely observed.  In response to inflammation the 
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expression levels of ATF-2 within the airways appeared to be unaffected. 
Furthermore, there was no significant difference in the expression levels of ATF-2 
between the cohorts. ATF-2 is a key enzyme involved in activating the inflammatory 
cytokine TNF-α. TNF-α is known to stimulate and recruit neutrophils and monocytes 
to a site of an infection. Thus, given the increase in neutrophil numbers in the 
airways at TP3 it was expected that ATF-2 levels would also be altered in response to 
induced inflammation within the airways (Tsai et al., 1996, Tesz et al., 2007, 
Thomas, 2001). Interestingly, a strong and controlled regulation of ATF-2 levels was 
observed within each individual’s airways within the cohorts. It is possible that the 
hypertonic saline used to induce inflammation within the airways, was too mild a 
stimulant to induce ATF-2 driven inflammatory pathways.   
Where the expression of ATF-2 appears to be unaffected by hypertonic saline, CBP 
was significantly increased at TP3 amongst all cohorts (Figure 4-7B). However, it 
appears that CBP levels within the healthy cohort had the greatest response to the 
inflammatory stimulus while a more restrained response is observed in the asthma 
cohorts. Previous studies have shown that glucocorticoids can activate anti-
inflammatory pathways via the recruitment of CBP to acetylate H4 to induce anti-
inflammatory gene expression which include genes such as β2 adrenergic receptors 
(Ito et al., 2000). Thus, CBP can activate β2 adrenergic receptors and is potentially 
utilised by inhaled corticosteroids to control inflammation (Barnes, 2006). Because 
of the daily use of corticosteroids by the ICS cohort, and the administration of β2 
agonists prior to sputum induction, it is possible that the asthma airways were far 
more adapt to dealing with this inflammatory stimulus than the healthy airways. 
However, Ito et al (2000) also showed that only in the absence of HDAC activity is 
CBP utilised by glucocorticoids to attenuate inflammation (Ito et al., 2000). Despite 
this, the increase in the expression of CBP due to inflammation independent of the 
cohorts corroborates the in vivo data; that demonstrate CBP plays an important role 
in inflammatory pathways. However, there is some ambiguity as to whether or not 
CBP is involved in pro or anti- inflammatory pathways within the airways. As 
discussed earlier, studies have shown that glucocorticoids can recruit CBP to 
acetylate H4 and induce anti-inflammatory pathways (Ito et al., 2000). Furthermore, 
previous studies have reported an active and important role for CBP in attenuating 
inflammation (McKay and Cidlowski, 2000). On the other hand, many studies 
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suggest a pro-inflammatory role for CBP, where its activation induces the 
transcription of a number of pro-inflammatory genes (Chen et al., 2007, Lim et al., 
2011b, Kino et al., 1999). Thus, while the investigation has shown that CBP levels 
are increased under inflammatory conditions within the airways whether or not this 
increase is reflective of a pro or anti-inflammatory pathway requires further 
investigation. Interestingly, changes in CBP levels were significantly associated with 
the concentration of lymphocytes within a sputum sample. The lymphocytes play a 
key role in the immune response; thus, changes in CBP expression within the 
airways may be reflective of induced gene expression occurring within the 
lymphocyte cell population.  
Steroid Receptor Co-activator 1 (SRC-1) was the final HAT investigated in this 
study. While regression analysis of ATF-2 and CBP revealed strong and controlled 
regulation of these enzymes within individuals, a similar relationship was not 
observed for the expression levels of SRC-1 within the airways of all cohorts. At TP3 
the ICS cohort indicated the expression of SRC-1 in subjects taking inhaled 
corticosteroids was not directly associated with their baseline levels. SRC-1 has been 
implicated in glucocorticoid pathways (Meijer et al., 2005). The range of inhaled 
corticosteroid medication utilised via the asthma ICS cohort may account for the 
instability of the expression of this enzyme within the airways of subjects from this 
cohort. Interestingly, studies have shown that for SRC-mediated transcriptional 
activity to occur, co-activators such as CBP and p300 are required to be recruited to 
the chromatin structure (Waters et al., 2006). This may explain why a similar change 
in expression across the cohorts in response to the inflammation is observed for CBP 
and SRC-1 (Figure 4-6B and 4-8B). However, unlike CBP, the increase in SRC-1 
levels is significant only within the healthy cohort at TP3. The lack of response by 
SRC-1 in the asthma cohorts could reflect a disrupted synergy between CBP and 
SRC-1 caused by the initiation of inflammation or the use of asthma medication. 
Alternatively, the results could simply indicate that in asthma airways there is a fault 
in the regulation of the function of SRC-1; an interesting concept given SRC-1 is a 
HAT that has an important role in regulating histone H4 K5 acetylation. H4K5 
acetylation is an area of the genome believed to induce gene expression for a number 
of inflammatory cytokines (Li et al., 2007, Li et al., 2003). However, given the 
perceived instability of SRC-1 in the airways of asthmatics using inhaled 
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corticosteroids and that, glucocorticoids potentially utilise CBP it is more likely that 
the use of inhaled corticosteroid medications influence the expression of SRC-1 in 
asthma airways. Thus, further investigation focusing on the function and role of 
SRC-1 in glucocorticoid pathways may provide key insights in to the molecular 
mechanisms that regulate inflammation within the airways.  
Of the histone deacetylases, the expression levels of HDAC1, HDAC2, SIRT1 and 
SIRT6 in response to induced inflammation were investigated in this study. In 
response to induced inflammation it was expected that the expression of these 
enzymes would be decreased in the asthma β2 cohort compared to the healthy 
controls and ICS cohorts. Thus, reflecting an over active inflammatory pathway 
within asthma β2 airways.  
Unlike, the HAT enzymes the inflammatory status of the airways at TP3 had no 
significant affect on the expression levels of HDAC1 or HDAC2. Interestingly, it 
appears that the expression levels of these enzymes at TP1 were significantly 
increased compared to baseline levels. Furthermore, the regression analysis for both 
HDAC1 and HDAC2 suggested that an irregular expression of these enzymes within 
the airways particularly within the asthma cohort may exist. This could potentially 
reflect the disruption of the airway epithelium barrier observed in asthma airways. 
Whereby, disruptions to this epithelium barrier cause the activation of heightened 
and exacerbated inflammatory pathways within the epithelial cells, and, as such alter 
the expression levels of HDAC1 and HDAC2 within these cellular populations.   
Interestingly, further statistical analysis revealed that the expression levels of 
HDAC2 (p < 0.01) and potentially HDAC1 (p = 0.094) was associated with the 
concentration of columnar epithelial cells within the airway samples.   Analysis of 
the differential cell counts demonstrate an increase in columnar epithelial cells in the 
asthma ICS cohort compared to the healthy and asthma β2 cohorts. Furthermore, the 
highest concentration of columnar epithelial cells within the ICS cohort is observed 
at TP1. Thus, the increased concentration of columnar epithelial cells within the 
airway samples from the ICS cohort are potentially the cause of the increased 
expression levels of HDAC1 and HDAC2 observed at TP1 compared to baseline 
levels within this cohort.   
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In agreement with the previous study (chapter 3), there appeared to be no significant 
difference in the expression levels of HDAC1 and HDAC2 in the asthma β2 airways 
compared to healthy airways. These results are contrary to previous studies (Ito et 
al., 2002a) that suggests a decrease in both HDAC1 and HDAC2 enzymes within 
asthma airways of individuals treating with bronchodilators. As discussed earlier 
these studies investigated HDAC expression in bronchial epithelial cells and alveolar 
macrophages extracted from asthma airways. As sputum samples consist of a 
heterogeneous cell population it is possible that changes of enzyme expression within 
a specific cell types are masked by other cell populations. Interestingly, statistical 
analysis for this study revealed a significantly higher number of epithelial cells 
within the airway samples of the ICS cohort. If HDAC1 and HDAC2 are expressed 
by the epithelial cells within the airways, then it would be expected that increased 
levels of HDAC1 and HDAC2 would be observed in the ICS cohort compared to the 
asthma β2 and healthy cohorts. However, this was not the case as the ICS cohort 
appeared to have a lower expression level, although not significant, of both enzymes 
compared to the other cohorts.  Thus, the lack of significance may inadvertently 
reflect a reduced level of HDAC1 and HDAC2 enzymes expression within airways 
of individuals suffering from severe asthma.    
It is well known that HDAC2 is utilised by glucocorticoids to deacetylate NF-κB to 
attenuate inflammation (Chen et al., 2012). The regression analysis of HDAC2 
revealed a strong relationship between baseline HDAC2 levels and TP3 levels within 
the airways of subjects from the ICS cohort. This suggests that the inhaled 
corticosteroids may have influenced the regulation of HDAC2 in the inflamed 
airways of the ICS cohort. 
Of the HDAC family, the Sirtuins are the least studied in airway disease however the 
results of this study suggest that the expression of SIRT1 and SIRT6 within the 
airways may be influenced by the asthma phenotype. The linear regression analysis 
of the HAT enzymes indicated relatively stable expression levels for these enzymes 
within the airways that responded proportionally to the inflammatory stimulus. 
However, in the asthma β2 cohort the linear regression analysis of SIRT1 revealed a 
different dynamic. There appeared to be no stability in the expression levels of SIRT1 
within the airways of subjects from the asthma β2 cohort. Furthermore, while the use 
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of ICS showed a slightly more stable expression for this enzyme within the airways 
of the asthma ICS cohort, the stability of the enzyme expression was not as strong as 
that observed in the airways of the healthy cohort. This suggests that mRNA 
expression of SIRT1 within the asthma airways is unstable and that the use of inhaled 
corticosteroids may slightly improve SIRT1 regulation within the airway. 
Interestingly studies have shown that SIRT1 is a mediator of genomic and epigenetic 
maintenance within a cell (Chen, 2012, Fatoba and Okorokov, 2011). Thus, the 
instability of this enzyme within the airways may cause a disruption to epigenetic 
pathways that ultimately contributes to the asthma phenotype. 
A study which utilised asthma murine models was able to reduce OVA stimulated 
allergic response by the use of the SIRT1 inhibitor, sirtinol.  They found that sirtinol 
reduced increased: SIRT1 levels, inflammatory cell numbers, airway 
hyperresponsiveness, and the cytokines IL-4, IL-5 and IL -13 expression, that was 
caused by OVA stimulation within the airways of the mice (Kim et al., 2010). Here, 
the data for the asthma β2 cohort shows an increase in SIRT1 expression when 
inflammation is induced in the airways. This increase was not observed in the ICS 
cohort at TP3. As such, it is possible that the use of inhaled corticosteroids may 
influence the expression of SIRT1 within the airways. However, similar to HDAC1 
and HDAC2 expression, the ICS cohort show a higher expression level of SIRT1 at 
TP1 compared to baseline levels. Statistical analysis also revealed a strong 
association between the concentration of columnar epithelial cells within samples 
and the expression levels of SIRT1. As higher numbers of columnar epithelial cells 
are observed in the ICS cohort at TP1, it is possible that this increase in SIRT1 levels 
is caused by the increased concentration of columnar epithelial cells within samples 
from the ICS cohort.   
Similar to SIRT1, a less controlled expression of SIRT6 is observed within asthma 
airways when compared to the healthy airways. Interestingly, it has been 
demonstrated that SIRT6 plays a major role in genomic stability. Researchers have 
shown that the suppression of SIRT6 within cells caused premature ageing and death 
in mice (Mostoslavsky et al., 2006). Thus, like SIRT1 instability of this enzyme 
within the airways may impact epigenetic pathways and contribute to a disease state.   
Furthermore, of all the HAT and HDACs investigated, SIRT6 was the enzyme most 
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likely to be differentially expressed within the asthma airways (p = 0.085). At 
present, no study exists which have investigated the role that SIRT6 may play in 
asthma. However, a study performed by Minagawa et al which investigated the role 
of SIRT6 in idiopathic pulmonary fibrosis, illustrated a function for SIRT6 whereby 
its over-expression inhibited TGF-β induced senescence in human bronchial 
epithelial cells (Minagawa et al., 2011). Thus, SIRT6 ability to prevent biological 
aging in epithelial cells may explain why there appears to be an increase in its 
expression in the asthma airways. Proliferation of epithelial cells and remodelling of 
the airways is a key feature of the asthma phenotype. Furthermore, Kawahara et al 
(2009) have shown that SIRT6 functions at a chromatin level to prevent NF-κB 
signalling, and that an increase in NF-κB driven gene expression and cellular 
senescence is observed in SIRT6 deficient cells. Thus, this further suggests that 
SIRT6 may play a key role in  controlling inflammation (Kawahara et al., 2009).   
Similar to HDAC1, HDAC2, and SIRT1 a statistical analysis suggested the 
concentration of columnar epithelial cells within the airways was strongly associated 
with SIRT6 expression levels. Interestingly, the statistical analysis indicated no 
association between neutrophils concentration within samples and elevated gene 
levels. This suggests that induced inflammation, caused by hypertonic saline, may 
cause an increase in HAT and HDAC expression levels within particular cell 
populations to initiate pathways that recruit neutrophils to the airways.  In particular 
the analysis suggests that expression of the HAT and HDAC enzymes within the 
epithelial cells may be important to airway inflammatory pathways and the onset of 
asthma. On the other hand, the expression of CBP was associated with lymphocytes 
concentration within sputum samples. CBP levels were increased within all cohorts 
at TP3. This result suggests that under inflammatory conditions CBP levels are 
increased within the airways, independent of disease. 
To determine associations between enzyme levels and cell concentrations within a 
sputum sample linear mixed models were used.  While there are some issues with 
using these statistical models for association analysis with smaller subject cohorts, in 
this study the significant associations reported, reflect findings observed within the 
literature; in that HDAC1, HDAC2, SIRT1 and SIRT6 are known to be expressed in 
bronchial epithelial cells (Minagawa et al., 2011, Ito et al., 2002a, Beane et al., 2012, 
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Cosio et al., 2004). However, it is noted that bias, caused by low subject numbers 
may exist within these results and as such further investigations are required to 
confirm observations made within this study.   
The findings of the study have shown that the mRNA expression levels of HDAC1, 
HDAC2, SIRT1 and SIRT6, may be differentially expressed as a function of asthma.  
Particularly, the stability of these enzymes within the airways may contribute to the 
asthma phenotype and impair their ability to respond to inflammatory conditions 
within the airways. However, this study has investigated these enzymes at a 
transcriptional level. For the findings to have biological relevance, the enzymes need 
to be investigated at a protein level: their biologically active form. Furthermore, 
despite changes observed in the mRNA expression of these enzymes, whether or not 
this causes an altered acetylation status within the airways is unknown. Thus, while 
the study implicates a potential role for HDAC1, HDAC2, SIRT1 and SIRT6 in 
contributing to the asthma phenotype, further studies investigating the protein 
expression of these enzymes within the airways is required to fully understand how 
changes in HDAC expression may impact cellular pathways.  
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CHAPTER 5:                                                                                                         
PROTEIN EXPRESSION OF HDAC ENZYMES IN THE AIRWAYS 
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5.1 INTRODUCTION 
Messenger RNA (mRNA) is the blue print for protein, the effector molecule. 
The experimental data from this project has indicated changes in mRNA expression 
levels of HAT and HDAC enzymes in asthma individuals. Furthermore, the 
expression levels of HDAC mRNA appear to be influenced via external stimulus. In 
the past, researchers have assumed levels of mRNA can be used as a reliable 
indicator of protein expression within a cell; however, this is not the case. The 
process of translation, not to mention protein degradation, is just as important as 
mRNA transcription and stability for steady state protein abundance. Correlations 
between mRNA expression and protein expression within cells have been 
investigated in both cell line and human patient samples. Collectively, the 
experimental data quite conclusively shows that mRNA levels cannot be used as 
surrogates for protein levels (Tian et al., 2004, Vogel et al., 2010, Taquet et al., 
2009, Dickson et al., 2007). For example, Sarro et al (2010) quantified CD20 mRNA 
and protein levels in chronic lymphocytic leukaemia (CLL) cells from patients. Their 
results showed that while CD20 mRNA levels appeared stable, CD20 protein levels 
were significantly decreased in CLL cells compared to healthy controls (Sarro et al., 
2010). Furthermore, a study investigating the affects of the human papiloma virus 
(HPV) vaccine on cytokine expression levels in peripheral blood mononuclear cells 
(PBMC) was unable to establish strong correlations between mRNA and protein 
expression for the cytokines investigated. Of the 20 cytokines studied, eleven showed 
weak to negative correlations between the mRNA levels and their respective 
proteins, and only IFNλ  appeared to have strong mRNA and protein expression 
correlation (r=0.9) (Shebl et al., 2010).  Thus, to determine if the changes in mRNA 
expression observed within the asthma cohort actively alters the asthma phenotype, 
similar changes need to be observed in the protein expression of these enzymes 
within the airways. 
Interestingly, while termed, ‘histone acetyltransferase’ (HAT) and ‘histone 
deacetylase’ (HDAC), HATs and HDACs do not only acetylate histone proteins. 
They also act upon non-histone proteins such as, transcription factors (Glozak et al., 
2005). Transcription factors are the proteins involved in the regulation of 
transcription. They exist in two classes: general transcription factor – proteins that 
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are essential for the transcription of all genes, and specific transcription factors – 
proteins required for the transcription of specific genes. After basal transcriptional 
machinery (RNA pol II and general transcription factors) assembles on the gene 
promoter, it can interact with a transcription factor that has bound to a specific 
enhancer sequence in the DNA and through this interaction stimulate gene 
expression (Urnov and Wolffe, 2001). Interestingly, in asthma the inflammatory 
genes are mainly regulated by the binding of transcription factors nuclear factor 
kappa B (NF-κB) and or activator protein 1 (AP-1), both of which have been shown 
to interact with HATs and HDACs (Adcock et al., 2005).  
NF-κB proteins are a family of transcription factors that play a vital role in 
orchestrating and attenuating the inflammatory response. NF-κB proteins exist as 
homo and hetero – dimers of different members of the RelA family. The most well-
known and studied NF-κB protein is the heterodimer RelA (p65)/p50 (Hayden and 
Ghosh, 2004). In its inactive form, NF-κB is located in the cytoplasm bound to the 
IκB proteins. Upon stimulation by specific inducers such as the inflammatory 
cytokines TNF-α and IL-1, NF-κB is released from IκB proteins and translocated to 
the nucleus where it can regulate gene expression (Hayden and Ghosh, 2004). The 
post translational modification, acetylation, plays an important role in regulating NF-
κB function. Acetylation of specific NF-κB lysine residues regulates transcriptional 
capacity, length of NF-κB activation and DNA-binding ability.  The precise effect 
that HATs and HDACs have on the NF-κB inflammatory pathways is not well 
understood. Previous research reveals a dynamic, complex and at times contradictory 
role for acetylation in the NF-κB pathways. Acetylation of lysines 218, 221 and 310 
by p300 and CBP appears to increase NF-κB binding ability to the DNA κB 
enhancer and impairs its ability to bind to IκB (Chen et al., 2002). However, 
acetylation of lysines 122 and 123 by p300 and PCAF decrease NF-κB activity and 
increases its ability to bind to IκB, thereby facilitating its exportation to the 
cytoplasm (Kiernan et al., 2003). Like its counterpart, deactylation can both impair 
and aid NF-κB’s binding ability to its DNA enhancer. Both HDAC3 and SIRT1 have 
been shown to deacetylate lysines 221 and 310 respectively increasing NF-κB 
binding affinity to IκB, reducing transcription ability (Chen et al., 2001, Yeung et al., 
2004). However, the deacetylation of lysine 122 and 123 increases NF-κB binding 
ability to its DNA κB enhancer and hence, increases its transcription ability. NF-κB 
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is known as the master regulator of inflammatory proteins including IL-8, GM-CSF, 
Eotaxin-1 and CXCL10 (Clarke et al., 2008, Ito et al., 2000, Nie et al., 2005b, 
Clarke et al., 2010). As such, targeting the NF-κB pathway therapeutically has 
become a growing area of interest in asthma research.  
Like NF-κB, activator protein – 1 (AP-1) is a specific transcription factor involved in 
the regulation of inflammatory genes (Roth and Black, 2006).  AP-1 is a dimeric 
transcription factor that is composed of proteins belonging to several families. The 
common denominator between the families is the possession of a basic leucine zipper 
(bZIP) which aids the transcription factor binding to the DNA enhancer. The Jun and 
Fos subfamilies are the major AP-1 proteins; however, the ATF protein family (ATF-
2) and the MAF subfamily are also known to comprise AP-1 transcription factor 
molecules (Erlanson et al., 1996) . Like NF-κB, AP-1 is also induced by the pro-
inflammatory cytokines, TNF-α and IL-1 (Turner et al., 2007). Furthermore, the 
increased activation and expression of AP-1 proteins have been demonstrated in the 
airways of asthmatic patients. AP-1, in cooperation with other transcription factors, 
induces the expression of inflammatory cytokines IL-4, IL-5 and IL-13 (Gilmour and 
Lavender, 2008). Furthermore, AP-1 also plays a role in airway remodelling with 
animal models suggesting epithelial injury, mucous gland hypertrophy, lumina 
reticularis thickening, airway smooth muscle hyperplasia and angiogenesis are 
influenced via the AP-1 pathway (Eynott et al., 2003). Whether acetylation directly 
influences AP-1 activation and pathways is yet to be determined. However, a study 
by Zhang et al (2010) showed at least in mice SIRT1 directly interacts with bZIP 
domains of the c-Fos and c-Jun components of AP1. This interaction suppressed the 
transcriptional activity of AP-1 suggesting that deacetylation of AP-1 may affect 
inflammatory pathways (Zhang et al., 2010).  
Thus, the final aim of this project was to investigate the protein expression of the 
enzymes HDAC1, HDAC2, SIRT1 and SIRT6 and how they may interact with the 
specific transcription factors NF-κB and AP-1 in healthy and asthma cohorts. 
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5.2 MATERIALS AND METHODS 
5.2.1 Specimen Samples 
The subject specimens were collected and processed as outlined in chapter 4, 
section 4.2. These samples were used to determine changes in protein expression 
within and between the three cohorts: healthy, asthma β2 and asthma ICS. The design 
of the study is outlined in Figure 5-1.   
 
 
 
Figure 5-1: Study timeline 
 
The figure represents the study timeline. At time point 1 (TP1), subjects underwent 
spirometry, sputum induction and filled out a MHQ followed by a waiting period of at least 
seven days.  Subjects then completed two consecutive sputum inductions six hours apart 
(time point 2 (TP2 -baseline) and time point 3 (TP3). 
5.2.2 Extraction of Nuclear Protein from Sputum Samples 
Nuclear protein fractions were extracted from sputum samples as outlined in 
chapter 2, section 2.5.  
5.2.3 Casting Gradient Gels 
Linear gradient gels (5-15%) were used to separate protein samples by 
molecular size. Gradient gels were poured using a Model 485 Gradient Former (Bio-
Rad) and the mini-PROTEAN
® 
Multi Casting chamber system (Bio-Rad).  Rather 
than pump action, gravity was used to make the gradient. As such, a magnetic stir 
plate and the Gradient Former was placed on a block that was 30 cm above the mini- 
PROTEAN
® 
Multi Casting chamber (Bio-Rad) and tubing was run from the short 
distance of the stopcock opening of the gradient former to the inlet of the chamber. A 
stir bar was placed in the mixing chamber, labeled light. Two acrylamide (Bio-Rad), 
solutions were made: one 5% Acrylamide (1.5 M Tris pH 8.8, 10% SDS, 10% APS, 
TEMED, H2O) labeled ‘Light’ and the second 15% Acrylamide (1.5 M Tris pH 8.8, 
10% SDS, 10% APS, TEMED, 20% Glycerol, H2O) labeled ‘Heavy’. Solutions were 
made initially without the addition of APS and TEMED (initiators). The initiators 
2
nd
 Visit (TP2 – Baseline) 3
rd
 Visit (TP3) 
1 week ≤ 6 hours 
1
st
 visit (TP1) 
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were added to the 5% solution which was poured into the mixing chamber (light). 
The initiators were then added to the heavy solution which was gently mixed and 
poured into the reservoir chamber. The valve stem and stopcock were then opened, 
and the acrylamide flowed down the tubing into the gel sandwich. 
5.2.4 Sodium Dodecyl Sulphate-Polyacrylamide Gel electrophoresis (SDS-
PAGE). 
SDS-PAGE gradient gels (5-15%) were used to separate protein samples by 
molecular size. Approximately 15 μg of nuclear protein was boiled at 95 oC for 5 
minutes in a loading buffer (250 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 20 
mM β-mercaptoethanol, 0.01% bromophenol blue) and electrophoresed in running 
buffer (0.025 M Tris, 0.25 M glycine, 0.1% w/v SDS, pH 8.8) on a Protean II mini 
gel apparatus  (Bio-Rad). The SDS Page gels were run at 120 V for 1 hr and 10 
minutes. A pre dual stained molecular weight protein marker (Bio-Rad) was used to 
determine the molecular sizes of the resulting bands.  
5.2.5 Coommaisse Blue Stain 
SDS-PAGE gradient gels were stained with the Coomassie brilliant blue 
reagent (0.1% w/v Coomassie blue G-250, 10% acetic acid, 40% ethanol, 40% 
ddH2O) for two hours at RT with mild agitation. Gels were incubated with the de-
stain solution (10% acetic acid, 45% methanol, 45% ddH2O) at RT with mild 
agitation until protein bands were clear from background staining.  
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Figure 5-2: Coommaise stain of nuclear extracts from sputum sample. 
The figure represents subjects’ nuclear extract sample over the time points of the study. The gel 
demonstrates how ubiquitous proteins dominate the protein concentrations in these heterogeneous cell 
populations. To control for unequal loading, β actin was used to normalise detection readings. The 
right hand panel gives the molecular weight of protein as determined using a molecular weight marker 
(Marker Precision Plus Protien
TM, 
BioRad, NSW). The arrows point to where the specific HDAC 
proteins should be detected within the samples. 
5.2.6 Western Blot Analysis 
The protein stored from the nuclear extract was quantified using the BCA 
protein assay (chapter 2, section 2.5.2), and 15 μg of each sample were mixed with 
SDS sample loading buffer and electrophoresed on SDS PAGE gradient gels. They 
were then electro-transferred using a transfer blot apparatus (BioRad) and transfer 
buffer (10% Methanol, 10 mM CAPS (Sigma Aldrich), pH 11) onto nitrocellulose 
membrane.  Membranes were blocked using Odyssey
®
 Blocking Buffer (LI-COR 
Biosciences, Lincoln, NE, USA) for 1 hour. The membrane was incubated overnight 
at 4 
o
C with the primary antibody diluted in blocking solution (Table 5-1). Following 
incubation, the membrane was washed in TBS-Tween (20 mM Tris-HCl, 150 mM 
NaCl and 0.1% tween 20) and incubated with the appropriate secondary antibody 
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(Table 5-1).  The protein bands were detected using the Odyssey
®
 Infrared Imaging 
System (Li-COR Biosciences). 
5.2.7 Stripping Protocol 
After each protein detection western blots were stripped, blocked and re-
probed for detection of another protein. The nitrocellulose membrane was placed in 
50 
oC warmed stripping buffer (2% SDS, 62.5 mM Tris HCl pH 6.8, 0.8% β 
mercaptoethanol) and incubated for 60 minutes with gentle rocking. After 
incubation, the membrane was washed in ddH2O for 30 minutes, and then washed 
three times in TBS-Tween (20 mM Tris-HCl, 150 mM NaCl and 0.1% tween 20) 
over 15 minutes before re blocking. All membranes were stripped, blocked and re-
probed in the same order.  
Table 5-1: Antibodies for Detection of HDAC Proteins 
Antibody Type Host Clonality Dilution Source 
β-Actin Primary Rabbit IgG Monoclonal 1:2000 
Genesearch, 
QLD, AUS 
SIRT6 Primary Rabbit IgG Polyclonal 1:1000 
Genesearch, 
QLD, AUS 
HDAC1 Primary Mouse IgG1 Monoclonal 1:500 
Santa Cruz, 
CA, USA     
HDAC2 Primary Rabbit IgG Polyclonal 1:500 
Santa Cruz, 
CA, USA     
SIRT1 Primary Mouse IgG2b Monoclonal 1:500 
Santa Cruz, 
CA, USA     
Anti-Rabbit Secondary Goat IgG Polyclonal 1:10 000 
Life Tech  
Aus 
Anti-Mouse Secondary Donkey IgG Polyclonal 1:10 000 
Rockland 
Scientific, B.C, 
Canada  
5.2.8 Histone Acetyltransferase (HAT), deacetylase (HDAC) and Sirtuin (SIRT) 
Activity assays 
Enzyme activity assays for overall HAT, HDAC and SIRT enzyme activity 
were performed on 3.5 µg of nuclear extract as outlined in chapter 2, section 2.6.  
5.2.9 Electromobiltiy Shift Assay (EMSA) and transfer of DNA probes onto 
nylon membranes 
The electromobility shift assays (EMSA) were used to determine binding affinity of 
the NF-κB and AP-1 transcription factors within subject sputum samples. EMSAs 
were performed using the LightShift Chemiluminescent EMSA kit (Thermo Fisher 
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Scientific) as per manufacturer’s instructions. Briefly, DNA/receptor complex 
formation reaction was performed by mixing either 5 µg of nuclear extract or control 
with specific binding reactions for each transcription factor (Table 5-2) and the 
appropriate 3’biotinylated DNA probe (Sigma Aldrich). DNA probes used in EMSA 
are designated as NF-κB (sense [BTN] 5'AGTTGAGGGGACTTTCCCAGGC-3' 
Anti-sense: [BTN] 5’GCCTGGGAAAGTCCCCTCAACT3’ and AP-1 (sense 
[BTN] 5'CGCTTGATGACTCAGCCGGAA’3 Anti-sense [BTN] 
5’TTCCGGCTGAGTCATCAAGCG‘3). The mixture was made to a total volume 
of 20 µL with the addition of DEPC H2O. The reaction was incubated at RT for 20 
minutes followed by the addition of 5µL of loading buffer (Thermo Fisher 
Scientific).  
Samples were then run on a 5% acrylamide gel (5%  29:1 acrylamide (40%), 0.05 M 
Tris pH 7.5, 0.19 M Glycine, 2 mM EDTA, H2O, APS, TEMED). The gel was 
electrophoresed in a Protean II gel chamber apparatus (Bio-Rad) and Run in 1x TBE 
buffer at 10 V/cm of gel. The Biotinylated DNA probes were then transferred to a 
nylon membrane by electro-transferring using a transfer blot apparatus (Bio-Rad). 
Electro transfer was performed in 1x TBE, at 4 
o
C, 100 V for one hour. The 
Biotinylated DNA probes were cross linked to the nylon membrane by a UVP
®
 
3UV
TM
 Benchtop UV Transilluminator (Bio-Strategy Distribution, Broadmeadows, 
VIC, Aus) at 302 nm for 15 minutes. 
Table 5-2: Binding reactions of NF-κB and AP-1 for EMSA experiments 
 
NF-κB 
Binding 
Reaction 
AP-1 
Binding Reaction 
Source 
10X Binding Buffer Y Y Thermo Fisher Scientific  
2.5 % Glycerol  Y Thermo Fisher Scientific  
1 mM MgCl2  Y Thermo Fisher Scientific  
1μg/μL Poly (di.dC) Y Y Thermo Fisher Scientific  
0.4 % NP-40 Y  Thermo Fisher Scientific  
100 mM NaCl Y  General Stock 
2.5 mM DTT Y Y Sigma Aldrich  
20 fMol [Btn] NF-κB Probe Y  Sigma Aldrich 
20 fMol [Btn] AP-1 Probe  Y Sigma Aldrich 
5.2.10 Chemiluminescent detection and quantification 
For the detection of the higher molecular shifts formed by the DNA /receptor 
complexes, chemiluminescence substrates were used essentially as per 
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manufacturer’s instructions of the LightShift Chemiluminescent EMSA kit (Thermo 
Fisher Scientific). The membrane was blocked in 10 mL of lighshift
®
 blocking buffer 
(Thermo Fisher Scientific) for 15 minutes at room temperature. The membrane was 
then given four by 15 minute washes in lighshift
®
 wash buffer (Thermo Fisher 
Scientific) followed by equilibration with 10 mL of lightshift
®
 equilibration buffer 
(Thermo Fisher Scientific). The detection was then performed by the addition of 12 
mL of luminal/enhancer (Thermo Fisher Scientific) and stable peroxidise solution 
(1:1 ratio) to the membrane for five minutes. The membrane was then washed twice 
in distilled water, and the detection was performed using x-ray imaging film and 
visualization of the chemiluminescence signal. Figure 5-3 demonstrates the predicted 
results of an EMSA reaction.  
 
Figure 5-3: Diagrammatic example of EMSA.  
DNA elements that bind to nuclear receptors present in nuclear extracts (NE) form a higher molecular 
weight complex than unbound DNA (lane 3).  In EMSA experiments to ensure that the protein is 
binding specifically to the DNA probe, competition probes are added in excess; despite the excess 
probe, the reaction should still be observed if specific (lane 2). Non complexed (free probe) migrates 
to the bottom of the gel (lane 1-3). Bi refers to biotin which is used to end label DNA to facilitate 
detection using chemiluminescence.  
5.2.11 Statistical Analysis 
All graphical results are plotted using box and whiskers plots of n 
determinants. N is stated in individual figure legends. Statistical analysis was 
performed using IBM SPSS 19.0 (IBM Corporation) and GraphPad Prism 5.0 
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(GraphPad Software Inc).  To determine significance and relationships within and 
between the cohorts, linear mixed models were used. Time of induction was used as 
both a fixed and random effect in nested individuals. Statistical significance was 
accepted where p < 0.05.  
5.3 RESULTS 
5.3.1 Subject Characteristics and Lung Function 
General characteristics, lung function and cell populations of the collected 
sputum samples are described in detail in chapter 4, section 4.3 of this thesis.  
5.3.2 Induced inflammation increases HDAC1 protein expression 
Western blot analysis was used to determine if HDAC1 protein levels were 
differentially expressed between the subject cohorts and if HDAC1 protein levels 
could be influenced by an inflammatory stimulus. Antibodies were specific for 
HDAC1 and a single HDAC1 band was observed on all immunoblots. No difference 
in the expression levels of HDAC1 protein was detected in sputum samples of 
subjects with (β2, ICS) and without asthma (Figure 5-4A and 5-4B). However, in 
response to repeat sputum induction, a significant increase in HDAC1 expression 
was detected in all three cohorts. Increased expression from baseline measurements 
are 0.340 ± 0.137 optical density (OD) units in the healthy cohort, 0.081 ± 0.044 OD 
units in the asthma β2 cohort and 0.382 ± 0.226 OD units in the asthma ICS cohort 
(Figure 5-4C). Although beyond significance (p < 0.06), the different cohorts appear 
to differ in their response to the inflammatory stimulus with the healthy and asthma 
ICS cohort showing a greater increase in HDAC1 expression in response to the 
hypertonic saline compared to the asthma β2 cohort.  
To determine if a relationship existed between the expression of HDAC1 mRNA and 
its respective protein, linear mixed models were used to analyse the data. Statistical 
analysis found no correlation between HDAC1 mRNA and HDAC1 protein levels 
within and between the cohorts. Furthermore, the protein expression levels of 
HDAC1 were not correlated with any particular cell type within the sputum sample.  
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Figure 5-4: Expression of HDAC1 in sputum samples. 
Figure 5-4A, represents a graphical demonstration of the relative expression of HDAC1 within the 
airways of healthy (n = 8), asthma β2 (n = 8) and asthma ICS (n = 10) subjects. Figure 5-4B, is a 
representative blot of HDAC1 expression levels detected using immunoblots. Each sample (S) was 
tested in duplicates thus, the blot represents: n = 2 Healthy (H), n = 2 asthma β2 (β2), n = 2 asthma 
ICS (ICS). β-Actin was used as a control for protein loading. Figure 5-4C depicts the changes in the 
expression levels of HDAC1 protein at TP1 and TP3, compared to baseline (TP2) levels. HDAC1 
expression is increased in response to the inflammatory stimulus. Results are considered significant 
where *p<0.05.  
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5.3.3 Induced Inflammation has no effect on HDAC 2 expression. 
No difference in the expression of HDAC2 protein is observed between subject 
cohorts (Figure 5-5A and 5-5B). A pronounced HDAC2 band was observed in all 
immunoblots. However, similar to its mRNA expression, the cohorts appear to have 
higher TP1 protein levels of HDAC2 compared to baseline levels although this 
observation is not considered statistically significant (Figure 5-5C).  
Further Analysis was performed to determine if a correlation existed between the 
expression of HDAC2 mRNA and its protein using linear mixed models. Similar to 
the analysis of HDAC1, no correlation between HDAC2 mRNA, and HDAC2 
protein was observed.  Furthermore, the expression levels of HDAC2 protein were 
not associated with one particular cell type within the sputum sample. 
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Figure 5-5: Expression of HDAC2 in sputum samples  
Figure 5-5A, represents a graphical demonstration of the relative expression of HDAC2 within the 
airways of healthy (n = 8), asthma β2 (n = 8) and asthma ICS (n = 10) subjects. Figure 5-5B, is a 
representative blot of HDAC2 expression levels detected using immunoblots. Each sample (S) was 
tested in duplicates thus, the blot represents: n = 2H, n = 2 β2, n = 2ICS. β-Actin expression was used 
as a control for protein loading. Figure 5-5C depicts the changes in the expression levels of HDAC2 
protein at TP1 and TP3 compared to baseline (TP2) levels.  Despite the appearance that the asthma 
cohorts have a higher HDAC2 protein expression level at TP1, this observation is not considered 
statistically significant (p = 0.098).  
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5.3.4 Protein Expression of SIRT6 is barely detectable in Sputum Samples 
Unlike the previous HDAC proteins, immunoblot analysis indicated limited 
detection of the SIRT6 enzymes within this sample. Previous correlation analysis has 
indicated that this enzyme is expressed by epithelial cells within the airways. As 
bronchial epithelial cells are a smaller cell population within sputum samples, this 
likely explains why detection of SIRT6 within sputum samples is low. This was the 
first protein analysed and, as such, stripping of the membranes would have had no 
effect on the level of protein detected within the sample. Despite these results, the 
immunoblots were analysed to determine changes in SIRT6 protein between and 
within cohorts in response to the hypertonic saline stimulus. While the antibody used 
for SIRT6 detection is specific for SIRT6 it detected two separate isoforms of the 
protein. Densitometry measurements were taken by averaging the OD units of both 
bands. No difference in SIRT6 expression levels were detected between the three 
subject cohorts, and as was observed in previous mRNA experiments, the hypertonic 
saline had no effect on SIRT6 expression. However, association analysis using linear 
mixed models was unable to determine significant correlations between SIRT6 
mRNA and SIRT6 protein expression.  
The protein expression levels of the enzyme SIRT1 was also investigated within this 
study. However, due to the stripping of the western blots and the close proximity in 
weights of HDAC 1 and SIRT 1 protein, the immunoblot analysis of SIRT1 was 
ambiguous in that the SIRT1 bands observed were very similar to those previously 
observed for HDAC1 indicating that some cross reactivity may have occurred.  As 
such these results are not reported.  
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Figure 5-6: Expression of SIRT6 in sputum samples 
Figure 5-6A, represents a graphical demonstration of the relative expression of SIRT6 within the 
airways of healthy (n = 8), asthma β2 (n = 8) and asthma ICS (n = 10) subjects. Figure 5-6B, is a 
representative blot of SIRT6 expression levels detected using immunoblots. Each sample (S) was 
tested in duplicates thus, the blot represents: n = 2H, n = 2 β2, n = 2ICS.  β-Actin expression was used 
as a control for protein loading. Figure 5-6C, depicts the changes in the expression levels of SIRT6 
protein at TP1 and TP3 compared to baseline levels. SIRT6 levels are unaffected by hypertonic saline.  
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5.3.5 HAT, HDAC and SIRT activity assays 
To determine if the changes in expression levels of HDAC proteins had an 
effect on the overall acetylation enzymatic activity, EpiQuik™ HAT, HDAC and 
SIRT activity assays were used to measure respective activity levels in nuclear 
extracts of sputum samples at baseline and TP3. No difference in HAT or HDAC 
activity levels was detected between the three cohorts, furthermore no difference in 
HAT and HDAC activity was observed in any of the cohorts in response to the repeat 
sputum induction. Interestingly, while not statistically significant, the healthy and 
asthma ICS cohort appears to have an average reduced HAT activity and increased 
HDAC activity level when compared to baseline measurements (Figure 5-7D and 5-
8D). However, the asthma β2 cohort shows the reversed result with an average 
increase in HAT activity and decrease in HDAC activity recorded.  
Activity assays were also performed for overall sirtuin activity within the sputum 
samples. However, during the development step of the experiment, the standard 
curve (provided by the company) showed no sirtuin activity, nor did any of the 
subject samples or positive and negative controls. It is thought that the NAD 
substrate (provided by the company), which the sirtuins enzymes deacetylate, was 
inactive at the time of experiment. As such, sirtuins activity within sputum samples 
could not be recorded.    
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Figure 5-7: Overall HAT activity in sputum samples 
Figure 5-7A, 5-7B and 5-7C represents the total HAT activity of individual sputum samples from the 
healthy (n =13), asthma β2 (n =13) and asthma ICS (n =14) cohorts respectively, at baseline and TP3. 
HAT activity was measured as OD/hr/mg protein.  Figure 5-7D is a graphical depiction of the overall 
change in HAT activity in response to hypertonic saline within cohorts.  Data represents the means ± 
SE.  
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Figure 5-8: Overall HDAC activity in sputum samples  
Figure 5-8A, 5-8B, 5-8C represents the overall HDAC activity of individual sputum samples from 
healthy (n=13), asthma β2 (n =13) and asthma ICS (n =14) cohorts respectively, at baseline and TP3. 
HDAC activity was measured as OD/hr/mL protein. Figure 5-8D is a graphical depiction of the 
overall change in HDAC activity in response to hypteronic saline within cohorts. Data represents the 
means ± SE.  
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5.3.6 The Binding Affinity of NF-κB and AP-1 
EMSAs were used to determine Nuclear factor –κB and Activator protein - 1 
binding activity in sputum samples from the airways of individuals with and without 
asthma. Figure 5-9 depicts the binding affinity of both NF- κB and AP-1 in healthy 
and asthma β2 cohorts. This figure clearly illustrates that detection of both of these 
transcription factors within the subject sputum samples was difficult. However, some 
samples show binding affinity within the nuclear extract to the labelled DNA probe. 
Furthermore, binding although slight, was observed in the presence of excess 
competition SP-1 probe. This confirms that the transcription factors NF-κB and AP-1 
bound specifically to the consensus sequence in their respective DNA probes. 
Despite equal protein loading, a higher binding affinity for NF-κB and AP-1 is 
evident in the healthy subjects compared to the asthma subjects.  
There has been recent evidence that the sirtuins — in particular SIRT1 and SIRT6 — 
aid in regulating NF-κB function and its binding affinity to DNA. To determine if 
inhibiting the sirtuins enzymes within the nuclear protein sample would affect the 
binding ability of either NF-κB or AP-1 in sputum cells, identical EMSA 
experiments were run with 1 mM of sirtinol added to the each reaction in the second 
experiment. These experiments were performed using cohort sputum samples that 
had shown the greatest binding affinity for these transcription factors. Figure 5-10 (B 
and D) demonstrates that the addition of sirtinol appears to disrupt the protein-DNA 
binding complex.  
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Figure 5-9: NF-κB and AP-1 binding affinity in sputum samples 
Figure 5-9A and 5-9C, represents the EMSA analysis of the healthy cohort (n = 10) for the 
transcription factors NF-κB and AP-1 respectively. While figure 5-9B and 5-9D, represents the EMSA 
analysis of the asthma β2 cohort for the transcription factors NF-κB and AP-1 respectively. The first 
lane in each blot labelled ‘free probe’ contains the free [BTN] labelled probe of the specific 
transcription factor that is investigated (NF-κB, 5-9A&B, AP-1, 5-9C&D). The second lane in each 
blot labelled, Probe/Comp probe/3.5 μg NE (NF-κB, 5-9A&B, AP-1, 5-9C&D), is the competition 
experiment performed with excesses of unlabelled SP1 oligonucleotide probe. Binding in this lane 
demonstrates that the NF-κB and AP-1 probes contain consensus sequences that are specific to these 
transcription factors.  The next 10 lanes in each blot represent the binding affinity for the transcription 
factors NF-κB and AP-1 of the nuclear extract from 10 subject sputum samples in the healthy and 
asthma β2 cohorts. 
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Figure 5-10: Effect of Sirtinol on NF-κB and AP-1 binding affinity in sputum samples 
Figure 5-10A and 5-10C represent the binding affinity for the NF-κB and AP-1 transcription factors in 
3 subject sputum samples from the healthy, asthma β2 and asthma ICS cohorts. The first lane in each 
blot labelled ‘free probe’ contains the free [BTN] labelled probe of the specific transcription factor 
that is investigated (NF-κB, 5-10A and AP-1, 5-10C). The second lane in each blot labelled, 
Probe/Comp probe/3.5 μg NE (NF-κB, 5-10A and AP-1, 5-10C), is the competition experiment 
performed with excess unlabelled SP1 oligonucleotide probe. Binding in this lane demonstrates that 
the NF-κB and AP-1 probes contain consensus sequences that are specific to these transcription 
factors. The next nine lanes represent the binding affinity of these transcription factors (NF-κB, 5-10A 
and AP-1, 5-10C), in the 3 sputum samples from the subject cohorts healthy, asthma β2 and asthma 
ICS. The final 3 lanes labelled control represents the EBNA control reaction provided within the 
chemiluminescent lightshift kits (thermo fisher scientific) to ensure the kit is working properly.  
Figure 5-10B and 5-10D are the exact same reactions as their 5-10A and 5-10C counterparts, 
respectively, except each reaction contained 1 mM of the universal SIRT inhibitor, sirtinol. The 
addition of sirtinol appears to have disrupted the binding affinity of these transcription factors. 
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5.4 DISCUSSION 
In this study, western blot analysis reveals an increase in HDAC1 protein 
expression in response to hypertonic saline within healthy and asthma individuals. 
However, unlike previous studies which report decreased HDAC1 protein expression 
in asthma airways (Butler et al., 2011, Ito et al., 2002a, Cosio et al., 2004), no 
significant difference in HDAC1 protein expression between asthma and healthy 
subjects is observed. Furthermore, no significant change in HDAC2 protein 
expression was detected within and between subject cohorts — a surprising 
observation as previous studies not only report decreases in HDAC2 protein 
expression in asthma airways, but also indicate that the restoration of this enzyme’s 
activities improve corticosteroid effectiveness in controlling severe asthma (Barnes, 
2009a, Biswas and Rahman, 2008, Butler et al., 2011, Ito et al., 2000, Ito et al., 
2002a, Ito et al., 2006, Li et al., 2010, Malhotra et al., 2011, Meja et al., 2008).  
Thus, it was expected that a decrease in HDAC2 protein would be observed in the 
asthma β2 cohort and some restoration of this decrease would be observed in the 
asthma ICS cohort however, this was not the case. As discussed in previous chapters, 
the contrary results are likely explained by the different specimen samples used 
amongst the different studies. The use of a heterogeneous cell sample here has 
potentially masked significant changes in the expression levels of these enzymes in a 
single cell population.   
Previous experiments from this project (chapter 3 and 4), have highlighted changes 
in the mRNA expression levels of HAT and HDAC enzymes within asthma airways 
when compared to healthy controls. Furthermore, the expression levels of these 
enzymes appear to be influenced by inflammatory stimuli. In particular, the enzymes, 
HDAC1, HDAC2, SIRT1 and SIRT6 have been implicated as possible contributors 
to the asthma phenotype. This study sought to determine if the differences in mRNA 
expression of these HDAC enzymes reflected equivalent changes at the protein level 
within the airways. Linear mixed model analysis was unable to define a significant 
relationship between each enzymes mRNA and protein expression within the 
airways.  The uncertain relationships between mRNA and protein levels of particular 
proteins are not well understood. However, it is postulated that this lack of synergy 
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between mRNA and protein expression may be caused by a number of cellular 
mechanisms.  
Depending on the type of stimulus, cells can increase and regulate specific proteins 
through a variety of pathways. Such pathways include up regulation of translation of 
existing mRNA within the cell to increase cytokine levels. This generally occurs if a 
cell requires rapid response to a stimulus as this is a faster approach than 
synthesising new mRNA to increase protein expression. Alternatively, for a 
sustainable increase in protein levels, cells increase their mRNA levels. Thus, the 
low mRNA HDAC 1 levels observed at time point three, coupled with an increase in 
HDAC1 protein levels at the same point, may reflect the airways rapid response to 
hypertonic saline. Thus, the HDAC1 enzyme could potentially influence and respond 
to airway hypersensitivity.   
Interestingly, while the results show an increase of HDAC1 protein expression across 
all three cohorts, the increased proteins levels are more pronounced in the healthy 
and asthma ICS cohorts compared to the asthma β2 cohort (p = 0.059). This could 
potentially reflect a dysfunction of the rapid synthesis of HDAC1 protein within 
asthma airways. The reduced HDAC1 protein expression in response to an 
inflammatory stimulus may have a negative impact on inflammatory pathways and 
limit cells’ abilities to attenuate inflammation. The similar increases in HDAC1 
protein expression observed within the healthy and asthma ICS cohorts suggests that 
inhaled corticosteroids may potentially restore HDAC1 function within these asthma 
airways. 
To determine if the changes in mRNA and protein HDAC levels affected the overall 
acetylation status within the airways, total HAT and HDAC activity assays were 
performed on nuclear extract of subject sputum samples. Despite increased HDAC1 
protein levels in response to hypertonic saline, no significant change in HAT or 
HDAC activity was observed within or between subject cohorts.  The enzyme kits 
used for this study measured total HAT and HDAC activity within the nuclear 
fractions of the samples. Thus, changes to the activity of a particular protein such as 
HDAC1 may be masked by the use of these HAT and HDAC activity assays. To 
establish if a change in HDAC1 protein expression alters HDAC1 deacetylation 
activity within asthma airways, a targeted enzyme activity assay is required. 
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Interestingly, previous studies report increased HAT activity and decreases in HDAC 
activity in asthma airway samples compared to healthy controls (Cosio et al., 2004, 
Ito et al., 2002a, Ito et al., 2002b). While not statistically significant, similar 
differences in overall enzymatic activity were observed in this study. The asthma β2 
cohort showed opposite enzymatic activity to the healthy cohort and asthma ICS 
cohort. The similar enzymatic activity observed in the health and asthma ICS cohorts 
are in agreement with previous research that has shown the use of inhaled 
corticosteroid can increase HDAC activity within the airways.  
Despite being termed, ‘histone acetyltransferases’ and ‘histone deacetylases’, HATs 
and HDACs acetylate a number of other proteins. Thus, they may contribute to the 
asthma phenotype not only by directly acting upon histones to alter regulation of 
inflammatory cytokines, but also through regulating the pathways of the 
inflammatory transcription factors NF-κB and AP-1 (Barnes and Adcock, 1998). 
HAT and HDACs alter transcription factors function via post translational 
modifications. These enzymes can activate or deactivate transcription factors 
allowing their translocation to and from the nucleus. They can also facilitate the 
binding of specific transcription factors to their DNA enhancer region thereby 
allowing transcription to begin. Finally, HATs and HDACs may inadvertently affect 
transcription factor function via activating specific cofactors that NF-κB or AP-1 
require for their activation. Thus, the final aim of this study was to investigate the 
DNA binding affinity of the transcription factors NF-κB and AP-1 in asthma 
airways.  
The electromobility shift assays revealed a low binding affinity of both NF-κB and 
AP-1 proteins within the asthma airways. This was an unexpected result since these 
transcription factors have previously been demonstrated to induce inflammation via 
activating gene expression of histone 4 cytokines (Lee et al., 2006, Clarke et al., 
2010, Clarke et al., 2008). As such, it was expected that the binding affinity of both 
NF-κB and AP-1 would be increased in the asthma airways compared to the healthy 
controls. However, the collected data also indicates clear issues with the 
measurement of these transcription factors in sputum samples collected from the 
healthy and asthma cohorts. 
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A major difficulty within this study was adequately detecting specific proteins within 
the nuclear extract of sputum samples.  Sputum samples are a mixed cell population. 
As different cells are functionally diverse and express different proteins, proteins 
expressed by a specific cell (but not others) in a heterogeneous cell sample can be 
difficult to detect.  Analysis of the immunoblots suggests SIRT6 is not an enzyme 
that is ubiquitously expressed within the sputum cell population. Furthermore, 
despite equal loading, variation in detection of specific proteins is observed within 
and between specific subject cohorts.  The most abundant proteins within the 
samples dominate protein concentration and this has a negative affect for the 
detection of less abundant proteins. This is most evident in the coommaise gel stain 
(Figure 5-2). Each lane within the coommaise stained gel contains 15 μg of nuclear 
extract protein as determined by repeat BCA assay experiments. However, the 
visualisation of these samples when separated on a gradient gel clearly shows that the 
most abundant protein dominates the concentration measurements, and there is 
variation in concentrations of other proteins between these sputum samples. This 
variation within the protein samples likely to explain the variation of the binding 
affinity between subjects for NF-κB and AP-1 observed in the EMSA experiments. 
Thus, the higher binding affinity of NF-κB and AP-1 that is apparent in subjects from 
the healthy cohort compared to the asthma cohorts rather than reflect altered 
inflammatory pathways, likely reflect the variability of these proteins within the 
nuclear extract of these subject sputum samples. While increasing the amount of 
protein used in these experiments (15 μg to 30 μg), could potentially improve 
binding affinity of the transcription factors to the DNA probe and increase detection 
of specific proteins it will not correct for the protein variation observed between 
these samples.  Alternatively, processing the samples to remove the high abundant 
proteins, leaving behind the proteins of lower concentrations could remove some of 
the variation observed between subjects. This purification method is performed using 
the molecular weight of protein as a threshold to remove proteins from the sample. 
However, given that the most abundantly expressed proteins varied in molecular 
weight a single cut off point would not be sufficient in removing all highly expressed 
proteins. Thus, using this method to purify these protein samples would not only be 
highly complex and time consuming but likely result in little reward.   
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The literature suggests that the HDAC enzymes particularly, SIRT1 and SIRT6 
influence NF-κB pathways. Thus, an original aim of this study was to investigate the 
interactions between these sirtuin enzymes and NF-κB. Initially, changes in the 
binding affinity of NF-κB between study cohorts were to be detected using EMSA 
analysis, and these interactions were to be further confirmed and elucidated using 
chromatin immunoprecipitation (ChIP).  The use of ChIP could have established 
whether these transcription factors bind to specific cytokine genomic regions 
associated with the asthma phenotype and furthermore, the histone modifications 
potentially associated with the transcription of these cytokines. However, the less 
than desirable EMSA results combined with the large number of Q-RT-PCR 
experiments meant that ChIP analysis at this stage was not a viable option and as 
such the interactions between these pathways could not be investigated. However, 
the addition of sirtinol to the EMSA binding reactions appeared to disrupt and reduce 
the binding affinity of NF-κB to the DNA probe. As, SIRT1 and SIRT6 appear to 
deacetylate NF-κB, and prevent pro-inflammatory pathways, it was expected that 
sirtinol would increase the binding affinity of NF-κB to the DNA probe. Thus, 
further investigations are required to elucidate the interactions between the Sirtuins, 
NF-κB and AP-1 and how they contribute to the asthma phenotype.    
Overall, this study’s findings reflect those found by previous researchers: mRNA 
expression cannot be used as a surrogate to determine protein expression. However, 
the study also demonstrates that HDAC1 levels increase in response to inflammatory 
stimuli and the limited increase in HDAC1 levels in the asthma cohort may be of 
importance to the asthma phenotype. On the other hand, despite previous research 
the study has found no difference in the expression levels of HDAC2 between the 
study cohorts, and no change in the expression levels of HDAC2 in response to the 
inflammatory stimuli. Furthermore, the low levels of SIRT6 found within the 
samples suggest that this enzyme is not ubiquitously expressed amongst the cell 
populations of sputum samples. Finally, the study has highlighted the difficulties in 
using complex samples to detect protein levels and determine protein-DNA 
interactions. While, sputum remains a useful and non-invasive technique to assess 
airway inflammation, future investigations into this area should first separate the cell 
populations of these samples as this will be of great advantage in understanding how 
epigenetic marks influence the asthma phenotype.  
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6.1 INTRODUCTION 
Over the last two decades, epigenetic modifications have been targeted as 
possible causes for inheritance of nonmendelian diseases. Asthma is one such disease 
that is thought to be caused and inherited through a change to a person’s epigenome. 
However, the epigenome is regulated and controlled by several epigenetic 
modifications including methylation, acetylation, phosphorylation and miRNA. 
Thus, discovering a direct ‘epigenetic cause’ for asthma has proved to be difficult. 
However, it has been suggested that uncontrolled acetylation pathways in innate and 
adaptive immune cells contribute to the underlying cause of the disease. Particularly, 
changes in HDAC1 and HDAC2 protein expression within the airways is thought to 
contribute to the chronic inflammation associated with asthma (Adcock et al., 2005, 
Durham et al., 2011). However, a direct link between these proteins and the cause of 
chronic inflammation in the airways has not been established. Thus, here it was 
hypothesised that dysfunction of other HAT and HDAC enzymes contribute to the 
asthma phenotype. It was the aim of this project to investigate the expression of a 
number of HAT and HDAC enzymes within the airways of individuals with and 
without asthma and to determine if the expression levels of these enzymes could be 
altered by induced inflammation.  
In addition to HDAC1, this project identified the HDAC enzymes SIRT1 and SIRT6 
as potential proteins that contribute to the asthma phenotype. Both SIRT1 and SIRT6 
have been implicated as regulators of NF-κB dependent gene transcription. In 
addition, SIRT1 has been shown to suppress NF-κB p65 transcriptional activity 
(Salminen et al., 2008). On the other hand, SIRT6 has been shown to deacetylate 
histone 3 lysine 9 (H3K9) on the promoters of NF-κB target genes to decrease 
promoter occupancy and attenuate NF-κB’s target pathways (Kawahara et al., 2009). 
Interestingly, correlation analysis performed in this project indicated a relationship 
between the level of expression of SIRT1 and SIRT6 enzymes and the concentration 
of columnar epithelial cells within the sputum sample. Previously, it has been 
proposed that overactive NF-κB pathways in airway epithelial cells may be the initial 
trigger of the innate immune response that instigates and exacerbates the 
inflammatory response in asthma (Lambrecht and Hammad, 2012). As SIRT1 and 
SIRT6 regulate NF-κB pathways, it is possible that dysfunctions of these enzymes 
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within epithelial cells have an impact on NF-κB signalling pathways, resulting in 
chronic inflammation of the airways.  
However, the results of this project suggest there is some ambiguity as to whether 
SIRT6 is increased or decreased in asthma airways. In the initial experiment, SIRT6 
was measured in the airways of individuals with and without asthma and found to 
have a lower expression level (p = 0.06) in asthma airways. On the other hand, the 
second investigation reported a higher expression level (p = 0.085) of SIRT6 in 
asthma airways. The contradictory results are thought to be caused by a low 
concentration of epithelial cells found within sputum samples. Smaller cell 
populations in heterogeneous samples are at a greater risk of mRNA degradation 
over the experimental time frame. Thus, if an investigated protein is not expressed in 
all cell types within a heterogeneous cell sample inconsistent experimental data can 
be obtained. However, while correlation analysis indicates a relationship between 
SIRT6 expression levels and epithelial cells, this enzyme could be expressed by other 
cell types in the sputum sample. Previous studies have suggested that the SIRT6 
enzyme is also expressed in macrophages. Furthermore, SIRT6 has been shown to 
have a compensatory role for SIRT1 when SIRT1 is inactive in macrophages (Schug 
et al., 2010). Thus, while the findings of this project suggest that dysfunction of 
SIRT1 and SIRT6 may contribute to the asthma phenotype; further investigations are 
required to clarify whether leukocytes and/or epithelial cells express SIRT1 and 
SIRT6 and, the function of these enzymes within these cells.   
As previously reported, the expression and activity of HDAC1 and HDAC2 within 
asthma airways has become of considerable interest in asthma research. Previous 
studies have found a decreased expression of both these enzymes in airways of 
individuals with asthma (Cosio et al., 2004, Durham et al., 2011, Ito et al., 2002a). 
Furthermore, low dose inhaled corticosteroids (ICS) have been shown to exert their 
anti-inflammatory effects through the recruitment of HDAC2 to deacetylate 
inflammatory proteins (Ito et al., 2000). The data obtained from this project indicates 
HDAC1 (but not HDAC2) as a likely contributor to the asthma phenotype. 
Interestingly, there is growing evidence that HDAC1 and HDAC2, as well as having 
distinct and separate functions also have similar and compensatory roles within 
specific cells (Jurkin et al., 2011, Luo et al., 2009, Ma et al., 2012, Montgomery et 
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al., 2007, Yamaguchi et al., 2010, Ye et al., 2009). Whether or not HDAC1 and 
HDAC2 have compensatory roles within leukocytes and cells of the airway 
epithelium is unknown. However, the ambiguity over the role of HDAC1 and 
HDAC2 in asthma caused by conflicting data between differing studies may reflect 
similar pathways for HDAC1 and HDAC2 within these airway cells. 
Increasing the expression levels of HDAC2 to improve inhaled corticosteroid therapy 
has been a focus of asthma research (Barnes, 2010). This direction of research can 
largely be attributed to the following discoveries: low dose ICS’s recruit HDAC2 to 
attenuate inflammation (Butler et al., 2011, Ito et al., 2000); severe asthmatics and 
COPD patients that are unresponsive to ICS therapy have reduced HDAC2 protein 
levels in their airways (Adenuga et al., 2010, Butler et al., 2011, Ito et al., 2000, Ito 
et al., 2002a, Ito et al., 2008, Ito et al., 2006, Li et al., 2010, Malhotra et al., 2011, 
Meja et al., 2008, Zijlstra et al., 2011). These findings have led to the hypothesis that 
low doses of ICSs are less effective in these patients because of the reduced HDAC2 
protein levels. In vitro experiments suggest that the combined use of theophylline (a 
potent bronchodilator) and corticosteroids increase HDAC2 expression and improve 
the effectiveness of corticosteroid medication (Marwick et al., 2007, Marwick et al., 
2008, Rahman et al., 2004). However, in vivo data suggests that theophylline has no 
effect on HDAC2 levels within the airways but increases HDAC1 protein levels (Ito 
et al., 2002b). However, the combination of theophylline and corticosteroid 
medication in this study by Ito et al (2002b) was still more effective in attenuating 
inflammation than corticosteroid therapy alone. Taken together these studies suggest 
that altering either HDAC1 or HDAC2 enzyme expression improves the therapeutic 
benefits of corticosteroids. 
The results from this project suggest an increase in HDAC1 protein levels (but not 
HDAC2 protein) in response to hypertonic saline across all three study cohorts 
(Healthy, asthma β2 and asthma ICS). However, while HDAC1 was increased across 
all cohorts in response to the inflammatory stimulus, a smaller increase was observed 
in the asthma β2 cohort compared to the healthy and asthma ICS cohorts. Thus, this 
result may reflect dysfunction of HDAC1 in asthma airways, whereby reduced 
protein levels prevent attenuation of inflammation. Alternatively, if HDAC1 and 
HDAC2 play compensatory roles within these cell types, the reduced HDAC1 
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protein levels may be compensated for by HDAC2. However, disruption to these 
compensatory mechanisms could potentially contribute to the chronic inflammation 
observed in asthma.  It is clear, that the mechanisms through which HDAC1 and 
HDAC2 operate and the pathways they induce in the cells of airways, needs to be 
unravelled before full comprehension of how they contribute to the asthma 
phenotype can be obtained.  
The original hypothesis for this project was; inflammation within asthma airways is 
caused by an increase in HAT enzyme expression and a decrease in HDAC enzyme 
expression. Furthermore, the expression levels of these enzymes respond to, and are 
altered under inflammatory conditions. This hypothesis was drawn from the 
observation that the dynamic acetylation equilibrium is mostly maintained through 
the physical and functional interplay between HAT and HDAC enzymes. Disruption 
to either one of these enzyme groups would have an opposing effect on the other and 
this would lead to a state of inflammation in the airways. However, in agreement 
with previous studies, while the expression levels of HDAC enzymes in the airways 
appear to be influenced by the asthma phenotype, the expression levels of the HAT 
enzymes are not (Cosio et al., 2004, Ito et al., 2002a).  Taking the findings from this 
project with those of previous studies, the following reformed hypothesis is 
proposed: Changes in the expression levels of HDAC enzymes increase the 
acetylation status of cells in the airways and thus, exacerbates and induces the 
cytokine pathways these enzymes regulate.  Interestingly, HDAC enzymes not only 
regulate acetylation pathways but also influence the epigenetic modifications DNA 
and histone methylation (Tost, 2010). Thus, changes in HDAC expression may not 
only affect acetylation pathways but may also influence the DNA and histone 
methylation status of a cell. 
6.2 METHYLATION  
Throughout this project, the focus and interpretation of results have been on 
how alterations in the expression of these enzymes affect acetylation pathways of 
either histones or transcription factors to regulate inflammatory gene expression 
observed in asthma. However, studies collectively reveal that a complex interplay 
between different modifications such as DNA methylation, histone modifications and 
chromatin remodelling exists. It is unlikely that any one modification occurs without 
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affecting another (Ptak and Petronis, 2008). Furthermore, an emerging paradigm for 
epigenetic regulation of gene expression is the relationship between DNA 
methylation and histone modifications. DNA methylation is the only genetically 
programmed DNA modification in mammals and is controlled by enzymes known as 
DNA methyltransferases (DNMTs) (Tost, 2010). DNMTs catalyse the transfer of a 
methyl group to DNA effectively methylating particular regions of DNA and 
rendering it inaccessible to transcription. Interestingly, DNMTs and HDACs are 
found in the same multiprotein complexes. Moreover, methyl-binding domains 
(MBDs) have been shown to interact with HDACs (Tost, 2010). Thus, an alternate 
mechanism through which HDACs may influence the asthma phenotype is through 
altering DNA and histone methylation pathways. 
Research has shown that SIRT1 regulates the activities of Dnmt1 via physically 
associating and deacetylating the Dnmt1 enzyme in both in vitro and in vivo 
experiments. The researchers of this study concluded that SIRT1 mediated 
deacetylation of Dnmt1 was crucial for its multiple gene-silencing effects (Peng et 
al., 2011).  Dnmt1 is the most abundant Dnmt and is essential for maintenance of 
methylation patterns, silencing of tumor suppressor genes and cell survival 
(Jurkowska et al., 2011). Interestingly, aside from acting upon DNA directly, Dnmt1 
can also repress transcription via recruiting HDAC enzymes such as HDAC1 and 
HDAC2 to methyl binding domains of DNA (Rountree et al., 2000, Fuks et al., 
2000). Aside from Dnmt1, the other Dnmt enzymes— Dnmt3a and Dnmt3b— also 
function to maintain and regulate methylation marks within DNA and Dnmt3b has 
been shown to associate with the histone deacetylase enzyme SIRT1 (Sun et al., 
2012).  
In asthma, the volume of knowledge in regards to Dnmt enzymes and their influence 
on disease state is slim. However, two studies exist that have investigated the roles of 
Dnmts within the airways. Liu et al (2010) investigated the role that cigarette smoke 
condensate (CSC) has in altering epigenetic profiles in airway cell lines. Their results 
indicated that CSC reduced H4K16 acetylation and H4K20 methylation while 
increasing H3K27 methylation. Furthermore, these changes to the epigenetic profile 
coincided with decreased Dnmt1 and increased Dnmt3b expression (Liu et al., 2010). 
In murine models, the enzyme Dnmt3a has been shown to regulate the expression of 
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T helper cell cytokines. The Il13 gene is prominently affected via Dnmt3a 
expression, with Dnmt3a deficiency accompanied by a decrease in DNA methylation 
and changes in H3K27 acetylation/methylation status at the Il13 locus (Yu et al., 
2012).  Many of the features of asthma such as airway hyper reactivity and goblet 
cell hyperplasia have previously been shown to be stimulated by the administration 
of IL-13 in asthma mouse models (Kuperman et al., 2002). Thus, changes to the 
epigenetic profile of the Il13 locus could influence an asthma phenotype.  
Previous research outlining the close association of HDAC enzymes and methylation 
patterns gives credibility to the concept that a change in the expression of HDAC 
enzymes may not reflect altered acetylation status. In fact, given the close association 
and intertwined functions of DNA methylation, histone modifications and chromatin 
remodelling in controlling the epigenetic profiles of cells, it is likely that these 
enzymes may have multiple functions in varying cell types.  
As asthma is an inherited disease it is possible that the inherited component of 
asthma occurs through changes in the DNA methylation profile of particular genes.  
On the other hand, it is possible that an environmental influence that causes an 
asthma exacerbation may do so through influencing and altering epigenetic 
modifications such as histone acetylation. Thus, a key discussion point in epigenetic 
studies is whether or not observed alterations in epigenetic profiles are a cause or 
consequence of the disease investigated.  
6.3 CAUSE OR CONSEQUENCE 
Epigenetics refers to the regulation of various genomic functions including 
gene expression that is brought about by heritable, but potentially reversible, changes 
to the DNA and histones. Thus, the promise that lies within epigenetic research is 
that, while genetically inherited, these alterations are potentially reversible and as 
such can be targeted therapeutically. However, because these epigenetic marks can 
be influenced and altered by external and internal stimulants it is possible that 
changes observed in complex diseases such as asthma are a consequence of the 
disease characteristics rather than a cause of the disease. A study performed by Ito et 
al (2005) investigated whether the HDAC2 enzyme was reduced in the airways of 
individuals with COPD. Their results showed decreased HDAC2 protein levels in 
COPD patients compared to healthy controls.  Furthermore, they found the more 
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severe the COPD, the greater the inflammation of the airways, the greater the 
reduction of HDAC2 (Ito et al., 2005). The authors concluded that decreased levels 
of HDAC2 protein lead to a heightened inflammatory status within the airways. 
However, an alternative interpretation of these results is that epigenetic pathways are 
influenced by external and internal stimuli and an increase in inflammation within 
the airways causes a decrease in HDAC2 protein expression. That is, if during an 
inflammatory response HDAC2 levels are reduced, then a finding of reduced 
HDAC2 levels may not be a cause of inflammation as much as it is a function of 
inflammation. Therefore, an important part of epigenetic research is in distinguishing 
changes to an epigenetic profile that may cause a disease, and changes observed that 
are a consequence of the disease state.  
This project recruited and collected sputum samples from individuals suffering from 
mild asthma (treating with β2 only).  Conventionally, individuals with severe asthma 
are considered a better study cohort as their symptoms are more pronounced and, as 
such, measured differences between the asthma population and healthy controls are 
more obvious. However, as the aim of this project was to investigate differences 
between the cohorts that may influence epigenetic pathways, mild asthmatics while 
still suffering from the disease, were less likely to exhibit the chronic underlying 
biological characteristics that influence epigenetic profiles. Therefore, changes in the 
expression levels of HAT and HDAC enzymes between asthma and healthy cohorts 
that are a result of genetic predispositions rather than an environmental influence 
were more likely to be detected in a mild asthma cohort. However, as in any disease 
state, the airways of mild asthmatics are affected from previous asthma exacerbation 
and exhibit forms of airway remodelling and inflammation, as such the disease state 
would still impact on epigenetic profiles.  Thus, while using mild asthmatics to 
investigate changes in the epigenetic profiles of this disease may avoid exacerbated 
results influenced by the symptoms of asthma, it does not remove the variable 
completely. In this study, the expression levels of SIRT6, while not significant, 
appeared to be influenced by the asthma phenotype and yet was unresponsive to the 
inflammatory stimulus. This result potentially suggests that alterations to SIRT6 
expression levels in the airways may contribute to the asthma phenotype. SIRT6 
expression was largely unaffected in response to the inflammatory stimulus 
suggesting, that its expression levels are not influenced by inflammation and, as 
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such, changes in its expression levels are unlikely to be a consequence of airway 
inflammation. Therefore, it is possible that a change in the expression levels of 
SIRT6 impacts acetylation and or methylation pathways and this contributes to the 
progression and prevalence of asthma within individuals. An altered expression level 
of the SIRT6 enzyme could be caused through dysfunction in its 
transcription/translation pathway or alterations at the sirt6 loci. However, as 
previously stated, a far more in-depth study is required to confirm and understand the 
potential roles of SIRT6 in asthma.  
To determine if epigenetic changes are a consequence of a disease phenotype, a 
greater understanding into how underlying biological processes influence epigenetic 
modifications within a cell is required. Thus, one of the aims of this project was to 
determine how these enzymes respond to an inflammatory stimulus that would 
initiate pathways similar to that observed during an asthma exacerbation.  
Interestingly, a number of studies report a role for CBP in inflammatory pathways 
(Liu et al., 2004, Clarke et al., 2010), yet when CBP has been investigated in asthma 
no difference in its expression is observed between healthy and asthma individuals 
(Ito et al., 2002a). In this study, induced inflammation within the airways caused an 
increase in CBP across all three cohorts. This result suggests that CBP is involved in 
inducing inflammatory pathways but its heightened activity is not a cause of asthma. 
Interestingly, HDAC1 protein levels were also increased in response to inflammation 
across all three cohorts. This also suggests that HDAC1 protein levels are increased 
as part of an inflammatory response. However, while all three cohorts showed 
increases in HDAC1 expression the increase within the asthma β2 cohort was 
substantially lower than the other cohorts. Thus, this may indicate that dysfunction of 
HDAC1 contributes to an exacerbated inflammatory response observed in asthma. 
Furthermore, the use of ICS may improve the function and expression of HDAC1 in 
asthma airways; as the ICS cohort reported similar HDAC1 expression levels as the 
healthy cohort.  
 This project investigated how induced inflammation effects the expression of these 
enzymes in the airways. However, the airway obstruction observed in asthma is 
caused not only by inflammation but also by bronchial constriction, bronchial 
hyperreactivity and excess mucus production. While, induced sputum samples 
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portray an accurate snapshot of airway inflammation, to investigate how epigenetic 
modifications influence bronchial constriction and the other asthma characteristics 
are more appropriate airway sample is required.   
6.4 SPUTUM AS A SPECIMEN SAMPLE 
Sputum induction is a non-invasive method used to measure inflammatory 
mediators of the airways. Sputum is defined as airway secretions from the lower 
respiratory tract and is composed of both a fluid and cellular phase (Djukanović et 
al., 2002). The fluid phase contains mucins and cytokines while the cellular phase 
contains inflammatory and epithelial cells that have been shed from the airway 
lumen (Kelly et al., 2002). There are two ways that a sputum sample can be 
processed: the first is by selectively removing mucus plugs from the expectorated 
sputum (Djukanović et al., 2002). This method avoids excess saliva contamination 
and as such improves the accuracy of differential cell counts. Furthermore, 
measurements of inflammatory mediators in the fluid phase are unaffected by saliva 
contamination. However, the disadvantage in processing sputum in this manner is 
that greater time is required and more manipulation of the sample occurs during the 
processing stage (Paggiaro et al., 2002). The second method used to process sputum 
samples is to process the entire sputum sample. This was the method chosen for this 
project, as this investigation focused largely on the cellular phase of the sputum 
samples. However, one of the key disadvantages of processing the entire expectorate 
is that the variable mixture of sputum plus saliva in the fluid phase may dilute the 
sputum and confound fluid phase analysis (Paggiaro et al., 2002). Ideally, correlating 
changes in HAT and HDAC enzyme expression levels with altered inflammatory 
cytokine levels in the asthma airways would have provided a stronger argument that 
dysfunction of HAT and HDAC enzymes contribute to inflammation within the 
airways. However, as the collected sputum samples for this project were processed 
using the complete expectorate it is likely that the measurement of inflammatory 
cytokines within this fluid phase would have given inaccurate data due to the saliva 
contamination. This observation compounded with logistical constraints meant that 
inflammatory cytokines levels within airways could not be measured for this project.  
However, further investigation in to the role of HAT and HDAC enzymes and their 
involvement in inducing inflammatory cytokines during an asthma exacerbation 
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would require cytokine measurements of the fluid phase of sputum samples. Thus, 
future studies in this area should process sputum samples by separating mucus plugs 
from the collected expectorate, this would provide accurate fluid phase 
measurements and a greater insight into how HAT and HDAC enzymes may 
influence inflammation in the airways.  However, while this method may reproduce 
more accurate findings, greater consideration of the use and processing of sputum 
samples is required for epigenetic studies.  
Unlike genetic studies, epigenetic studies must utilise tissue samples that are likely to 
contribute to the phenotype of interest. Unfortunately these tissues samples often 
consist of a variety of cell populations, as is the case with sputum samples. As a 
cell’s epigenetic profile influences the phenotype of the cell, when a complete 
sputum sample is analysed there is a risk that critical epigenetic signals are missed as 
a result of cellular heterogeneity. For example, previous studies have shown changes 
in the expression of HDAC1 and HDAC2 enzymes in bronchial epithelial cells and 
alveolar macrophages found in asthma airways (Cosio et al., 2004, Ito et al., 2002a). 
However, in this project where heterogeneous cell populations were used neither of 
these enzymes was found to be significantly decreased in asthma. Thus, the 
expression level of HDAC1 and HDAC2 enzymes in other cell types has potentially 
masked any reduced expression levels of these enzymes in bronchial epithelial and 
alveolar macrophage cell types. The complex pathways that initiate an inflammatory 
response in the airways do so via cells signalling other cells. Thus, detecting changes 
in the epigenetic profiles of specific cell types is of great importance in further 
understanding how epigenetic profiles influence disease.  
A number of methods have been suggested to correct for cell heterogeneity in 
epigenetic studies. Researchers from Baltimore and Sweden recognised that white 
blood cells can be distinguished from each other through differentially methylated 
regions (DMR) (Houseman et al., 2012, Liu et al., 2013). Thus, they used these 
DMRs as markers, to identify the various immune cell populations and monitor 
changes within a specific population. This method allowed them to correct their 
results for cell heterogeneity. However, the method also has a major drawback, as it 
does not take into account variations within the DNA methylation of a specific 
immune cell type that may cause new bias in the resulting analysis. Similar to using 
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DMRs as markers, cell markers may also be used to normalise data obtained from 
heterogeneous cell population. In this project hypertonic saline caused an increase in 
neutrophil numbers within the airways, and despite the lack of correlation this 
increase in neutrophil population may have caused altered HAT and HDAC enzyme 
levels if neutrophils express these enzymes. Furthermore, analysis of the mRNA data 
from this project suggested a strong correlation between the expression levels of 
HAT and HDAC enzymes and concentration of epithelial cells within the airways. 
The asthma ICS cohort had a significantly higher number of columnar epithelial cells 
in the airways compared to the healthy and asthma β2 cohort. Thus, if particular 
HDAC enzymes are produced predominantly by epithelial cells a statistical bias in 
the results may exist. To correct for a bias caused by the epithelial cell or from an 
increased neutrophil population, cell markers such as C-reactive protein for 
neutrophils and Surfactant protein D for epithelial cells can be used to normalise the 
Q-RT-PCR and protein data. This normalisation method would correct for a potential 
bias in different gene and protein expression between cohorts that may be caused by 
varying cell populations. Alternatively, researchers can also isolate the numerous cell 
populations that make up these complex samples however, these procedures can be 
technically demanding and highly complex.  
The decision to use whole sputum samples in this study was based on the fact that 
the investigation largely focused on the cellular phase of the sample and that the 
processing and collection of whole sputum samples, rather than mucus plugs would 
be beneficial in future diagnostic tests. In the future, changes in epigenetic profiles 
within sputum samples could be used diagnostically to confirm not only asthma, but 
the type of asthma patients suffer from. Collecting and processing a whole sputum 
sample would remove laborious processing methods, and speed up the diagnostic 
process. At a clinical level, this would translate into a more effective therapeutic plan 
and better patient management. However, at this point during the cell and molecular 
stage of research the use of a heterogeneous cell sample appeared to be more 
detrimental than beneficial particularly during the analysis of results.  
Few studies have discussed the feasibility of sputum as a viable biofluid to detect 
epigenetic changes. A number of studies have used sputum to detect changes in 
epigenetic profiles of lung cancer and COPD patients (Guzman et al., 2012, Hubers 
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et al., 2012, Leng et al., 2012a, Leng et al., 2012b, Markopoulou et al., 2012, Hwang 
et al., 2011, Hsu et al., 2007, Belinsky et al., 2006, Cirincione et al., 2006, Miozzo et 
al., 1996, Palmisano et al., 2000). These studies have investigated changes in 
methylation status of specific genes associated with COPD and lung cancer. While, 
differing levels of methylation have been found for particular genes (e.g RARβ, 
p16
INK4α 
and RASSFIA) in the disease cohorts particularly in terms of lung cancer, 
all of the studies fail to discuss how the complexity of the sputum sample may have 
impacted upon their findings (Belinsky et al., 2006, Cirincione et al., 2006, Miozzo 
et al., 1996, Palmisano et al., 2000). Furthermore, none of the above studies have 
reported on the cellular composition of the sputum samples thus; the reported 
changes in the epigenome, rather than reflecting an altered phenotype, may 
potentially reflect an alteration of the cellular composition between cohort sputum 
samples. However, it should be noted that one of the studies did suggest that the poor 
correlation between total DNA within a sputum sample and severity of lung cancer 
was likely caused by the complexity of the sputum sample, but they did not discuss 
this point any further (Guzman et al., 2012).It is clear that before sputum can be 
considered a viable biofluid to investigate epigenetic changes, a standardised 
processing protocol for sputum samples in epigenetic research needs to be 
developed. This protocol should address a number of technical issues which include 
but are not limited to: the heterogeneous cell sample, high mucus content, low cell 
population and the degradation of protein, DNA and RNA within the sample.  
6.5 SAMPLE SIZE AND STATISTICS 
An accurate sample size within a study is extremely important as the relevance 
and the reliability of experimental findings can be severely affected by a sample size 
that is either too small or too large. The optimal sample size for epigenetic studies is 
not known. The original power analysis for this project calculated that a sample size 
of 124 was required to detect an effect size of 50% between the healthy and asthma 
cohorts. However, due to logistical constraints the size of the subject cohorts was 
reduced to 15 subjects. This number was chosen, based on previous research where 
investigators have found significant differences in the inflammatory status of the 
airways of healthy and asthma cohorts of this size (Witten et al., 2005, Cosio et al., 
2004). Despite this, the observed differences in enzyme expression between the 
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cohorts of this project never quite reached significance. However, the study does 
indicate the degrees of possible epigenetic differences between the asthma cohorts 
and healthy controls and, as such; a more meaningful power analysis can be 
performed for future studies.  
Power analysis – which is used to compute the minimum sample size for a study - 
requires several different variables as well as the statistical test most likely to be used 
when analysing the resultant data. The key variables within a power analysis are:  
 Effect size, the effect size refers to the extent of difference between your 
null and alternative hypothesis that is to be detected. Simply put, the effect 
size is the change or rather difference between the two cohorts that is 
likely to have significant implications. It is hypothesised that the effect 
size for epigenetic modifications could be as low as 5% however, this 
study detected a difference in expression levels of SIRT6 between the 
healthy and asthma cohorts of about 40% and as such the following power 
analysis is based on this number.   
 Alpha (α) refers to the significance level (p-value) of the test, or rather the 
probability of rejecting the null hypothesis even when it is true. Alpha is 
more often than not 0.05.   
 Beta (β) refers to the probability of accepting the null hypothesis even 
though it is false, and this is where the power of the test lies. Most 
experiments use a power of 0.8 or higher.   
 Standard Deviation (SD) is required for experiments that collect 
continuous experimental data and refers to the amount variation within a 
cohort from the mean result.  
The most important variable within a power analysis is the statistical test used to 
analyse the collected data as this test alone can greatly alter the required sample size.  
Although characteristics of differing cohorts may vary based on the type of 
investigation, in asthma research generally three cohorts are used during an 
investigation. Usually the cohorts are divided by the severity of their asthma, the type 
of asthma or the medication used to treat their asthma. In choosing a statistical test 
whether or not the researcher is likely to perform correlation analysis is also 
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required. In a disease such as asthma, correlation between general characteristics 
such as FEV1 and measured cellular events are usually performed to determine if 
changes in particular cellular events can be related to symptoms of the disease. Thus, 
the statistical test used in the following power analysis was an analysis of covariance 
(ANCOVA). This test allows for comparisons of more than two cohorts, as well as 
taking into account relationships between measurable variables that may influence 
results. Figure 6-1 and 6-2 show appropriate sample sizes for this type of study. As is 
observed in Figure 6-2, to detect small effect sizes of 5 – 10%, enormous sample 
sizes are required. To detect a significant change of 5% between the three cohorts, an 
overall total sample size of 6000 is required (Power 0.8). This number is made 
significantly smaller (1500) with an effect of 10% but the sample size is still quite a 
large cohort. However to detect a significant change of 40% between the three 
cohorts a total sample size of 100 is required (Figure 6-1).  
 
Figure 6-1: Total sample size required to detect moderate effect size in asthma epigenetic profile.  
The above graph demonstrates the sample size required to detect effect sizes from 0.2 – 0.4. To detect 
a 40% effect size, a total sample of 150 is require for 95% power. 
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Figure 6-2: Total sample size required to detect a small effect size in asthma epigenetic profile.  
The above graph demonstrates the large sample sizes that are required to detect significant changes of 
0.5 (red) to 0.15 (green) within an epigenetic profile. For a power of 0.9, a total subject cohort of 7000 
is required to detect a 5% change.  
Analysis of the data from the second experiment was performed using linear mixed 
models (LMM). Mixed models are statistical models containing both fixed effects 
and random effects. Fixed effects include characteristics such as age, gender, 
experimental conditions and time that are likely to influence statistical analysis 
while, random effects account for the correlation within the data set.  A mixed model 
analysis was used to analysis repeated results instead of a repeated measured 
ANOVA because the mixed model accommodated for and determined if changes in 
gene expression were likely caused by a particular cell type within the sample. The 
issue with using linear mixed models in this project is that with smaller samples sizes 
the risk of over manipulating data and creating a new bias in the analysis exists.  
However, when the results were analysed using a repeated measure ANOVA rather 
than the linear mixed model the same level of significance was achieved. 
Furthermore, experimental evidence in the literature suggests that the correlations 
between gene expression and cell type found within the project are likely to exist. 
Several studies have demonstrated that the HDAC enzymes HDAC1, HDAC2, 
SIRT1 and SIRT6 are expressed by bronchial epithelial cells within the airways 
(Minagawa et al., 2011, Ito et al., 2002a, Beane et al., 2012, Cosio et al., 2004). 
However, to confirm the analysis of this project further studies are required.   
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6.6 THE THERAPEUTIC FRONTIER 
The overall aim of this project was to identify enzymes that influence the 
asthma phenotype and, as such, could potentially be targeted therapeutically. The 
present therapies used to relieve asthma symptoms, do so through attenuating airway 
inflammation. However, individuals suffering from asthma that are resistant to 
corticosteroid medications are on the rise. Furthermore, asthma exacerbations are not 
caused by airway inflammation alone: bronchoconstriction, airway 
hyperresponsiveness and excess mucus production also contribute to the obstruction 
of the airways. At present no therapeutic intervention exists that concurrently 
addresses all of these aspects of asthma.  
Individuals with asthma present with inflammation of the airways however; the 
pathogenetic mechanisms behind the inflammatory response between individuals 
may vary. To date four different inflammatory subtypes of asthma are known: 
eosinophilic, neutrophilic, paucigranulocytic and mixed granulocytic (Simpson et al., 
2006). Present anti-inflammatory medications (corticosteroids) do not target specific 
inflammatory subtypes and as such may not be as effective in one patient as it is in 
another. Thus, therapeutic intervention of specific cellular pathways that cause these 
subtypes of inflammation would provide a more effective, phenotype specific 
treatment for asthma patients.  
Epigenetic drugs can reverse aberrant gene expression profiles associated with 
different disease states.  At present epigenetic therapies largely refer to chromatin 
and DNA methylation modifying drugs. Chromatin modifying drugs are therapies 
that can alter the state of the chromatin structure in both directions and as such 
include HAT inhibitors (HATis) and HDAC inhibitors (HDACis). Interestingly, 
research into the use of HDACis as a treatment option for asthma, has demonstrated 
their effectiveness in attenuating airway hyperresponsiveness, excess mucus 
production and airway remodelling, suggesting that they could be beneficial in 
treating asthma symptoms (Banerjee et al., 2012, Grabiec et al., 2010, Orecchia et 
al., 2011, Royce et al., 2011, Royce et al., 2012a). On the other hand, there is 
substantial evidence that decreased HDAC expression levels cause an increase in 
inflammation in the airways (Barnes, 2009a). Thus, the use of HDAC inhibitors 
while effective in attenuating airway hyperresponsiveness, excess mucus production 
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and airway remodelling may cause increased inflammation in the airways. In the 
same way increasing HDAC activity to attenuate inflammation may aggravate these 
other aspects of asthma. Furthermore, the interrelation between the state of chromatin 
and DNA methylation suggests that drugs targeting chromatin could potentially alter 
DNA methylation states of nearby gene promoter and enhancer regions (Figure 6-3). 
While this knowledge is advantageous for pharmaceutical researchers it is also likely 
to present a number of problems in drug design and development. Thus, in the 
development of epigenetic drugs great consideration should be given to how these 
therapies alter cell transcription and translation of the whole cell and the impact this 
will have on the disease state. 
 
Figure 6-3: Altering histone acetylation pathways within a cell type may influence methylation status.   
The altering of HAT and HDAC pathways through therapeutic intervention, while inhibiting gene 
transcription of specific proteins, may also results in the demethylation of nearby CpG regions. Figure 
was created using MOTIFOLIO
©
 – Biomedical PowerPoint Tool Kits. 
The results from this project indicate that the HDAC enzymes: HDAC1, SIRT1 and 
SIRT6 contribute to the asthma phenotype. Thus, there is potential that these HDAC 
enzymes can be manipulated and targeted through therapeutic intervention to relieve 
asthma symptoms. Developing cell specific therapies to target causative agents of 
disease is essential. The importance of developing cell specific therapies will become 
more and more evident as the contributing epigenetic modifications that cause 
specific diseases become unravelled. There is evidence that HDAC1, SIRT1 and 
SIRT6 are expressed in airway epithelial cells of the airways and, as such targeting 
the specific pathways through which these enzymes operate may prove to be 
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therapeutically beneficial (Figure 6-4). Findings from this project highlight a possible 
dysfunction of SIRT1 and SIRT6 in asthma airways and correlate the expression of 
these enzymes with the concentration of epithelial cells. Previous studies have 
demonstrated SIRT1 and SIRT6’s ability to deacetylate NF-κB pathways (Galli et 
al., 2010). Activation of NF-κB within the airway epithelium has not only been 
shown to be necessary to induce airway inflammation but also causes mucus 
overproduction. Thus, the manipulation of SIRT1 and/or SIRT6 profiles in epithelial 
cells may be a viable therapeutic option for the treatment of asthma.  
On the other hand, the therapeutic manipulation of HDAC1 may influence a different 
set of cellular pathways in the airway epithelium that the sirtuins are not involved in. 
Recently, researchers have shown that a HDAC1/2 deficiency in airway epithelial 
cells leads to a loss of expression of the transcription factor Sox2 (Wang et al., 
2013). The loss of Sox2 appears to prevent airway epithelial cell development. 
Furthermore, the loss of HDAC1/2 also caused an increased expression of inhibitors 
of cell proliferation such as the proteins Rb1, p16 and p21. This resulted in decreased 
epithelial proliferation in lung injury and inhibition of regeneration (Wang et al., 
2013). Thus, while HDAC1, SIRT1 and SIRT6 may contribute to the asthma 
phenotype, their contribution to different aspects of the disease may differ 
significantly. Targeting different pathways within specific cell types may be of great 
therapeutic advantage. This could potentially allow for the targeting of the different 
inflammatory subtypes of asthma and at the same time attenuating the other 
underlying features of the disease.  
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Figure 6-4: Targeting specific pathways within specific cells is an attractive therapeutic option for 
treating asthma. 
Therapeutic intervention, that target specific enzyme pathways within epithelial cells that cause 
different types of inflammation within asthma airways, may prove to be a more effective way to 
manage the varying subtypes of asthma patients. Figure was created using MOTIFOLIO
©
 – 
Biomedical PowerPoint Tool Kits. 
 
There is a great possibility that epigenetic therapies will be extremely beneficial in 
treating environmentally influenced diseases such as asthma. However, before 
designing the therapies, we first need to understand the epigenome machinery 
involved in disease onset.   
6.7 FUTURE DIRECTIONS AND CONCLUSIONS 
The work embodied in this thesis demonstrates that the dysfunction of the 
HDAC enzymes: HDAC1, SIRT1 and SIRT6 are likely to contribute to the 
pathogenesis of asthma and may be potential therapeutic targets. However, to truly 
understand how these enzymes influence certain aspects of asthma, further research 
is required to elucidate the cellular pathways they control. Particularly, future 
research should focus on whether dysfunctions of these enzymes exist in the airway 
epithelium of asthmatic individuals. Once the expression levels of these enzymes 
within the airway epithelium has been determined, research should then focus on 
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how, dysfunction of these enzymes, particularly SIRT1 and SIRT6 influence the 
master inflammatory transcription factor NF-κB. A foreboding task, given that NF-
κB dependent gene profiles include: chemokines, cytokines, receptors, apoptopic 
regulators, intracellular signalling molecules and transcription factors.  
 This project also highlights the difficulties associated with using a heterogeneous 
cell sample in epigenetic research. The variables associated with heterogeneous cell 
samples in research can be managed with the use of statistical analysis and cellular 
markers. However, this type of analysis is comparatively inferior to the actual 
analysis of specific cell population.  Further adaption to the standardized methods for 
processing sputum samples need to be made to incorporate the use of these samples 
into epigenetic research. This method needs to focus particularly on the best ways to 
isolate cell populations from the sample. In addition, the findings of this project have 
also highlighted the difficulties in obtaining appropriate sample size for significant 
epigenetic research. If subject numbers required to show significance differences in 
the epigenome between cases and controls extend into the thousands a new approach 
to recruiting participants for epigenome research is required. A national database, 
where individuals can anonymously volunteer to participate in epigenetic research 
and provide live tissue samples such as blood, sputum, saliva and urine will be of 
great advantage in furthering our knowledge and understanding of complex diseases.  
 Finally, this project also demonstrates that HAT and HDAC expression levels can be 
altered by external stimuli. Thus, there is potential that changes in the expression of 
these enzymes may be a consequence of a disease state rather, than the cause of the 
disease. Distinguishing between changes in the epigenome that cause or are a 
consequence of the disease is the Achilles hill of epigenetic research. Future research 
in this area must focus on designing experiments that distinguish between these two 
aspects. 
Epigenetic research provides great hope in understanding and managing complex 
diseases such as asthma. However, there are many obstacles that need to be 
overcome before we can truly appreciate the role epigenetics play in complex 
diseases.   
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Appendix A1 
Participation Information and Consent Form 
 
    PARTICIPANT INFORMATION for QUT 
RESEARCH PROJECT        
 
8.1.1.1.1.1.1.1.1 Airway Inflammation in Asthma 
 
Research Team Contact 
Dr. Colin Solomon: Principal Investigator 
Telephone: 3138 1427 
Email: c.solomon@qut.edu.au 
 
Description 
This project is being undertaken as part of the asthma research program directed by Dr. 
Solomon at the Queensland University of Technology (QUT).  The purpose of this project is 
to investigate how specific genes, proteins, and cells, control inflammation in the airways of 
people with asthma and to compare this to people without asthma.  The research team 
requests your assistance because you do, or do not, have asthma, and are otherwise 
healthy.  The biological samples will be destroyed after completion of the project. 
Participation 
Your participation in this project is voluntary. If you do agree to participate, you can 
withdraw from participation at any time during the project without comment or penalty. 
Your decision to participate, or not, will in no way impact upon your current or future 
relationship with QUT (for example, your grades). Your participation will involve three 
testing sessions, throughout a period of at least one week, each of one hour duration, at 
the Institute of Health and Biomedical Innovation at QUT.  Prior to the testing sessions you 
will need to abstain from certain asthma and other medications (unless you need to take 
these).  During the testing sessions you will be required to complete: 
Medical Health Questionnaire;(first session only) You will complete a medical health 
questionnaire to determine your medical health status. 
Breathing Tests: You will be required to inhale and exhale forcefully through a tube to 
measure the volume and flow of air in your lungs.  You will do this before and after taking 
the bronchodilator medication and during the sputum sampling. 
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Bronchodilator Medication:  You will take a bronchodilator medication (non-prescription 
asthma puffer) to assess your airways and for safety.  
Sputum Sampling: You will inhale a saline (salty water) mist for 20 minutes and periodically 
cough up sputum into a container to collect cells and fluid from your airways. 
You will be compensated for your time ($20 voucher at the QUT Bookshop for each visit) 
and transport costs. 
Expected benefits 
It is expected that this project will not benefit you. However, it may benefit people with 
asthma in the future by adding to our understanding of the biological factors involved 
in asthma. 
 
Risks 
Breathing Tests: Whilst performing the breathing test you could feel light-headed.  For your 
safety you will be seated during the test. 
Bronchodilator Medication: The bronchodilator medication could give you a headache, 
nausea, shaking or tense feeling, irregular or fast heart beat, warm feeling, irritated throat 
or mouth, or rarely muscle cramps or decreased blood potassium.  The medication is a 
commonly used non-prescription medication. 
Sputum Sampling: During the sputum sampling procedure you could cough involuntarily, or 
could have a salty taste in your mouth, or experience some constriction in your lungs.  To 
minimise any constriction in your lungs you will be given the bronchodilator medication 
before, and if necessary, after the procedure.   
You will be monitored throughout the testing session. 
Due to any potential unknown risks, women who are pregnant or breastfeeding are not to 
participate in this project. 
In the event that you suffer an injury as a result of participating in this research project, 
hospital care and treatment will be provided by the public health service at no extra cost to 
you. 
Confidentiality 
The information and data obtained during this project will be kept confidential, within the law. 
Consent to Participate 
We request you sign a written consent form (enclosed) to confirm your agreement to 
participate. 
Questions / further information about the project 
Please contact the researcher team member named above to have any questions answered, or 
if you require further information about the project. 
Concerns / complaints regarding the conduct of the project 
This study has been reviewed and approved by the QUT University Human Research Ethics 
Committees.  QUT is committed to researcher integrity and the ethical conduct of research 
projects.  However, if you do have any concerns or complaints about the ethical conduct of the 
project you may contact the QUT Research Ethics Officer on telephone (07) 3138 2340 or E-mail 
ethicscontact@qut.edu.au.  The QUT Research Ethics Officer is not connected with the research 
project and can facilitate a resolution to your concern in an impartial manner. 
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 CONSENT FORM for QUT RESEARCH PROJECT          
 
Airway Inflammation in Asthma 
 
Statement of consent 
 
By signing below, I am indicating that I: 
 have read and understood the information document regarding this project 
 have had any questions answered to my satisfaction 
 understand that if I have any additional questions I can contact the research team 
 understand that I am free to withdraw at any time, without comment or penalty 
 understand that I can contact the QUT Research Ethics Officer by telephone (07) 
3138 2340 or E-mail ethicscontact@qut.edu.au if I have concerns about the ethical 
conduct of the project 
 agree to participate in the project 
 
Name  
Signature  
Date  /  /   
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Appendix A2: Medical Health Questionnaire: Aim One 
 
MEDICAL HEALTH QUESTIONNAIRE 
 
DATE OF SESSION:  ___ ___ - ___ ___- ___ ___ ___ ___     
 
PERSONAL INFORMATION: 
NAME:           
Date of Birth: __ __-__ __-__ __ __ __  AGE:    
SEX: F  M 
ADDRESS:           
    (Number and Street) 
            
(City)      (State)      (Postcode) 
 
TELEPHONE: Home: (____ ____)    ____ ____ ____ ____ ____ ____ ____ 
   Mobile: ____ ____ ____ ____ ____ ____ ____ ____ ____ ____    
EMAIL ADDRESS ____________________________________________________________ 
EMERGENCY CONTACT: 
NAME:           
ADDRESS:           
  (Number and Street)                                                                                   
(City)      (State)    (Postcode 
TELEPHONE:  Home: (____ ____)    ____ ____ ____ ____ ____ ____ ____ 
               Mobile: ____ ____ ____ ____ ____ ____ ____ ____ ____ ____    
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Medical Doctor who manages your health: 
Name:        Telephone:     
Are you pregnant or possibly pregnant?        
       YES  NO  N/A 
Are you currently breastfeeding?        
       YES  NO  N/A 
 
When was the last time you had a respiratory infection (cold, flu, other)?    
 
ASTHMA: 
 
Have you ever been told by a Medical Doctor that you have asthma?  YES NO 
Do you still have episodes of asthma?      YES NO 
IF YES: (tick all that apply) 
 Have you visited a Hospital Emergency Department for your asthma? 
        Ever  Past year  Past month   
 Have you required rescue medication for your asthma? 
        Ever  Past year  Past month   
Have you been hospitalized for your asthma? 
        Ever  Past year  Past month   
 Have you required intubation (a breathing tube) for your asthma? 
        Ever  Past year  Past month   
On average during the past year, how often would you have an asthma attack? 
  per Day  per Month  per Year 
On average during the past year, how often would you have episodes of coughing due 
to your asthma? 
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 per Day   per Month   per Year  
On average during the past year, how often would you wake up due to your asthma? 
 per Day   per Month   per Year  
Is your asthma currently well controlled?           YES    NO 
What are the factors or situations that bring on an asthma attack for you? 
            
             
            
             
IF NO: (tick all that apply) 
Do you ever have episodes of: 
Chest tightness    
Wheezing    
Difficulty breathing   
Excessive mucus production from your airways    
If so, describe these episodes and symptoms (what factors or situations that bring the 
episode on, how long does it last, what do you feel): 
           
           
           
           
           
            
Does anyone in your family (siblings, parents, grandparents) have asthma? 
YES  NO  DK 
IF YES: Provide details:          
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ALLERGIES: 
Are you allergic to anything?        
     YES  NO  DK 
IF YES:  Provide details:         
           
            
Have you ever been told by a Medical Doctor that you had "allergic rhinitis" or "hay fever"? 
YES  NO  DK 
IF YES: 
Have you had symptoms from this anytime in the past 12 months?  
YES  NO  DK 
Do you have seasonal symptoms of itchy throat or red teary eyes?    
YES  NO  DK 
IF YES: 
 Which seasons:         
Did you have eczema as a child or do you have it now?      
       YES  NO  DK 
What are the factors or situations that bring on an allergy attack for you? 
            
             
             
Have you ever received treatment using allergy injections? 
 YES  NO  DK 
IF YES: 
Are you currently receiving allergy injections? YES  NO  DK 
Most recent treatment (Date)         
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MEDICATIONS 
List all your asthma medications and dosages and periods used in the past six (6) months: 
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
 
List all your asthma medications and dosages and periods used prior to the last six (6) 
months: 
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Could you tolerate stopping short-term bronchodilators (Ventolin) for 8 hours prior to 
testing? 
YES  NO  DK 
List all your current and past allergy medications and dosages and periods used: 
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Name   Dosage   Started   Stopped  
Could you tolerate stopping your allergy medication for up to 3 days prior to testing? 
YES  NO  DK 
Are you currently taking any other medications (prescription or non-prescription)? 
    
YES  NO  DK 
IF YES: 
 Name these          
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Are you allergic to any medications?   YES                  NO  DK 
IF YES: 
 Name these          
             
SMOKING (any substance): 
 
Do you currently smoke?     YES  NO 
Have you smoked anything in the past 12 months?  YES  NO 
Have you ever smoked anything?    YES  NO 
IF YES: 
When did you start smoking?      
When did you stop smoking?      
On average how much did you smoke?        
[Calculate pack years (or equivalent):   average packs per day X    total years 
=   pack years] 
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 MEDICAL CONDITIONS 
Describe any current medical conditions: 
            
             
            
             
            
             
             
 
Describe any past medical conditions: 
            
             
            
             
            
             
             
Medical Clinician’s Report: 
            
             
            
             
            
             
Asthma Status:  Non-Asthma   Asthma  Unknown 
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Appendix B: Medical Health Questionnaire: Aim Two 
MEDICAL HEALTH QUESTIONNAIRE 
DATE OF SESSION: ___  ___  –  ___  ___  –  ___  ___  ___  ___ 
PERSONAL INFORMATION: 
NAME:_____________________________________________________________________ 
Date of Birth: __  __  –  __  __  –  __  __  __  __ 
AGE: _______________  SEX:      Female Male 
ADDRESS:__________________________________________________________________ 
 (Number and Street) 
_____________________________________________________________________ 
(City) (State) (Postcode) 
TELEPHONE: Home: (____ ____) ____ ____ ____ ____ ____ ____ ____ ____ 
 Mobile: ____ ____ ____ ____ ____ ____ ____ ____ ____ ____ 
EMAIL ADDRESS:__________________________________________________________ 
 
EMERGENCY CONTACT: 
NAME:__________________________________________________________________ 
ADDRESS:________________________________________________________________ 
 (Number and Street) 
_____________________________________________________________________ 
(City) (State) (Postcode) 
TELEPHONE: Home: (____ ____) ____ ____ ____ ____ ____ ____ ____ ____ 
 Mobile: ____ ____ ____ ____ ____ ____ ____ ____ ____ ____ 
Medical Doctor who manages your health: 
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Name:_____________________________________________________________________ 
Telephone:_________________________________________________________________ 
Are you pregnant or possibly pregnant? YES NO N/A 
Are you currently breastfeeding?             YES NO N/A 
When was the last time you had a respiratory infection (cold, flu, other)? ______________ 
 
GENERAL HEALTH: 
1. Do you have a family history of: 
A. Diabetes                                                                                   YES NO UNSURE 
B. Heart Disease                                                                          YES NO UNSURE 
C. Cancer                                                                                      YES NO UNSURE 
D. Asthma                                                                                     YES NO UNSURE 
2. Have you ever had pneumonia?                                                        YES NO UNSURE 
3. Have you ever had Tuberculosis?                                                      YES NO UNSURE 
4. Have you ever been diagnosed with swine flu?                             YES NO UNSURE 
5. Have you ever been diagnosed with hepatitis (A, B or C)?           YES NO UNSURE 
6. Have you ever been told by a Medical Doctor that you have 
 vocal cord dysfunction?                                                                      YES NO UNSURE 
7. Have you ever had a tracheotomy, bronchoscopy etc.?              YES NO UNSURE 
8. Have you recently had surgery of the facial or respiratory areas 
 (wisdom teeth, tonsils removed etc.)?                                            YES NO UNSURE 
9. Can you think of any medical reason that you would not be able  
to take part in this study where participation involves breathing  
tests, and repetitive forced coughing?                                            YES NO UNSURE 
 If YES:  Please explain 
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ASTHMA: 
1. Have you ever been told by a medical Doctor that you have chronic bronchitis, 
emphysema, or Chronic Obstructive Pulmonary Disease (COPD)?                              
  YES NO UNSURE 
2. Have you ever been told by a Medical Doctor that you have asthma? 
YES NO UNSURE 
3. Do you still have episodes of asthma?  
 YES NO UNSURE 
 IF NO: – Please turn to question 19. 
 In the past four weeks, did you feel that your asthma was well 
 controlled?                                                            YES NO UNSURE 
4. In the past four weeks, did you miss any work, school or normal  
activity (i.e. household chores or social engagement) because of your asthma? 
                                                                                 YES NO UNSURE 
5. In the past four weeks did your asthma wake you up at night?  
                                                                                          YES NO UNSURE 
6. In the past twelve months, did you miss any work, school or 
 normal activity (i.e. household chores or social engagement) because of your 
asthma? 
  
                                                                                 YES NO UNSURE  
 If YES: 
On average during the past twelve months, how often would you have an asthma 
attack? 
Per Day__________ Per Month__________ Per Year __________ 
On average during the past twelve months, how often would you have episodes of 
coughing due to your asthma? 
Per Day__________ Per Month__________ Per Year __________ 
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7. In the past twelve months, did your asthma wake you up at night? YES NO
UNSURE 
If YES: 
On average during the past twelve months, how often would you wake up due to your 
asthma? 
Per Day__________ Per Month__________ Per Year __________ 
8. Have you visited a Hospital Emergency Department for your asthma? YES NO
UNSURE 
9. Have you been hospitalized for your asthma? YES NO UNSURE 
If YES: 
When were you hospitalized for your asthma? (Please tick) 
Child 
Adolescent 
Adult 
In the last 10 years__________ Past year__________ Past 
month__________ 
10. Have you required intubation (a breathing tube) for your asthma? YES NO
UNSURE 
11. In the past twelve months, have you at any time taken  
 medicine(s) for your asthma? YES NO UNSURE 
12. Do you believe you are able to take your asthma medicine(s) 
 as directed? YES NO UNSURE 
13. Do you believe your medicine(s) is useful in controlling your  
 asthma? YES NO UNSURE 
15. What are the factors or situations that bring on an asthma attack for you? 
 
 
 
 
16. Do you experience worsening of your asthma symptoms during or  
 prior to menstruation?  YES NO UNSURE N/A 
If N/A: Please turn to page 5. 
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If YES: 
At what stage (days) during your menstrual cycle do you feel a worsening of your 
asthmasymptoms? 
 
 
 
 
17. Do you feel you are using more rescue medication at any stage  
 during your menstrual cycle?   
 YES NO UNSURE 
18. What was date of the first day of your last or current menstrual cycle menses/period? 
 
 
 
IF NO: (Tick all that apply) 
19. Do you ever have episodes of: 
Chest tightness 
Wheezing 
Difficulty breathing 
Excessive mucus production from your airways 
If so, describe these episodes and symptoms (what factors or situations that bring the 
episode on, how long does it last, what do you feel): 
 
 
 
 
20. Does anyone in your family (siblings, parents, grandparents) have asthma? 
YES NO DON’T KNOW (DK)  
IF YES: Provide details: 
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ALLERGIES: 
1. Are you allergic to anything? YES 
NO DK 
 IF YES:  Provide details: 
 
 
 
2. Have you ever been told by a Medical Doctor that you had 
"allergic rhinitis" or "hay fever"? YES NO DK 
IF YES: 
Have you had symptoms from this anytime in the past 12 months? YES NO DK 
Do you have seasonal symptoms of itchy throat or red teary eyes? YES NO DK 
Which seasons:__________________________ 
3. Did you have eczema as a child or do you have it now? YES N DK 
4. What are the factors or situations that bring on an allergy attack for you? 
 
 
 
5. Have you ever received treatment using allergy injections? YES NO DK 
 IF YES: 
Are you currently receiving allergy injections? YES NO DK 
Most recent treatment(Date)__________________________ 
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MEDICATIONS: 
List all your asthma medications and dosages and periods used in the past six (6) months: 
Name  Dosage  Started  Stopped  
        
Name  Dosage  Started  Stopped  
        
Name  Dosage  Started  Stopped  
 
List all your asthma medications and dosages and periods used prior to the last six (6) 
months: 
Name  Dosage  Started  Stopped  
        
Name  Dosage  Started  Stopped  
        
Name  Dosage  Started  Stopped  
1. Do you use an inhaler for quick relief from asthma symptoms? YES NO 
If YES;  In the past twelve months, what was the highest No puffs 
 Number of puffs a day you took of this inhaler?   1 to 4 puffs 
        5 to 8 puffs 
        9 to 12 puffs 
        More than 12 puffs 
2. Have you ever been prescribed an asthma inhaler or pill that is  
 NOT used for quick relief of symptoms?  YES NO 
If YES, what best describes how you take this medicine? Take every day 
Take some days 
Used to take 
              Take when I have symptoms 
              Never took  
3. Could you tolerate stopping short-term bronchodilators  
(Ventolin) for 8 hours prior to testing? YES NO DK 
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List all your current and past allergy medications and dosages and periods used: 
Name  Dosage  Started  Stopped  
        
Name  Dosage  Started  Stopped  
        
Name  Dosage  Started  Stopped  
        
Name  Dosage  Started  Stopped  
4. Could you tolerate stopping your allergy medication for up to  
three days prior to testing? YES NO DK 
5. Are you currently taking any other medications (prescription or non-prescription)? 
Medications include vitamins, minerals, and contraceptive medication/devices 
YES NO UNSURE 
IF YES: 
 Name these
 _______________________________________________________________________ 
6. Are you allergic to any medications?                                                          YES NO DK 
 IF YES: 
 Name these
 _______________________________________________________________________ 
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SMOKING (ANY SUBSTANCE): 
1. Do you currently smoke? YES NO 
2. Have you smoked anything in the past 12 months? YES NO 
3. Have you ever smoked anything? YES NO 
IF YES: 
When did you start smoking?__________________________ 
When did you stop smoking?__________________________ 
On average how much did you smoke? __________________________ 
Calculate pack year (or equivalent): 
 
x 
 
= 
 
average packs per day total years pack years 
4. Have or do your parents smoke?  YES NO UNSURE 
If YES:  please tick:  MOTHER 
 FATHER 
 BOTH 
If YES: 
When did they start smoking?
 __________________________ 
When did they stop smoking? 
 __________________________ 
5. Did you grow up in an environment where you were 
 exposed to smoke?                                                                         YES NO    UNSURE 
Did your parents smoke while they were pregnant with you or your other siblings? 
        YES NO UNSURE 
6. Do you feel your asthma symptoms are more severe when you are in a smokey 
environment?       YES NO UNSURE 
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MEDICAL CONDITIONS: 
Describe any current medical conditions: 
 
 
 
 
Describe any past medical conditions: 
 
 
 
 
Medical Clinicians Report: 
 
 
 
 
Asthma Status: NON-ASTHMA 
 ASTHMA 
 UNKNOWN 
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Appendix C: Subject Characteristics for Aim one 
Table 1: Healthy Subject Characteristics: RTI – Respiratory tract infection, BMI – Body Mass Index, FEV1– Forced Expiratory Volume in 1 second, FVC – Forced Vital 
Capacity,, S.Vol – Sputum Volume, Yr- Year, Mth – Months, cm – Centimetres, kg – kilograms, L – Litres, mL – millilitres, , ICS – Inhaled Corticosteroids, CS – 
Corticosteroids, NR – No response (subject could not remember last RTI),  U – Unsure, Y – Yes, N – No.  
 
  Age 
(yr) 
Gender RTI 
(mth) 
Height  
(cm) 
Weight 
(kg) 
BMI FEV1 
(L) 
FVC 
(L) 
FEV1/FVC% Post 
FEV1 (L) 
Reversibility 
(%) 
S. Vol 
(mL) 
Family 
History 
Smoker 
< 12mths 
Allergy 
1 35 M 4.0 170 75.1 25.99 3.08 3.47 88.76 2.89 -6.17 6.49 Y N Y N 
2 19 F 0.5 171 62.7 21.44 2.91 3.26 89.26 2.83 -2.75 8.69 N Y Y N 
3 32 M 12.0 178 90.0 28.41 4.67 5.43 86.00 4.68 0.21 2.57 N N N N 
4 24 F 5.0 171 53.7 18.36 3.19 3.57 89.36 3.24 1.57 3.40 Y N N N 
5 20 M 3.0 183 83.0 24.78 4.67 5.17 90.33 4.71 0.86 3.37 Y N Y N 
6 23 F 12.0 167 57.3 20.55 3.41 3.71 91.91 3.31 -2.93 3.50 N N N N 
7 22 F NR 163 56.4 21.36 3.40 3.94 86.29 3.56 4.71 3.24 N N N Y 
8 18 F 11.0 173 79.9 26.85 4.15 5.02 82.67 4.02 -3.13 3.51 N N N Y 
9 35 M 6.0 173 66.1 22.09 4.59 5.32 86.28 4.74 3.27 4.18 N N N N 
10 18 F 1.0 168 123.1 43.88 4.02 4.47 89.93 3.70 -7.96 3.10 Y N N N 
11 26 M 12.0 174 78.2 25.83 3.24 3.69 87.80 3.61 11.42 5.28 Y N N Y 
12 25 F 5.0 149 67.5 30.40 2.69 3.04 88.49 2.55 -5.20 4.04 Y N N N 
13 24 M 24.0 166 72.3 26.40 4.24 4.35 97.47 4.39 3.54 7.59 N N N N 
14 50 M 12.0 174 72.6 23.98 3.43 3.96 86.62 3.50 2.04 4.29 U N N N 
15 28 F 0.5 166 73.7 26.75 3.51 4.02 87.31 3.47 -1.14 3.49 N N N N 
16 27 M NR 172 71.0 24.00 4.09 4.66 87.77 3.98 -2.69 5.97 N N N N 
17 27 F NR 156 51.1 21.00 2.81 3.15 89.21 2.74 -2.49 2.14 N N N N 
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Table 2: Asthma Subject Characteristics: RTI – Respiratory tract infection, BMI – Body Mass Index, FEV1 – Forced Expiratory Volume in 1 second, FVC – Forced Vital 
Capacity, , S.Vol – Sputum Volume, Yr- Year, Mth – Months, cm – Centimetres, kg – kilograms, L – Litres, mL – millilitres, ICS – Inhaled Corticosteroids, CS – 
Corticosteroids, NR – No response ( occurred when subject couldn’t remember their last RTI),  U – Unsure, Y – Yes, N – No 
  Age 
(yr) 
Gender RTI 
(mth) 
Height  
(cm) 
Weight 
(kg) 
BMI FEV1 
(L) 
FVC 
(L) 
FEV1/FVC% Post FEV1 
(L) 
Reversibility 
(%) 
S. Vol 
(mL) 
Family 
History 
Smoker 
< 12mths 
Allergy 
1 19 M 3.0 184 75.0 22.15 5.09 6.09 83.58 5.27 3.54 4.08 Y N Y N 
2 29 F 1.0 173 64.5 21.68 3.62 4.44 81.53 3.76 3.87 3.60 Y N N N 
3 19 M 1.0 180 65.8 20.31 3.83 5.30 72.26 4.23 10.44  Y N N Y 
4 34 F 12.0 173 67.3 22.49 3.35 4.18 80.14 3.34 -0.30 2.32 Y N Y Y 
5 37 M 4.0 187 105.9 30.28 4.69 5.98 78.43 4.75 1.28 6.16 N N N Y 
6 21 F 0.5 168 59.8 21.31 3.08 3.27 94.19 2.99 -2.92 0.60 Y N N N 
7 23 M 3.0 190 76.7 21.25 3.81 5.95 64.03 4.49 17.85  Y N N Y 
8 20 F 3.0 160 45.1 17.62 3.40 3.48 97.70 3.19 -6.18 7.76 Y N N N 
9 23 M 2.0 187 91.1 26.05 5.22 6.34 82.33 5.53 5.94 3.44 Y N N Y 
10 49 F 12.0 159 76.3 30.18 2.16 2.71 79.70 2.32 7.41  Y N N Y 
11 24 M 2.0 178 77.2 24.37 3.02 4.30 70.23 3.33 10.26 4.44 Y N N N 
12 43 F 15.0 159 50.8 20.09 2.55 3.39 75.22 2.64 3.53 4.10 Y N N N 
13 39 M 1.0 193 109.2 29.32 3.06 5.07 60.36 4.07 33.01 5.20 Y N N Y 
14 18 M 6.0 166 70.0 25.40 2.59 3.14 82.48 2.65 2.32 2.10 N N Y Y 
15 18 M 4.0 173 57.8 19.31 2.44 3.19 76.49 2.33 -4.51 5.91 N N N N 
16 19 F 1.0 168 71.2 25.23 3.45 4.63 74.51 3.75 8.70 11.19 Y N Y Y 
17 18 M 0.5 178 118.1 37.27 3.13 4.65 67.31 2.82 -9.90 1.49 Y N N N 
18 29 F 3.0 169 88.5 30.99 2.98 3.58 83.24 2.99 0.34 2.77 U N Y Y 
19 25 M 0.75 190 74.1 20.53 5.69 7.06 80.59 6.29 10.54 5.50 U N N Y 
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Appendix D: General Characteristics and Subject Pulmonary Function – 
Inflammation Study 
GENERAL CHARACTERISTICS 
Code Gender Age (yr) Height (cm) Weight (kg) BMI Ethinicity Smoker 
H1 F 34 171 110.2 37.69 C N 
H2 F 24 159 54.4 21.52 NC N 
H3 F 18 175.5 80.8 26.23 C N 
H4 F 24 174.5 68.7 22.56 C N 
H5 F 19 158 56 22.43 C N 
H6 F 25 149 58 26.12 C Ex 
H7 F 28 166 72.8 26.42 C N 
H8 F 22 169 52.9 18.52 C N 
H9 M 27 185 76.1 22.24 C N 
H10 F 21 172.5 65 21.84 C N 
H11 F 42 175 76.2 24.88 C N 
H12 M 28 181 73.3 22.37 C N 
H13 M 27 174 73.4 24.24 NC N 
H14 M 20 166 63.4 23.01 NC N 
H15 M 21 185 77.1 22.53 C N 
Abbreviations: H – healthy; F – Female; M – Male; Yr – Year; cm – centimetres, kg – kilograms, 
BMI – Body Mass Index, N – No, Y- Yes, Ex – Ex smoker, C- Caucasian, NC-Non-caucasian 
TP2-BASELINE 
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
H1 4.13 4.68 3.94 0.88 95.40 2.32 
H2 2.43 2.75 2.42 0.88 99.59 1.42 
H3 3.95 4.78 3.94 0.83 99.75 1.74 
H4 3.96 4.63 3.96 0.86 100.00 7.49 
H5 2.99 3.26 2.98 0.92 99.67 3.22 
H6 2.71 2.97 2.72 0.91 100.37 3.60 
H7 3.37 3.96 3.51 0.85 104.15 3.65 
H8 3.56 3.88 3.65 0.92 102.53 2.83 
H9 4.68 5.66 5.05 0.83 107.91 8.14 
H10 3.01 3.77 3.35 0.80 111.30 1.47 
H11 3.53 4.76 3.23 0.74 91.50 3.01 
H12 4.28 4.82 4.25 0.89 99.30 2.22 
H13 3.83 4.59 3.69 0.83 96.34 4.74 
H14 3.54 4.10 3.63 0.86 102.54 2.77 
H15 4.95 6.01 4.99 0.82 100.81 2.72 
Abbreviations: H- Healthy, FEV1 – Forced Expiratory Volume in 1 second, FVC – Forced Vital 
Capacity, S.Vol – Sputum Volume, L – Litres, mL – millilitres. Reversibility refers to the change in 
airway volume 15 minutes after β2 agonists were given to subjects. 
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TP1  
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
H1 3.85 4.39 3.86 0.88 100.26 3.08 
H2 2.73 3.16 2.63 0.86 96.34 2.55 
H3 4.02 4.94 4.18 0.81 103.98 2.48 
H4 4.02 4.66 3.92 0.86 97.51 2.99 
H5 2.91 3.11 2.91 0.94 100.00 4.16 
H6 2.66 3.01 2.69 0.88 101.13 5.18 
H7 3.30 3.86 3.49 0.85 105.76 3.64 
H8 3.70 4.34 3.75 0.85 101.35 3.50 
H9 5.16 5.92 4.99 0.87 96.71 6.08 
H10 2.87 3.71 3.14 0.77 109.41 1.02 
H11 3.64 4.78 3.63 0.76 99.73 2.73 
H12 4.28 4.82 4.25 0.89 99.30 3.54 
H13 3.75 4.38 3.72 0.86 99.20 4.86 
H14 3.41 3.91 3.59 0.87 105.28 4.56 
H15 5.40 6.30 5.41 0.86 100.19 3.28 
Abbreviations: H- Healthy, FEV1 – Forced Expiratory Volume in 1 second, FVC – Forced Vital 
Capacity, S.Vol – Sputum Volume, L – Litres, mL – millilitres. Reversibility refers to the change in 
airway volume 15 minutes after β2 agonists were given to subjects. 
TP3 
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
H1 3.94 4.49 4.03 0.88 102.28 1.86 
H2 2.41 2.76 2.46 0.87 102.07 1.24 
H3 3.81 4.54 3.94 0.84 103.41 1.74 
H4 4.12 4.64 4.13 0.89 100.24 5.27 
H5 2.79 2.99 2.94 0.93 105.38 2.62 
H6 2.74 3.00 2.68 0.91 97.81 3.28 
H7 3.61 4.16 3.42 0.87 94.74 7.09 
H8 3.57 4.08 3.53 0.88 98.88 3.00 
H9 4.88 5.65 4.91 0.86 100.61 6.46 
H10 3.05 3.70 3.36 0.82 110.16 1.42 
H11 3.10 4.88 3.39 0.64 109.35 3.60 
H12 4.42 4.90 4.43 0.90 100.23 3.10 
H13 3.57 4.16 3.61 0.86 101.12 5.39 
H14 3.52 3.98 3.64 0.88 103.41 1.31 
H15 4.62 5.61 4.76 0.82 103.03 2.49 
Abbreviations: H- Healthy, FEV1 – Forced Expiratory Volume in 1 second, FVC – Forced Vital 
Capacity, S.Vol – Sputum Volume, L – Litres, mL – millilitres. Reversibility refers to the change in 
airway volume 15 minutes after β2 agonists were given to subjects. 
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GENERAL CHARACTERISTICS 
Code Gender Age (yr) Height (cm) Weight (kg) BMI Ethinicity Smoker 
β21 M 18 181 74.4 22.71 C N 
β22 M 18 173 57.8 19.31 NC N 
β23 F 18 166 70 25.40 C N 
β24 M 24 190 81.2 22.49 C N 
β25 M 20 191 86.2 23.63 C N 
β26 F 29 169 88.5 30.99 C N 
β27 F 19 163 54.9 20.66 C N 
β28 F 39 169 76.3 26.71 C N 
β29 F 33 154 49.8 21.00 NC N 
β210 F 27 169 66.1 23.14 C N 
β211 M 19 187 61.2 17.50 C N 
β212 F 19 176 55.8 18.01 C N 
β213 F 18 171.5 62.8 21.35 C N 
β214 F 22 158 53.1 21.27 NC N 
β215 M 24 181 97.1 29.64 C N 
Abbreviations: β2 – Asthmatics using salbutamol to treat asthma; F – Female; M – Male; Yr – Year; 
cm – centimetres, kg – kilograms, BMI – Body Mass Index, N – No, Y- Yes, Ex – Ex smoker, C- 
Caucasian, NC-Non-caucasian 
TP2-BASELINE 
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
β21 4.04 4.75 4.31 0.85 106.68 5.48 
β22 2.88 3.31 2.91 0.87 101.04 4.44 
β23 2.66 3.17 2.81 0.84 105.64 1.41 
β24 3.77 5.68 4.06 0.66 107.69 3.30 
β25 4.97 6.25 5.30 0.80 106.64 2.48 
β26 2.99 3.52 2.90 0.85 96.99 3.24 
β27 2.80 3.18 2.87 0.88 102.50 3.81 
β28 3.02 3.38 2.94 0.89 97.35 1.31 
β29 1.73 2.14 2.01 0.81 116.18 3.50 
β210 3.24 3.65 3.39 0.89 104.63 10.0 
β211 3.68 3.84 4.06 0.96 110.33 4.38 
β212 3.23 3.49 3.16 0.93 97.83 1.40 
β213 2.88 3.31 2.87 0.87 99.65 1.43 
β214 2.05 2.60 2.21 0.79 107.80 0.55 
β215 5.38 6.57 5.65 0.82 105.02 2.25 
Abbreviations: : β2 – Asthmatics using salbutamol to treat asthma, FEV1 – Forced Expiratory Volume 
in 1 second, FVC – Forced Vital Capacity, S.Vol – Sputum Volume, L – Litres, mL – milliliters. 
Reversibility refers to the change in airway volume 15 minutes after β2 agonists were given to 
subjects. 
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TP1  
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
β21 4.04 4.75 4.31 0.85 106.68 7.22 
β22 2.71 3.23 2.53 0.84 93.36 5.45 
β23 2.46 3.14 2.82 0.78 114.63 1.77 
β24 3.82 5.58 4.24 0.68 110.99 4.15 
β25 4.97 6.32 5.07 0.79 102.01 2.25 
β26 2.98 3.58 2.99 0.83 100.34 3.05 
β27 3.01 3.3 3.05 0.91 101.33 3.49 
β28 3.03 3.47 2.98 0.87 98.35 1.24 
β29 2.04 2.37 2.05 0.86 100.49 4.56 
β210 3.01 3.37 3.28 0.89 108.97 5.90 
β211 3.79 4.5 4.22 0.84 111.35 4.34 
β212 3.09 3.27 3.01 0.94 97.41 2.30 
β213 2.79 3.42 2.99 0.82 107.17 2.41 
β214 2.18 2.76 2.43 0.79 111.47 1.11 
β215 5.47 6.47 5.27 0.85 96.34 3.28 
Abbreviations: : β2 – Asthmatics using salbutamol to treat asthma, FEV1 – Forced Expiratory Volume 
in 1 second, FVC – Forced Vital Capacity, S.Vol – Sputum Volume, L – Litres, mL – millilitres. 
Reversibility refers to the change in airway volume 15 minutes after β2 agonists were given to 
subjects. 
TP3  
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
β21 4.2 4.75 4.38 0.88 104.29 3.81 
β22 3.03 3.23 2.94 0.94 97.03 6.34 
β23 2.22 3.06 2.62 0.73 118.02  
β24 3.93 5.63 4.21 0.70 107.12 3.98 
β25 5.23 6.06 5.28 0.86 100.96 1.15 
β26 2.88 3.36 2.97 0.86 103.13 2.11 
β27 2.93 3.3 2.98 0.89 101.71 3.03 
β28 2.88 3.29 3.12 0.88 108.33 0.83 
β29 1.72 2.15 1.68 0.80 97.67 3.15 
β210 3.17 3.55 3.33 0.89 105.05 7.02 
β211 3.34 3.56 3.94 0.94 117.96 2.12 
β212 3.3 3.4 3.21 0.97 97.27 1.3 
β213 2.7 3.12 3.08 0.87 114.07 2.49 
β214 2.04 2.67 2.34 0.76 114.71 0.63 
β215 5.27 6.48 5.47 0.81 103.80 2.44 
Abbreviations: : β2 – Asthmatics using salbutamol to treat asthma, FEV1 – Forced Expiratory Volume 
in 1 second, FVC – Forced Vital Capacity, S.Vol – Sputum Volume, L – Litres, mL – millilitres. 
Reversibility refers to the change in airway volume 15 minutes after β2 agonists were given to 
subjects. 
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GENERAL CHARACTERISTICS 
Code Gender Age (yr) Height (cm) Weight (kg) BMI Ethinicity Smoker 
ICS1 M 48 177 89.9 28.70 C N 
ICS2 F 43 165 57.3 21.05 C N 
ICS3 M 18 177 58.2 18.58 C N 
ICS4 M 20 184 79.5 23.48 C N 
ICS5 M 24 180 80 24.69 C Ex 
ICS6 F 28 172 78 26.37 C N 
ICS7 F 24 161 57.2 22.07 C N 
ICS8 F 19 167 70.6 25.31 C N 
ICS9 F 37 177 83.7 26.72 C Ex 
ICS10 F 19 173 70 23.39 C N 
ICS11 F 23 163 63.2 23.79 C N 
ICS12 F 35 157 90 36.51 C N 
ICS13 F 26 169 55.5 19.43 C Ex 
ICS14 F 20 167 67.1 24.06 C N 
Abbreviations: ICS – Asthmatics using inhaled corticosteroids to treat asthma, F – Female; M – Male; 
Yr – Year; cm – centimetres, kg – kilograms, BMI – Body Mass Index, N – No, Y- Yes, Ex – Ex 
smoker, C- Caucasian, NC-Non-caucasian 
TP2-BASELINE 
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
ICS1 3.92 4.76 3.98 0.82 101.53 4.26 
ICS2 2.92 3.89 3.15 0.75 107.88 2.30 
ICS3 3.75 5.04 4.34 0.74 115.73 2.60 
ICS4 4.71 6.11 4.81 0.77 102.12 5.10 
ICS5 3.39 4.64 3.62 0.73 106.78 2.38 
ICS6 3.4 4.21 3.48 0.81 102.35 4.97 
ICS7 2.95 3.12 2.93 0.95 99.32 4.34 
ICS8 3.96 4.24 3.9 0.93 98.48 1.44 
ICS9 2.99 3.74 3.08 0.80 103.01 5.37 
ICS10 3.54 3.74 3.5 0.95 98.87 6.64 
ICS11 3.31 3.79 3.36 0.87 101.51 2.50 
ICS12 2.82 3.44 2.82 0.82 100.00 2.10 
ICS13 4.01 4.37 3.9 0.92 97.26 3.25 
ICS14 3.09 4.08 3.49 0.76 112.945 2.02 
Abbreviations: ICS – Asthmatics using inhaled corticosteroids to treat asthma, FEV1 – Forced 
Expiratory Volume in 1 second, FVC – Forced Vital Capacity, S.Vol – Sputum Volume, L – Litres, 
mL – millilitres. Reversibility refers to the change in airway volume 15 minutes after β2 agonists were 
given to subjects. 
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TP1 
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
ICS1 4.01 4.93 4.06 0.81 101.25 4.10 
ICS2 3.02 3.98 3.13 0.76 103.64 4.80 
ICS3 3.47 5.43 4.37 0.64 125.94 1.40 
ICS4 4.68 5.61 4.61 0.83 98.50 4.56 
ICS5 3.39 4.64 3.61 0.73 106.49 4.85 
ICS6 3.49 4.22 3.56 0.83 102.01 4.71 
ICS7 2.92 3.16 2.89 0.92 98.97 4.98 
ICS8 3.90 4.12 3.90 0.95 100.00 2.40 
ICS9 3.02 3.93 3.07 0.77 101.66 5.70 
ICS10 3.46 3.63 3.26 0.95 94.22 5.10 
ICS11 3.43 3.92 3.49 0.88 101.75 2.62 
ICS12 2.90 3.25 2.89 0.89 99.66 1.86 
ICS13 4.10 4.54 4.09 0.90 99.76 2.63 
ICS14 2.93 3.67 3.20 0.80 109.22 3.15 
Abbreviations: ICS – Asthmatics using inhaled corticosteroids to treat asthma, FEV1 – Forced 
Expiratory Volume in 1 second, FVC – Forced Vital Capacity, S.Vol – Sputum Volume, L – Litres, 
mL – millilitres. Reversibility refers to the change in airway volume 15 minutes after β2 agonists were 
given to subjects. 
TP3 
Code FEV1(L) FVC (L) Post FEV1(L) FEV1/FVC % Reversibility S.Vol (mL) 
ICS1 3.89 4.89 3.96 0.80 101.80 3.52 
ICS2 2.95 3.87 3.13 0.76 106.10 2.93 
ICS3 4.43 4.96 4.51 0.89 101.81 2.00 
ICS4 4.58 5.5 4.8 0.83 104.80 5.15 
ICS5 3.17 4.45 3.44 0.71 108.52 1.04 
ICS6 3.47 4.22 3.5 0.82 100.86 4.64 
ICS7 2.86 3.1 2.97 0.92 103.85 4.50 
ICS8 3.72 4.03 4.03 0.92 108.33 2.50 
ICS9 2.98 3.76 3.15 0.79 105.70 4.86 
ICS10 3.42 3.57 3.31 0.96 96.78 6.51 
ICS11 3.16 3.58 3.21 0.88 101.58 3.20 
ICS12 2.72 3.11 3.06 0.87 112.50 2.57 
ICS13 4.01 4.3 4.08 0.93 101.75 1.02 
ICS14 3.23 3.95 3.5 0.82 108.3591 2.63 
Abbreviations: ICS – Asthmatics using inhaled corticosteroids to treat asthma, FEV1 – Forced 
Expiratory Volume in 1 second, FVC – Forced Vital Capacity, S.Vol – Sputum Volume, L – Litres, 
mL – millilitres. Reversibility refers to the change in airway volume 15 minutes after β2 agonists were 
given to subjects. 
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